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I 
 
OVERVIEW 
___________________________________________________________________________ 
This thesis consists of two volumes and is submitted by Caroline Richards for the Clinical 
Psychology Doctorate at the University of Birmingham. Volume One comprises the research 
component of the doctorate and contains three papers. The first paper is a meta-analytic 
review of the prevalence of autism spectrum disorder phenomenology in rare genetic and 
metabolic syndromes, which will be submitted to Psychological Bulletin. The second paper is 
an empirical study of the behavioural phenotype and prevalence and profile of autism 
spectrum disorder in Phelan-McDermid syndrome, which will be submitted to Research in 
Developmental Disabilities. The final paper is an executive summary which provides an 
accessible overview of the two preceding papers. The executive summary will be used to 
disseminate the findings of the meta-analysis and empirical paper to families and 
professionals.  
 
Volume Two of the thesis consists of five clinical practice reports that were completed over 
the course of the doctorate. The first report describes the assessment and formulation of 
symptoms of low mood which were experienced by a young man. His difficulties were 
formulated using cognitive-behavioural and systemic models. The second report describes an 
evaluation of service user satisfaction in a Child and Adolescent Mental Health Service. The 
third report details the assessment, formulation, intervention and evaluation of cognitive-
behavioural therapy for a man experiencing depression and anxiety. The fourth report presents 
a series of experimental functional analyses, conducted to ascertain the function of self-injury 
displayed by a young girl with Smith-Magenis syndrome. The final report presents an abstract 
of an oral presentation case study. 
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CHAPTER 1 
 
The Prevalence of Autism Spectrum Disorder 
Phenomenology in Rare Syndromes:  
A Meta-Analytic Study 
___________________________________________________________________________ 
 
1.1 Abstract 
Background: Autism spectrum disorder (ASD) phenomenology is reported to be more 
common in some genetic and metabolic syndromes, compared to other syndromes. However, 
despite several systematic reviews, no statistical meta-analysis has yet been conducted, 
synthesising the prevalence data within and between syndromes. 
Methods: A literature search identified research reporting the prevalence of ASD 
phenomenology in syndromes. Reliable quality criteria were developed and a quality 
weighting used to weight the prevalence estimates in the most robust studies more heavily. 
Data from 168 papers across 16 syndromes were included in the meta-analysis. Pooled 
prevalence estimates were generated and compared between syndromes and to a general 
population estimate of the prevalence of idiopathic ASD. 
Results: Robust estimates for the prevalence of ASD phenomenology were generated for 12 
syndromes. ASD phenomenology was evident in all syndromes and significantly more likely 
in all syndromes compared to the general population (Rett syndrome, prevalence of ASD 
phenomenology 61%, Odds Ratio compared to general population 104.5; Cohen syndrome, 
54%, OR 78.7; Cornelia de Lange syndrome, 43%, OR 50.5; Tuberous Sclerosis Complex, 
36%, OR 37.7; Angleman syndrome, 34%, OR 34.5; CHARGE syndrome, 30%, OR 28.7; 
Fragile X syndrome males only 30%, OR 28.7, Fragile X syndrome mixed gender, 22%, OR 
18.9; Neurofibromatosis Type 1, 18%, OR 14.7; Down syndrome, 16%, OR 12.8; Noonan 
syndrome, 15%, OR 11.8; Williams syndrome, 12%, OR 9.1 and 22q11.2 deletion syndrome, 
11%, OR 8.3). Between syndrome variation was also evident. ASD phenomenology was 
significantly more likely in Rett syndrome, compared to nine other syndromes and in Cohen 
syndrome, compared to eight other syndromes. ASD phenomenology was significantly less 
likely in Williams and 22q13.2 deletion syndromes, compared to six other syndromes. 
Discussion: Results are discussed in relation to service provision for syndromes, identifying 
the genetic aetiology of idiopathic ASD and areas for future research.  
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1.2 Introduction 
The term Autism Spectrum Disorder (ASD) is an umbrella term which describes a group of 
behaviourally defined neurodevelopmental disorders, including Autistic disorder, Childhood 
autism, Pervasive Developmental Disorder – Not Otherwise Specified (PDD-NOS), and 
Asperger syndrome (Diagnostic and Statistical Manual of Mental Disorders, DSM-IV, 
American Psychiatric Association, 1994; International Classification of Diseases, ICD-10, 
World Health Organization, 1992). Despite diagnostic variation between ASD subcategories, 
all disorders are defined by the presence of a triad of impairments: abnormalities or 
impairments in social interaction and communication with accompanying restricted or 
repetitive behaviours, activities or interests. Given the association between impairments in 
social interaction and social communication, DSM-V (American Psychiatric Association, 
2013) consolidated social and communication difficulties resulting in a dyad of impairments. 
DSM-V also removed the subcategories of ASD, resulting in a dichotomous distinction 
between ASD and Social (pragmatic) Communication Disorder
1
.  
 
ASD is highly prevalent, with recent total population estimates ranging from 1 in 100 (Baird 
et al., 2006; Center for Disease Control, 2009) to 1 in 68 (Center for Disease Control, 2014). 
However, despite the high prevalence of ASD and robust research documenting its heritability 
(e.g., Ronald et al., 2006), the genetic aetiology of ASD is unknown. This may in part be due 
to the behavioural heterogeneity present within the spectrum and the associated 
methodological challenges to delineation of the genetic underpinnings of a vastly 
heterogeneous population (Bill & Geschwind, 2009). 
 
Whilst the genetic aetiology of idiopathic ASD remains unclear, there is growing evidence 
that ASD phenomenology is more prevalent in specific rare genetic and metabolic syndromes 
relative to other syndromes (e.g., Bruining et al., 2014; Oliver, Berg, Moss, Arron & 
Burbidge, 2011). It is argued that the study of the prevalence and phenomenology of ASD in 
and across these rare syndromes may illuminate the genetic and biological pathways that 
underlie idiopathic ASD (Abrahams & Geschwind, 2007; Bill & Geschwind, 2009; Persico & 
Bourgeron, 2006). It is hypothesised that through the study of relatively homogenous 
syndromes, models could be developed which establish causal links from genes to 
                                                 
1
 Social (Pragmatic) Communication Disorder is defined by the presence of social communication deficits, 
without the accompanying restricted and repetitive behaviours. 
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neuropathology and from these biological markers to specific cognitive deficits which 
underpin characteristic idiopathic ASD behaviours. An understanding of the variation in the 
prevalence of ASD phenomenology between syndromes would target these attempts at model 
building to the syndromes in which ASD phenomenology is most common.  
 
The translation of prevalence findings between syndromes to inform an understanding of the 
pathways implicated in idiopathic ASD is predicated on an assumption that ASD 
phenomenology in syndromes is commensurate with idiopathic ASD. However, some authors 
have argued that ASD phenomenology in certain biologically defined syndromes is a 
categorically different construct to that seen in behaviourally defined idiopathic ASD (Hall, 
Lightbody, Hirt, Rezvani & Reiss, 2010). There is emerging evidence in some syndromes of 
an atypical ASD profile, which may support a categorical distinction between ‘syndromic’ 
variants of ASD and idiopathic ASD (see Moss, Howlin & Oliver, 2011 or Moss & Howlin, 
2009 for a review of this literature). In order to progress this debate, fine-grained analysis of 
the phenomenology of ASD behaviours within syndromes is necessary. However, a recent 
review identified over 100 syndromes that are now documented to evidence an association 
with ASD (Zafeiriou, Ververi, Dafoulis, Kalyva & Vargiami, 2013). The size and scope of 
evaluating the profile of ASD in each of these rare syndromes, with the necessary inclusion of 
appropriate contrast groups with idiopathic ASD, is likely unachievable. A more pragmatic 
strategy would be to target fine-grained analysis of phenomenology towards those syndromes 
in which prevalence estimates for ASD are consistently high. However, despite many 
systematic reviews (Fombonne, 1999; Moss & Howlin, 2009; Moss et al., 2011; Zafeiriou, 
Ververi & Vargiami, 2007; Zafeiriou et al., 2013) there have been no meta-analytic studies 
documenting the consistency of prevalence data within syndromes, detailing the variation of 
prevalence estimates between syndromes or comparing these prevalence estimates to those 
identified in the general population. Therefore, there is a need to synthesise published 
prevalence data to provide estimates of the risk of ASD phenomenology within and between 
syndromes. These data would highlight ‘high risk’ syndromes and thus provide a useful 
starting point for structured investigation of ASD phenomenology. This delineation could 
then answer the wider question of whether ASD phenomenology in syndromes is synonymous 
to idiopathic ASD 
. 
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An additional motivation for the delineation of ASD phenomenology in syndromes is to aid 
planning and provision of clinical and educational services. The presence of idiopathic ASD 
is known to increase risk of inpatient hospital admission (Cowley, Newton, Sturmey, Bouras 
& Holt, 2005), psychotropic medication use (Tsakanikos, Costello, Holt, Sturmey & Bouras, 
2007), mental health disorder (Bradley, Summers, Wood & Bryson, 2004; Brereton, Tonge & 
Einfeld, 2006) and repetitive, self-injurious and aggressive behaviour (McClintock, Hall & 
Oliver, 2003; Richards, Oliver, Nelson & Moss, 2012). ASD also has a negative impact upon 
carer stress and carer mental health (Griffith, Hastings, Nash & Hill, 2009; Olsson & Hwang 
2001). The national financial costs associated with idiopathic ASD in the UK are high, 
estimated at £2.7 and £25 billion a year for children and adults respectively (Knapp, Romeo & 
Beecham, 2009). It is likely that the human and economic costs of ASD in syndromes would 
be similar to those identified in idiopathic ASD and thus there is significant clinical incentive 
to delineate statistically the prevalence and phenomenology of ASD in individual syndromes.  
 
There are a number of methodological challenges to synthesising the prevalence literature for 
ASD phenomenology across syndromes. First, the diagnosis of ASD in clinical practice 
requires rigorous multi-component assessment. NICE clinical guidance for autism assessment 
(NICE, 2011) suggests that this should include: detailed questions about parent’s/carer’s 
concerns, and if appropriate the child’s concerns; details of the child’s experiences of home 
life, education and social care; a developmental history; assessment through interaction and 
observation with the child; a medical history; a physical examination and exclusion of 
numerous differential diagnoses. This depth and breadth of diagnostic assessment is rarely 
replicated in research, and thus any prevalence estimates may be more accurately described as 
estimates of the presence of ASD phenomenology, rather than estimates of the presence of 
diagnostically defined ASD. This caveat must be considered when extrapolating from data in 
order to inform clinical and educational service provision. 
 
An additional methodological issue concerns the wide variation in the mode and psychometric 
properties of the assessment measures utilised. Many studies rely solely upon screening 
measures which confer time and resource advantages when attempting to measure ASD 
phenomenology across small and geographically widespread samples. However, screening 
measures often have low levels of specificity and sensitivity (Charman & Gotham, 2013; 
Chapter 1: A Meta-Analysis of ASD in Syndromes 
5 
 
Moss et al., 2011) and thus the prevalence data obtained have wide confidence intervals. 
Diagnostic measures have greater sensitivity and specificity, however, the resultant 
prevalence data may still be biased as accuracy for ASD assessments is lowest for marginal or 
unusual cases, such as those with intellectual disability and/or syndromes (Charman & 
Gotham, 2013). Therefore, the differing limitations of the assessment methodologies must be 
taken into account when attempting to synthesise prevalence literature within and between 
syndromes, when varying assessments may have been employed.  
 
Despite the challenges and complexities outlined above, the need to inform service provision 
for syndromes, address the question of similarities and differences from idiopathic ASD and 
to contribute to an understanding of the gene, brain, cognition, behaviour pathways implicated 
in idiopathic ASD remains. The present meta-analysis will describe and evaluate the literature 
estimating the prevalence of ASD phenomenology in genetic and metabolic syndromes in 
order to: 
i. generate pooled prevalence estimates for ASD phenomenology within each syndrome, 
weighted by the quantity and quality of the available evidence; 
ii. conduct preliminary comparisons of the pooled prevalence estimates across 
syndromes; 
iii. compare pooled prevalence estimates in the syndromes to prevalence estimates of 
ASD phenomenology in the general population
2
. 
 
 
 
 
                                                 
2
 It could be argued that comparison to the prevalence of ASD phenomenology in populations with intellectual 
disability would provide a more useful contrast, than the general population.  However, it was felt that a 
comparison to the general population was methodologically and clinically warranted. Estimates of the 
prevalence of ASD phenomenology in individuals with heterogeneous intellectual disability would inevitably 
include individuals with the syndromes being investigated in the present study, and thus any statistical 
comparisons would be compromised by the inadvertent inclusion of these individuals.  Additionally, comparison 
to those with intellectual disability would minimise the purported heightened probability of ASD in these 
syndromes, which undermines the aim of this paper to inform service provision and planning.  
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1.3 Methods 
1.3.1 Search Strategy 
In order to focus the literature search on syndromes that were most likely to be associated 
with ASD phenomenology, a list of syndromes to be investigated was generated from a recent 
review of ASD phenomenology in syndromes (Moss & Howlin, 2009
3
). This resulted in 21 
syndromes being selected for review. 
 
Literature searches were conducted in Ovid PsycINFO, Ovid MEDLINE, Ovid Embase and 
PubMed Central. A list of the syndrome groups, search dates, inclusion dates and search 
terms are displayed in Table 1.1. Searches were conducted by combining all variations of the 
syndrome search terms with autism search terms. The autism search terms included: Autis*, 
Autism*, Autistic*, ASD, Autism spectrum disorder*, PDD-NOS, PDDNOS, Unspecified 
PDD, Pervasive developmental disorder*, Pervasive developmental disorder not otherwise 
specified, Asperger*, Asperger* syndrome. In addition, a hand search of the references from 
Moss and Howlin (2009) was conducted and any identified papers were included alongside 
those from the literature searches.  
 
 
                                                 
3
 Moss and Howlin (2009) identified these syndromes through inspection of previous systematic reviews which 
had noted associations between ASD phenomenology and genetic and metabolic syndromes (Gillberg & 
Coleman, 2000; Fombonne, 1999). Moss and Howlin (2009) focused their review upon the seven syndromes in 
which ASD had been most frequently reported or where five or more papers had been published. However, in 
order to broaden the scope of this review, the full 21 syndromes in which associations with ASD phenomenology 
had initially been reported, were entered into the literature search.   
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Table 1.1. Syndrome groups, search details and search terms. 
 PsycINFO MEDLINE Embase PubMed Central 
Search terms  
 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Fragile X 
syndrome 
(FraX) 
14/03/14 
1967 to 
March Week 
2 2014 
14/03/14 
1946 to 
March week 
1 2014 
14/03/14 
1974 to 2014 
Week 10 
30/03/14 
1950 to 30
th
 
March 2014 
Fragile X; Fragile-X; Fragile X 
syndrome; FXS; FRAXA 
syndrome; AFRAX; Martin-Bell* 
syndrome; Marker X syndrome; 
fraX syndrome; fra(X) syndrome; 
X-linked mental retardation; 
Macroorchidism; Escalante* 
syndrome; Escalante* 
          
Tuberous 
Sclerosis 
Complex 
(TSC) 
15/04/14 
1967 to 
April Week 
2 2014 
15/04/14 
1946 to 
April week 1 
2014 
15/04/14 
1974 to 2014 
Week 15 
30/03/14 
1950 to 30
th
 
March 2014 
Tuberous sclerosis; Tuberous 
sclerosis syndrome; Bourneville* 
disease; Bourneville* 
phakomatosis; Cerebral sclerosis; 
Cerebral sclerosis syndrome; 
Epiloia; Sclerosis tuberose; 
Tuberose sclerosis; Tuberose 
sclerosis syndrome; Tuberous 
sclerosis complex; TSC; TSS 
          
Rett’s syndrome 
(Rett) 
28/04/14 
1967 to 
April Week 
4 2014 
28/04/14 
1946 to 
April week 3 
2014 
28/04/14 
1974 to 2014 
Week 17 
30/03/14 
1950 to 30
th
 
March 2014 
Rett*; Rett* syndrome; Rett* 
disorder; RTS; RTT; 
Cerebroatrophic hyperammonemia; 
Autism-dementia-ataxia-loss of 
purposeful hand use syndrome 
          
Down syndrome 
(DS) 
01/04/14 
1967 to 
March Week 
4 2014 
01/04/14 
1946 to 
March week 
3 2014 
01/04/14 
1974 to 2014 
Week 13 
30/03/14 
1950 to 30
th
 
March 2014 
Down*; Down* syndrome; 
Trisomy 21; Trisomy G; 
47,XX,+21; 47,XY,+2 
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4
 Both Neurofibromatosis type 1 and type 2 were included in the literature search, however only papers concerning NF1 met the inclusion criteria for review 
 PsycINFO MEDLINE Embase PubMed Central 
Search terms  
 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Phenylketonuria 
syndrome 
(PKU) 
30/04/14 
1967 to 
April week 4 
2014 
30/04/14 
1946 to 
April Week 
3 2014 
30/04/14 
1974 to 2014 
Week 17 
30/03/14 
1950 to 30
th
 
March 2014 
Phenylketonuria; Phenylalanine 
hydroxylase; Folling* disease; 
Folling* syndrome; PAH 
deficiency; PAH deficiency 
disease; Phenylalanine hydroxylase 
deficiency disease; Phenylalanine 
hydroxylase deficiency; PKU; 
Oligophrenia phenylpyruvica; 
Deficiency Disease, Phenylalanine 
Hydroxylase 
          
CHARGE 
syndrome 
(CHARGE) 
11/04/14 
1967 to 
April Week 
2 2014 
11/04/14 
1946 to 
April week 1 
2014 
11/04/14 
1974 to 2014 
Week 14 
25/06/14 
1950 to 25
th
 
June 2014 
CHARGE; CHARGE syndrome; 
CHARGE association; Hall-
Hittner* syndrome; Hall* Hittner* 
syndrome 
          
Angelman 
syndrome 
(AS) 
30/03/14 
1967 to 
March Week 
4 2014 
30/03/14 
1946 to 
March week 
3 2014 
30/03/14 
1974 to 2014 
Week 13 
30/03/14 
1950 to 30
th
 
March 2014 
Angelman*; Angelman* syndrome; 
AS; Happy puppet syndrome; 
Happy puppet 
          
Neurofibromatosis 
Type 1 
(NF1)
4
 
 
30/04/14 
 
 
1967 to 
April week 4 
2014 
 
 
30/04/14 
 
 
1946 to 
April Week 
3 2014 
 
 
30/04/14 
 
 
1974 to 2014 
Week 17 
 
 
25/04/14 
 
 
1950 to 25
th
 
April 2014 
 
 
Neurofibromatosis; 
Neurofibromatosis type 1; 
Neurofibromatosis 1; NF1; 
Peripheral Neurofibromatosis; 
Recklinghausen* disease; 
Neurofibromatosis type 2; 
Neurofibromatosis 2; NF2; Central 
neurofibromatosis; Bilateral 
acoustic neurofibromatosis; BANF; 
Familial acoustic neuromas 
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 PsycINFO MEDLINE Embase PubMed Central 
Search terms  
 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Joubert 
syndrome 
(JS) 
30/03/14 
1967 to 
March Week 
4 2014 
30/03/14 
1946 to 
March week 
3 2014 
30/03/14 
1974 to 2014 
Week 13 
09/04/14 
1950 to 9
th
  
April 2014 
Joubert*; Joubert* syndrome; 
Joubert-Bolthauser* syndrome; 
JBTS; Cerebello-oculo-renal 
syndrome; Cerebello-oculo-renal 
syndrome 1; Cerebellooculorenal 
syndrome 1; Cerebellooculorenal 
syndrome; CORS; CORS1; 
Cerebellar vermis agenesis; 
Cerebelloparenchymal disorder 4; 
Cerebelloparenchymal disorder; 
CPD; CPD4; Familial aplasia of the 
vermis 
          
William’s 
syndrome 
(WS) 
30/03/14 
1967 to 
March Week 
4 2014 
30/03/14 
1946 to 
March week 
3 2014 
30/03/14 
1974 to 2014 
Week 13 
25/06/14 
1950 to 25
th
 
June 2014 
William*; William* syndrome; 
Beuren* syndrome; Elfin Facies 
syndrome; Hypercalcemia-
Supravalvar Aortic Stenosis; 
Infantile hypercalcemia; 
Supravalvar aortic stenosis 
syndrome; WBS; Williams-
Beuren* syndrome; WMS; WS 
          
Goldenhar 
syndrome 
(GS) 
30/04/14 
1967 to 
April week 4 
2014 
30/04/14 
1946 to 
April Week 
3 2014 
30/04/14 
1974 to 2014 
Week 17 
25/04/14 
1950 to 25
th
 
June 2014 
Goldenhar*; Goldenhar* syndrome; 
Oculoauriculovertebral spectrum; 
Oculoauriculovertebral syndrome; 
Oculoauriculovertebral dysplasia; 
OAV; OAVD; OAVS; Oculo-
Auriculo-Vertebral syndrome; 
Oculo-Auriculo-Vertebral 
spectrum; Oculo-Auriculo-
Vertebral dysplasia; Brachial arch 
syndrome; Facioauriculovertebral 
syndrome; FAV;  FAVS; Lateral 
facial dysplasia 
 
Chapter 1: A Meta-Analysis of ASD in Syndromes 
10 
 
 PsycINFO MEDLINE Embase PubMed Central 
Search terms  
 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Hypomelanosis 
of Ito syndrome 
(HoI) 
30/04/14 
1967 to 
April week 4 
2014 
30/04/14 
1946 to 
April Week 
3 2014 
30/04/14 
1974 to 2014 
Week 17 
09/04/14 
1950 to 9
th
  
April 2014 
Hypomelanosis of Ito; Ito 
hypomelanosis; Incontinentia 
pigmentosa achromians; Ito 
syndrome; ITO; IPA; HMI 
          
Noonan 
syndrome 
(Noonan) 
30/04/14 
1967 to 
April week 4 
2014 
30/04/14 
1946 to 
April Week 
3 2014 
30/04/14 
1974 to 2014 
Week 17 
25/04/14 
1950 to 25
th
  
April 2014 
Noonan*; Noonan* syndrome; 
Nunan*; Nunan* syndrome; 
Familial Turner* syndrome; Female 
pseudo-Turner syndrome; Male 
Turner* syndrome; Noonan-
Ehmke* syndrome; Nunan-Ehmke* 
syndrome; Pseudo-Ullrich-Turner* 
syndrome; Turner-like syndrome; 
Ullrich-Noonan* syndrome; 
Ullrich-Nunan* syndrome; Turner* 
phenotype, karyotype normal; 
Turner syndrome in female with X 
chromosome 
          
Sotos syndrome 
(Sotos) 
28/03/14 
1967 to 
March Week 
4 2014 
28/03/14 
1946 to 
March week 
3 2014 
28/03/14 
1974 to 2014 
Week 12 
09/04/14 
1950 to 9
th
  
April 2014 
Sotos*; Sotos* syndrome; Cerebral 
gigantism; Sotos* sequence 
          
Leber’s  
Amaurosis 
syndrome 
(Leber's) 
12/03/14 
1967 to 
March Week 
1 2014 
12/03/14 
1946 to 
February 
Week 4 
2014 
12/03/14 
1974 to 2014 
Week 10 
05/05/14 
1950 to 5
th
 
May 2014 
Leber* amaurosis; Leber* 
congenital amaurosis; LCA; 
Congenital retinal blindness; CRB; 
Dysgenesis neuroepithelialis 
retinae; Hereditary epithelial 
dysplasia of retina; Hereditary 
retinal aplasia; Heredoretinopathia 
congenitalis; Leber* abiotrophy; 
Leber* congenital tapetoretinal 
degeneration 
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 PsycINFO MEDLINE Embase PubMed Central 
Search terms  
 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
22q11.2 deletion 
syndrome 
(22q11.2) 
 
24/04/14 
 
 
1967 to 
April Week 
4 2014 
 
 
24/04/14 
 
 
1946 to 
April week 3 
2014 
 
 
24/04/14 
 
 
1974 to 2014 
Week 17 
 
 
25/04/14 
 
 
1950 to 25
th
  
April 2014 
 
 
VCF; VCFS; Velocardiofacial 
syndrome;  CTAF; Velo-cardio-
facial syndrome; DiGeorge* 
syndrome; Conotruncal anomaly 
face syndrome;  CATCH22; 
Autosomal dominant Opitz G/BBB 
syndrome; Autosomal dominant 
Opitz G BBB syndrome; Cayler 
cardiofacial syndrome; Deletion 
22q11/2 syndrome; 22q11/2 
deletion syndrome; 22q11/2DS; 
22q11 deletion syndrome; 
Sedlackova* syndrome; 
Shprintzen* syndrome 
          
Cohen syndrome 
(Cohen) 
27/02/14 
1967 to 
February 
Week 3 
2014 
27/02/14 
1946 to 
February 
Week 3 
2014 
27/02/14 
1974 to 2014 
Week 08 
09/04/14 
1950 to 9
th
  
April 2014 
Cohen* syndrome; Norio* 
syndrome; Obesity-hypotonia 
syndrome; Pepper* syndrome; 
Prominent incisors-obesity-
hypotonia syndrome; Hypotonia 
obesity and prominent incisors 
          
Cornelia de 
Lange syndrome 
(CdLS) 
26/02/14 
1967 to 
February 
Week 3 
2014 
26/02/14 
1946 to 
February 
Week 2 
2014 
26/02/14 
1974 to 2014 
Week 08 
09/04/14 
1950 to 9
th
  
April 2014 
Cornelia de Lange* syndrome; 
CDLS; De Lange* syndrome; 
Branchmann-De Lange* syndrome; 
BDLS; Brachmann* syndrome; 
Amstelodamensis typus 
degenerativus; Amsterdam dwarf 
syndrome; Amsterdam dwarfism 
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 PsycINFO MEDLINE Embase PubMed Central 
Search terms  
 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Date 
searched 
Inclusion 
dates 
Ehlers-Danlos 
syndrome 
(EDS) 
11/03/14 
1967 to 
March Week 
1 2014 
11/03/14 
1946 to 
February 
Week 4 
2014 
11/03/14 
1974 to 2014 
Week 10 
05/05/14 
1950 to 5
th
 
May 2014 
Ehlers-Danlos; Ehlers-Danlo*; 
Ehlers-Danlos syndrome; Ehlers-
Danlo* syndrome; EDS; Ehlers-
Danlos disease; Ehlers-Danlo* 
disease; Ehlers Danlos; Ehler* 
Danlo*; Ehlers Danlos syndrome; 
Ehler* Danlo* syndrome; Ehlers 
Danlos disease; Ehler* Danlo* 
disease; ED syndrome; vascular-
Ehler* Danlo* syndrome; vascular 
ehler* danlo* syndrome; vascular 
ehler* danlo*; vascular-Ehler* 
Danlo*; vEDS 
          
Lujan-Fryns 
syndrome 
(LFS) 
11/03/14 
1967 to 
March Week 
1 2014 
11/03/14 
1946 to 
February 
Week 4 
2014 
11/03/14 
1974 to 2014 
Week 10 
05/05/14 
1950 to 5
th
 
May 2014 
Lujan-Fryns*; Lujan-Fryn*; Lujan-
Fryns* syndrome; LFS; Lujan* 
syndrome; X-linked intellectual 
deficit with marfanoid habitus; X-
linked intellectual deficit with 
marfanoid features; X-linked 
mental retardation with marfanoid 
features; X-linked mental 
retardation with marfanoid habitus; 
XLMR with marfanoid features; 
XLMR with marfanoid habitus 
          
Moebius 
syndrome 
(Moebius) 
 
04/03/14 
 
1967 to 
February 
Week 3 
2014 
 
04/03/14 
 
1946 to 
February 
Week 3 
2014 
 
04/03/14 
 
1974 to 2014 
Week 09 
 
05/05/14 
 
1950 to 5
th
 
May 2014 
 
Moebius*; Mobius*; Moebius* 
syndrome; Mobius* syndrome; 
Moebius* spectrum; Mobius* 
spectrum; Moebius* sequence; 
Mobius* sequence; Congenital facial 
diplegia; Congenital ophthalmoplegia 
and facial paresis; Moebius* congenital 
oculofacial paralysis; Mobius* 
congenital oculofacial paralysis 
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1.3.2 Selection Strategy 
A total of 32,230 papers were identified by the searches. These papers were assessed for 
suitability using the following three stages.  
 
1.3.2.1 Stage 1: Screening 
Papers were screened by review of abstracts and titles. Table 1.2 outlines the inclusion and 
exclusion criteria used at this stage. For any papers where suitability was unclear a second 
researcher was asked to review the paper and consensus was derived. 
 
Table 1.2. Inclusion and exclusion criteria for screening. 
Inclusion Criteria Exclusion Criteria 
Empirical papers Conference proceedings, magazines, 
dissertations, review articles and books  
Papers published or available in English Papers published in a language other than 
English 
Abstract indicates that the paper reports on 
the prevalence of ASD within syndrome 
group 
Participants recruited because of a previous 
or suspected autism diagnosis 
Participant sample N≥10 Participant sample N<10 
 
1.3.2.2 Stage 2: Eligibility 
The full texts of the screened papers were then read to assess the eligibility of the data. The 
same inclusion and exclusion criteria were utilised at screening and eligibility. However, the 
following additional criteria were specified at the eligibility stage (see Table 1.3 for details).  
 
Table 1.3. Additional inclusion and exclusion criteria for eligibility assessment. 
Inclusion Criteria Exclusion Criteria 
The paper reports the number of participants 
in the syndrome group who met a clinical  
cut-off for ASD 
The paper only reports average scores on a 
measure of ASD phenomenology 
 
Participants were recruited without any 
specific bias 
Participants were recruited because they 
showed some additional feature e.g., self-
injury, seizures etc.  
Study reports on a unique sample (or a 
potentially overlapping sample, but the 
proportion of overlap cannot be readily 
determined) 
Study reports on exactly the same sample as 
reported in a previous study. 
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1.3.2.3 Stage 3: Quality 
The quality of the remaining papers was then assessed according to the quality criteria (see 
below, Section 1.3.3). Papers were included if they had a minimum quality weighting of 0.33, 
obtained over at least two of the quality criteria.  
 
Papers which met the criteria at each stage were included in the meta-analysis. However, if at 
any stage the number of papers remaining in a syndrome group was N<2, the group was 
removed from the analysis. The table presented below in Table 1.4, adapted from Moher, 
Liberati, Tetzlaff and Altman (2009) and Liberati et al. (2009) utilising the PRISMA model, 
outlines the number of papers excluded at each stage for each syndrome. 
 
1
 Syndrome group removed at this point as papers remaining in syndrome group was N<2 
2
 Sample N<10 
3
 Participants recruited or excluded due to a previous or suspected ASD diagnosis  
4
 Participants recruited because of additional features e.g., seizures, self-injury, pre-mutation of Fragile X etc.  
5
 Study did not report the prevalence of sample meeting clinical cut off for ASD 
6
 Paper is a review article and does not present any new data 
7
 Paper reported on the same sample as another paper 
8
 Study altered the scoring algorithms of the assessments 
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Table 1.4. Number of papers included and excluded at each stage of selection 
 
 
 
     
 
Records 
identified 
through 
database 
searching 
Records 
identified 
through 
hand 
searching 
Records 
after 
duplicates 
removed 
Number of 
papers 
screened 
Excluded 
Full text 
papers 
assessed 
for 
eligibility 
Excluded 
with 
reasons 
Papers 
assessed 
for 
quality 
Excluded 
Papers 
included in 
meta-
analysis 
FraX 5207 30 5211 5211 5110 101 42b, c, d, e, i
 
59 3 56 
TSC 2251 24 2256 2256 2218 38 12b, d, e, f, i
 
26 1 25 
22q11.2 1213 0 1213 1213 1195 18 4e
 
14 0 14 
CdLS 315 1 315 315 302 13 1e
 
12 0 12 
DS 8530 16 8536 8536 8511 25 14b, c, e 11 1 10 
AS 1898 7 1898 1898 1882 16 9e, f
 
7 0 7 
NF1 629 0 629 629 621 8 2e, f 6 0 6 
WS 4200 0 4200 4200 4189 11 5b, c, e
 
6 1 5 
Rett 2352 18 2356 2356 2330 26 21b, e, f,  i
 
5 0 5 
CHARGE 1086 8 1086 1086 1078 8 3g, h 5 1 4 
Moebius 63 0 63 63 49 14 10e, g
 
4 0 4 
PKU 292 7 292 292 283 9 5e, f
 
4 0 4 
Cohen 1944 0 1944 1944 1938 6 4e, f, i
 
2 0 2 
Noonan 359 0 359 359 356 2 0 2 0 2 
JS 452 0 452 452 448 4 2b, c 2 0 2 
HoI 532 0 532 532 529 3 0 3 2a --- 
GS 241 0 241 241 237 4 3a, g, h --- --- --- 
L-F 97 0 97 97 93 4 3a, f
 
--- --- --- 
Leber’s 254 1 254 254 252
 
2 1a, e --- --- --- 
Sotos 149 0 149 149 148a --- --- --- --- --- 
E-D 147 0 147 147 147a --- --- --- --- --- 
Total 32211 112 32230 32230 31916 312 141 168 9 158 
Included Quality Eligibility Screening Identification 
a
 Syndrome group removed at this point as papers remaining in syndrome group was N<2 
b
 Sample N<10 
c
 Participants recruited or excluded due to a previous or suspected ASD diagnosis  
d
 Participants recruited because of additional features e.g., seizures, self-injury, pre-mutation of Fragile X etc.  
e
 Study did not report the prevalence of sample meeting clinical cut off for ASD 
f
 Paper is a review article and does not present any new data 
g
 Paper reported on the same sample as another paper 
h
 Study altered the scoring algorithms of the assessments 
i
 Unable to obtain access to paper from either University of Birmingham Library or the British Library 
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1.3.3 Quality Review  
A numerical quality weighting for each study was generated through a quality review and the 
data were used to weight the influence of individual studies in the quality-effects pooled 
prevalence estimate for each syndrome. As this was the first statistical meta-analysis of ASD 
phenomenology in syndromes, a pragmatic decision was taken to delineate broad quality 
criteria that allowed for the maximum inclusion of studies, whilst weighting prevalence 
estimates more heavily by the most robust of these studies. This was particularly important 
due to the rarity of some of the genetic syndromes and the scarcity of research with these 
groups. 
 
The quality criteria were generated through reviewing standardised quality criteria for 
intervention studies (e.g., Downs & Black, 1998) and prevalence studies (Shamliyan et al., 
2011). In order to control for key threats to validity, idiosyncratic quality criteria were devised 
for: 1) the selection of the samples with syndromes, 2) the confirmation of syndrome and 3) 
the assessment of ASD. For each of these criteria, literature reviews were conducted and 
active research experts in the field of autism and rare syndromes were consulted for advice on 
areas of methodological concern. A full description of this process and justification of the 
assigned quality ratings is provided in Appendix A.  
 
Table 1.5 presents all three quality criteria. The criteria for each article were coded as red for 
a score of 0, yellow for a score of 1, amber for a score of 2 and green for a score of 3 to 
provide a simple visual matrix for the evidence quality for each genetic syndrome. The quality 
weighting was calculated by dividing the total quality score by the maximum possible total of 
nine. All studies which met the inclusion criteria were read by the first author and rated for 
quality using these criteria. In order to establish the reliability of these criteria, 31% (N = 52) 
of all studies were independently rated by a second researcher. Correlation coefficients for 
Sample identification (r(52) = 0.67, p <.001), Confirmation of syndrome (r(52) = 0.62, p 
<.001), ASD assessment (r52) = 0.86, p <.001) and total Quality weighting (r(52) = 0.78, p 
<.001) were all good.  
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Table 1.5. Quality Criteria for sample identification, confirmation of syndrome and ASD assessment. 
 Quality Rating 
 0 
Poor 
1 
Adequate 
2 
Good 
3 
Excellent 
     
Sample Identification Not specified/reported 
Single restricted or non-
random sample e.g., a 
specialist clinic or 
previous research study
5
 
 
Single regional sample 
e.g., a regional parent 
support groups 
Multiple restricted or non-
random samples e.g., 
multi-region specialist 
clinics 
 
National non-random 
sampling e.g., national 
parent support groups 
Random or total 
population sample 
     
Confirmation of 
syndrome 
Not confirmed/reported 
 
Clinical diagnosis only 
suspected  
Clinical diagnosis by 
‘generalist’ e.g., General 
Practitioner or 
Paediatrician 
Clinical diagnosis by 
‘expert’ e.g., Clinical 
Geneticist or Specialist 
Paediatrician 
Molecular/Cytogentic/ 
Metabolic confirmation of 
diagnosis
6
 
     
ASD assessment 
Not specified/reported 
 
Clinician judgement only  
Screening instrument e.g., 
SCQ, M-CHAT 
 
Clinician judgement 
against specified 
diagnostic criteria e.g., 
DSM-IV or ICD-10 
Diagnostic instrument 
e.g., ADI-R, DISCO, 
ADOS, 3Di 
 
Consensus from multiple 
assessments, including at 
least one diagnostic 
instrument 
  
                                                 
5
 For individuals recruited as part of a larger ongoing study, if the recruitment strategy is described, it is coded. If not, it is coded as 1, indicating the sample has come from 
one source (i.e., the larger ongoing study). 
6
 For syndromes where genetic causes are only currently identified for a proportion of cases (e.g., in CdLS, the NIP-BL gene deletion is thought to account for only 50% of 
cases), the study will receive a score of 3 if they tested all participants, even if all participants did not evidence the genetic marker and were subsequently confirmed through 
clinical assessment of features.  
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1.3.4 Data analysis 
In order to describe the prevalence of ASD phenomenology in each syndrome, the number 
and percentage of the samples meeting clinical cut-off
7
 for ASD phenomenology were 
extracted from each paper. These data were analysed using MetaXL 2.0 (Barendregt & Doi, 
2011) to generate pooled prevalence estimates. Fixed-effects models of pooled prevalence 
assume that the differences in the prevalence estimates between studies are simply a function 
of sampling error (Barendregt & Doi, 2011), and that there is a common true effect across 
studies. Given the significant heterogeneity in the extracted prevalence rates within and 
between syndromes, a random-effects model was felt to be more appropriate. The random-
effects model assumes two sources of variability; one from sampling error and one from study 
level differences, and controls for these in the weighting assigned to each study.  However, 
the random-effects model does not allow or control for variability that arises due to 
differences in the quality or execution inherent in the studies. Therefore, a quality-effects 
model was also generated, in which the quality weighting derived through the quality review 
process was used to weight the prevalence estimates.  
 
In order to make comparisons across syndromes, the random-effects and quality-effects 
pooled prevalence estimates for each group were plotted against one another. Relative risk 
statistics using 99
8
% confidence intervals were then calculated to evaluate the relative 
likelihood of ASD phenomenology in each syndrome utilising the quality-effects prevalence.  
 
Finally, in order to compare ASD phenomenology in each syndrome with an estimated 
prevalence in the general population, odds ratios with 95% confidence intervals were 
generated, comparing the quality-effects pooled prevalence for each syndrome with the most 
recent total population prevalence estimate for ASD diagnosis (1 in 68; Center for Disease 
Control, 2014). Whilst this total population prevalence estimate of ASD diagnosis is 
significantly higher than previous estimates, it was felt to be the most appropriate comparison 
for meta-analysis, as any identified increased likelihood of ASD phenomenology in the 
syndrome groups could not be attributed to overly conservative estimates for the general 
population prevalence. 
                                                 
7
 The clinical cut-off varied for each measure of ASD assessment used. Where an assessment provided multiple 
cut-offs (e.g., PDD-NOS vs autistic disorder), the most conservative cut off, requiring the highest level of ASD 
phenomenology was entered into the meta-analysis. 
8
 More conservative confidence intervals were selected due to the large number of relative risk calculations 
performed. 
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1.4 Results  
1.4.1 Identified papers 
A total of 168 papers were identified as suitable for review, across 16
9
 syndromes. In order to 
assess the first aim of the meta-analysis, each study was evaluated against the quality criteria, 
and data describing the study, sample characteristics and prevalence of ASD phenomenology 
were extracted. These data were then analysed to generate pooled prevalence estimates. The 
results for each syndrome are presented below with a brief summary of the evidence carrying 
capacity of each literature. The syndromes are presented in order of the size of the evidence 
base, beginning with the syndrome with the largest number of included papers, through to the 
syndrome with the least number of included papers. 
 
Across all syndromes, only nine (5.4%) papers met criteria for the highest quality rating for 
Sample Identification, whereas 89 (53.0%) obtained the highest quality rating for Syndrome 
Confirmation and 43 (25.6%) for ASD Assessment. Only one (0.6%) paper met the highest 
quality rating for all three quality criterion. Nine (5.4%) papers were excluded from the 
pooled prevalence estimates as they did not meet the required quality inclusion criteria. In 
total, 54 (32.1%) papers reported on the profile of ASD phenomenology within the syndrome, 
in addition to reporting the prevalence. The majority of papers (N=91, 54.1%) reported the 
proportion of the sample that had an intellectual disability.  
 
1.4.2 Fragile X syndrome 
The literature search identified 59
10
 papers that reported the prevalence of ASD 
phenomenology in Fragile X syndrome. These are presented in Table 1.6. It is notable that the 
quantity of research investigating or reporting ASD phenomenology in Fragile X syndrome 
far outweighs the quantity identified for all other syndrome groups. Whilst the quality of the 
identified papers was variable (quality weightings ranging from 0.11 to 1.00), the large 
number of higher quality papers included in the meta-analysis for Fragile X syndrome means 
that the resultant prevalence estimates can be considered to be relatively robust.  Confirmation 
                                                 
9
 Given the large number of identified papers and syndromes, it is beyond the scope of this review to provide a 
summary of the genetic, clinical and behavioural phenotypes of each syndrome in relation to the ASD 
phenomenology. Readers are directed towards Moss & Howlin, 2009, Moss et al., 2011, Zafeiriou et al., 2007 
and Zafeiriou et al., 2013 for further helpful reviews. 
10
 Two further papers met the initial screening criteria; however it was not possible to obtain these papers from 
either University of Birmingham Library or the British Library. 
Chapter 1: A Meta-Analysis of ASD in Syndromes 
20 
 
of Fragile X syndrome was undertaken and reported well across the studies, with 50 papers 
using genetic testing to confirm the diagnosis. However, only 15 studies obtained the 
maximum quality rating for ASD assessment, and only one study obtained the maximum for 
sample identification. A total of 20 papers provided data on the profile of ASD in Fragile X 
syndrome. These may provide sufficient data for future fine-grained meta-analysis of the 
profile of ASD phenomenology in the syndrome. 
 
The study by Bailey, Raspa, Olmsted and Holiday (2008) is notable in presenting data on a 
very large sample with genetically confirmed Fragile X syndrome (N=1235). The sampling 
strategy used in this study also received a good rating, suggesting that the prevalence data 
obtained in this large scale study were obtained in a representative sample. The data are 
limited by reliance on parental report rather than direct assessment. However, this 
methodological decision is understandable with such a large sample. A number of additional 
studies with very high quality weightings were identified (Hall et al., 2010; McDuffie, Kover, 
Abbeduto, Lewis & Brown, 2012; McDuffie, Thurman, Hagerman & Abbeduto, 2014;  
Philofsky, Hepburn, Hayes, Hagerman & Rogers, 2004; Pierpont, Richmond, Abbeduto, 
Kover & Brown, 2011; Scambler, Hepburn, Hagerman & Rogers, 2007; Wolff, Hazlett, 
Lightbody, Reiss & Piven, 2013). All of these studies measured ASD phenomenology using 
clinical consensus of diagnostic measure and at least one other tool and confirmed Fragile X 
syndrome genetically. The inclusion of these studies further strengthens the pooled prevalence 
estimates. In total, three papers were excluded from the statistical meta-analysis as they did 
not meet the pre-defined quality inclusion criteria. The first of these was a very large study 
conducted by Bailey and colleagues (2012) reporting medication use in Fragile X syndrome. 
Whilst the sampling strategy employed was good, the study did not report confirmation of 
Fragile X syndrome, and relied upon parental report of treatment for ASD. Secondly, the 
study by Partington (1984) was excluded as it did not meet minimum quality ratings on any of 
the three criteria. However, it is a notable study as it is one of the first descriptions of atypical 
social interaction and communication in Fragile X syndrome. Additionally, the study by 
Cohen (1995) was excluded as it did not meet the minimum quality criteria for Sample 
Identification or Confirmation of Fragile X syndrome. 
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Table 1.6. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in Fragile X 
syndrome. 
 
Quality 
Criteria 
Fragile X Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD Measure 
Professional
11
  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Alanay et al., 2007 
   
24 100.0 Not reported 79.1 Genetic DSM-IV Not reported No PDD-NOS: 32.0 
32.0 
(7) 
0.56    
   
Bailey et al., 2001 
   
55 100.0 
58.5
12
 
24.0 – 94.0 
Not 
reported 
DNA analysis CARS
13
 
Trained 
researchers 
No 
Severe autism: 3.6 
Mild/mod autism: 21.8 
3.6 
(2) 
0.67    
   
Bailey et al., 1998 
   
57 100.0 
66.7
14
 
24.0 - 133 
Not 
reported 
DNA analysis CARS 
Trained 
researchers 
Yes 
Severe autism: 3.5 
Mild/mod autism: 21.1 
3.5 
(2) 
0.44    
   
Bailey et al., 2012 
   
1363 78.1 
 
33.8
15
 
 
Not 
reported 
Parental report 
Parental 
report 
N/A No 
      Diagnosed or  
treated for autism:~37.0 
37.0 
(504) 
0.22    
   
Bailey et al., 2008 
   
1235 79.0 Not reported 13.0 Genetic 
Parental 
report of 
diagnosis 
N/A No Autism: 5.0  
5.0 
(62) 
0.56    
   
                                                 
11
 Where interpretation of clinical criteria (e.g., DSM-III) or assessment results (e.g., ADOS; ADI-R) is necessary, data are reported (where given) on the profession or 
training of the person interpreting the assessments. 
12
 Age in months 
13
 Childhood Autism Rating Scale  
14
 Age in months 
15
 Ability rated as ‘poor’ 
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Quality 
Criteria 
Fragile X Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD Measure 
Professional
11
  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Baranek et al., 2005 
   
11 90.9 
49.0
16
 
(22.0) 
Mild ID
17
 DNA analysis CARS Not reported No Autism: 27.3 
27.3 
(3) 
0.56    
   
Borghgraef et al., 1987 
   
23 100.0 2.5 – 11.9 100.0 Cytogenetic Autiscale N/A No 
Moderate autism: 30.4 
Slight autism: 8.7  
30.4 
(7) 
0.56    
   
Bregman et al., 1988 
   
14 100.0 
 
3.0 – 27.0 
 
52.0
18
 Cytogenetic 
ABC
19
 
DSM-III 
Experienced 
Child and 
Adolescent 
Psychiatrists 
No Infantile autism: 7.1  
7.1 
(1) 
0.56    
   
Chonchaiya et al., 2010 
   
61
20
 60.7 
9.61 
(5.59) 
1.5 – 24.0 
62.75
21
 
Cytogenetic 
ADOS
22
 
ADI-R
23
 
Team 
consensus 
No 
Autism: 36.1 
PDD-NOS: 26.2  
33.5 
(53) 
0.67    
97 78.4 
9.41 
(6.31) 
0.9 – 25.2 
60.80 
Autism: 32.0 
PDD-NOS: 25.8    
 
 
              
                                                 
16
 Age in months 
17
 Average classification for group using the Batelle Developmental Inventory 
18
 Mean IQ score 
19
 Autism Behavior Checklist 
20
 The results of this study were presented in two groups; those whose mother’s had experienced an autoimmune disease (top), and those who had not (bottom). 
21
 Mean full scale IQ 
22
 Autism Diagnostic Observation Schedule 
23
 Autism Diagnostic Interview - Revised 
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Quality 
Criteria 
Fragile X Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD Measure 
Professional
11
  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
 
Cianchetti et al., 1991 
   
36 100.0 
36.2 
7.0 – 78.0 
68.5
24
 Cytogenetic 
ADI 
DSM-III-R 
ICD-10 
Examiners No Autism: 5.6  
5.6 
(2) 
0.78    
   
Clifford et al., 2007 
   
64
25
 51.6 
23.2 
5.8 – 60.7 
Not 
reported 
for full 
sample 
DNA analysis 
SCQ
26
 
ADOS 
ADI-R 
Not reported Yes 
 SCQ ASD: 46.9 
ADOS autism: 10.9  
ADOS ASD: 15.6  
ADI-R autism: 10.9  
Consensus autism: 14.1  
 
14.1 
(9) 
0.78    
   
Cohen, 1995 
   
109 100.0 
 
1.9 - 51 
 
Not 
reported 
Not reported DSM-III-R Not reported No Autism: 27.5  
27.5 
(30) 
0.11    
   
Cordeiro et al., 2011 
   
97 59.8 
12.8 
(5.8) 
5.0 – 33.3 
58.0 DNA analysis 
ADOS-G
27
 
ADI-R 
DSM-IV 
Team 
consensus; 
trained 
clinician 
No 
Autism: 28.9 
ASD: 20.0 
28.9 
(28) 
0.78    
   
Demark et al., 2003 
   
15 80.0 
11.8 
(2.6) 
100.0 DNA analysis CARS 
Trained 
assessor 
No 
Mild/mod autism: 46.7 
Severe autism: 6.7  
6.7 
(1) 
0.56    
   
               
                                                 
24
 Mean IQ score 
25
 Study also presented data on permutation carriers; only data on cases with full mutation presented here. 
26
 Social Communication Questionnaire 
27
 Autism Diagnostic Observation Schedule - Generic 
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Quality 
Criteria 
Fragile X Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD Measure 
Professional
11
  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Einfeld et al., 1989 
   
45 80.0 
 
12.6 
2.0 – 42.0 
 
56.0
28
 Cytogenetic DSM-III-R 
Child 
Psychiatrist 
Yes Autism: 8.9  
8.9 
(4) 
0.67    
   
Flenthrope & Brady, 
2010 
   
25 84.0 
27.0
29
 
(7.1) 
15.0 – 40.0 
Not 
reported 
Not reported CARS Not reported No Mild/mod autism: 64.0 
64.0 
(16) 
0.33    
   
Frankland et al., 2004 
   
10 100.0 13.2 50.2
30
 Not reported ASQ
31
 N/A No Autism: 40.0 
40.0 
(4) 
0.33    
   
Fryns et al., 1984 
   
21 100.0 2.0 – 21.0 100.0 
Human 
genetics 
department 
Not 
reported 
Not reported No Autism: 14.3  
14.3 
(3) 
0.33    
   
Gabis et al., 2011 
   
28 82.1 14.2 
Not 
reported 
DNA analysis 
Screening 
Measure
32
 
N/A No 
    Autism/schizoid 
personality: 31.8 
31.8 
(7) 
0.67    
   
                                                 
28
 Mean IQ score 
29
 Age in months 
30
 Mean IQ score 
31
 Autism Screening Questionnaire 
32
 Early Childhood Inventory-4 Screening Manual, Child Symptom Inventory-4 Screening and Norms Manual, or Adolescent Symptom Inventory-4 Screening Manual 
(Screening measure selected dependent on age; all measures were translated into Hebrew) 
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Quality 
Criteria 
Fragile X Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD Measure 
Professional
11
  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Hagerman et al., 1986 
   
50 100.0 4.11 – 34.9 
Not 
reported 
Cytogenetic 
testing and 
clinical 
features 
DSM-III 
ABC 
N/A Yes 
DSM-III Infantile 
autism: 16.0  
ABC autism: 30.0  
16.0 
(8) 
0.56    
   
Hall et al., 2010 
   
120 60.8 
13.2
33
   13.5 
(3.3)    (4.6) 
5.0 – 24.0 
45.7
34
 
76.8 DNA analysis 
SCQ 
ADOS 
Trained 
researcher or 
clinician 
Yes 
SCQ ASD: 44.2 
ADOS autism:  21.7 
Consensus autism: 13.3 
13.3 
(16) 
0.89    
   
Hall et al.,2008 
   
60 51.7 
13.2
35
    13.1 
(3.2)    (3.9) 
5.0 – 20.0 
46.3
36
 
70.8 DNA analysis ADOS-G 
Trained 
experimenters 
Yes 
Autism: 36.7 
ASD: 60.0  
36.7 
(22) 
0.56    
   
Harris et al., 2008 
   
63 100.0 
7.9 
(4.3) 
2.8 – 19.5 
56.0
37
 DNA analysis 
ADOS 
ADI-R 
DSM-IV 
Trained 
researchers; 
team 
consensus 
Yes 
Autistic disorder: 30.2 
PDD-NOS: 30.2 
ASD: 60.3  
30.2 
(9) 
0.67    
   
Hatton et al., 2006 
   
179 82.1 
54.4
38
 
(33.9) 
Not 
reported 
DNA analysis CARS 
Trained data 
collectors 
No Mild/mod autism: 21.2 
21.2 
(38) 
0.56    
   
             
                                                 
33
 Mean age and SD are presented separately for male (left) and female (right) participants. 
34
 Mean IQ scores are presented separately for male (left) and female (right) participants 
35
 Mean age and SD are presented separately for male (left) and female (right) participants 
36
 Mean IQ scores are presented separately for male (left) and female (right) participants 
37
 Mean IQ score 
38
 Age in months 
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Quality 
Criteria 
Fragile X Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD Measure 
Professional
11
  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Hatton et al., 2003 
 
70 85.7 
75.7
39
 
(33.5) 
12.0 – 143.0 
Not 
reported 
DNA analysis CARS Not reported No Mild/mod autism: 64.3 
64.3 
(45) 
0.67    
 
Kaufmann et al., 2004 
   
56 100.0 57.1
40
 55.2
41
 DNA analysis 
ADI-R 
DSM-IV 
Two trained 
interviewers 
Yes 
Autistic disorder: 25.0 
PDD-NOS: 17.9 
ASD: 42.9 
25 
(14) 
0.78    
   
Ke et al., 2005 
   
12 83.0 2.0 – 7.0 
Not 
reported 
Chromosome 
studies 
CARS Not reported Yes Severe autism: ~ 8.0 
8.3 
(1) 
0.44    
   
Largo & Schinzel, 1985 
   
13 100.0 2.6 – 12.5 100.0 
Cytogenetic 
testing 
Develop-
mental and 
behavioural 
history 
Not reported No Autistic features: 69.2  
69.2 
(9) 
0.56    
   
Maes et al., 1993 
   
58 100.0 
41.0 
(13.1) 
21.0 – 67.0 
100.0 Genetic testing ABC N/A Yes Autism: 6.9  
6.9 
(4) 
0.67    
   
Mazzocco et al., 1997 
   
30 0.0 
10.7 
(3.2) 
6.1 – 16.2 
33.3 DNA analysis 
NDI
42
 
DSM-III 
Not reported Yes 
Autistic disorder: 3.3 
PDD-NOS: 17.0 
3.3 
(1) 
0.56    
   
               
                                                 
39
 Age in months 
40
 Age in  months 
41
 Mean IQ score 
42
 Neuropsychicatric Developmental Interview 
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Quality 
Criteria 
Fragile X Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD Measure 
Professional
11
  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
McDuffie et al., 2010 
   
51 68.6 10.0 – 16.0 
Not 
reported 
Molecular 
genetic testing 
ADI-R 
Research-
reliable 
examiners 
Yes Autism: 47.1 
47.1 
(24) 
0.78    
   
McDuffie et al., 2012 
   
34 100.0 
13.0 
(1.7) 
45.6
43
 
Molecular 
genetic testing 
ADI-R 
ADOS 
Research-
reliable 
examiners 
No  Both Autism: 47.1  
47.1 
(16) 
0.89    
   
McDuffie et al., 2014 
   
49 100.0 
7.5 
(2.0) 
57.9
44
 Genetic testing 
ADI-R 
ADOS 
Research 
reliable staff 
Yes Both autism: 81.6 
81.6 
(40) 
0.89    
   
Moss et al., 2013a 
   
177 100.0 
16.9 
(8.8) 
4.0 – 40.0 
Not 
reported 
Physician/ 
Paediatrician/ 
Geneticist 
SCQ N/A Yes 
Autism: 45.6  
ASD: 83.6  
48.6 
(86) 
0.44    
   
Oliver et al., 2011 
   
191 100.0 
16.6 
(8.8) 
4.0 – 47.0 
9.9
45
 
Physician/ 
Paediatrician/ 
Geneticist 
SCQ N/A Yes 
Autism: 46.3 
ASD: 83.6  
46.3 
(82) 
0.44    
   
Ornstein et al., 2008 
   
42 100.0 
129.3 
(18.7) 
53.4
46
 DNA analysis CARS Not reported No Mild/mod autism: 23.8 
23.8 
(10) 
0.56    
   
               
                                                 
43
 Mean IQ score 
44
 Mean non-verbal IQ 
45
 Defined as not able on the Wessex 
46
 Mean IQ score 
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Quality 
Criteria 
Fragile X Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD Measure 
Professional
11
  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Partington, 1984 
   
61 100.0 2.0 – 59.0 100.0 Not reported 
Clinical 
examination 
Psychiatrists No Autism: 4.9 
4.9 
(3) 
0.00    
   
Philofsky et al., 2004 
   
18 100.0 26.0 – 45.0
47
 
Not 
reported 
Molecular 
genetic testing 
DSM-IV 
ADOS 
ADI-R 
Psychologist 
with expertise 
in autism 
Yes Consensus autism: 44.4 
44.4 
(8) 
0.89    
   
Pierpont et al., 2011 
   
44 68.2 
12.6 
(1.8) 
10.0 – 16.0 
46.0
48
 
66.9 
Molecular 
genetic testing 
ADOS 
ADI-R 
Research 
reliable 
examiner 
No Both autism: 25.0 
25.0 
(11) 
0.89    
   
Reiss & Freund, 1990 
   
17 100.0 
11.0 
3.0 – 24.0 
50.0
49
 
Cytogenetic 
testing 
NDI 
DSM-III-R 
Trained 
research 
assistant or 
Child 
Psychiatrist 
Yes 
Autistic disorder: 17.6 
PDD-NOS: 41.2   
17.6 
(3) 
0.56    
   
Roberts et al., 2009a 
   
55 100.0 8.0 – 48.0 
Not 
reported 
Genetic report CARS 
Consensus of 
two examiners 
No Mild-severe autism:~31  
30.9 
(~17) 
0.56    
   
 
 
 
               
                                                 
47
 Age range in months 
48
 Non-verbal mean IQ, reported separately for males (left) and females (right) 
49
 Mean IQ score 
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Quality 
Criteria 
Fragile X Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD Measure 
Professional
11
  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Roberts et al., 2009b 
   
51 100.0 4.0
50
 8.1 
Not 
reported 
DNA analysis CARS 
Examiner 
consensus 
No Mild/Mod autism: 35.3  
35.3 
(18) 
0.67    
   
Roberts et al., 2001 
   
39 100.0 
57.3
51
 
(15.9) 
20.6 – 86.1 
Not 
reported 
DNA analysis CARS Examiner No Mild/Mod autism: 20.5 
20.5 
(8) 
0.67    
   
Roberts et al., 2007 
   
86 100.0
52
 
79.4
53
 
(52.11) 
53.37
54
 DNA analysis CARS 
Examiner 
consensus 
No Mild/mod autism: 32.6 
32.6 
(28) 
0.56    
   
Rogers et al., 2001 
   
24 95.8 
 
35.1
55
 
(7.1) 
 
Not 
reported 
DNA testing 
ADI-R 
ADOS-G 
DSM-IV 
Reliable 
trained raters 
Yes 
Autism: 33.3 
PDD: 16.7  
33.3 
(8) 
0.89    
   
 
 
 
 
              
                                                 
50
 Age reported in two groups; those who scored below the CARS threshold (left) and those who scored above the threshold (right) 
51
 Age in months 
52
 The study also presents data on a sample of females with Fragile X syndrome; however, the data regarding the prevalence of ASD phenomenology in the female sample is 
not reported, therefore only data on the male sample is presented here. 
53
 Age in months 
54
 Mean non-verbal IQ 
55
 Age in months 
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Quality 
Criteria 
Fragile X Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD Measure 
Professional
11
  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Sabaratnam et al., 2003 
   
23 95.7 
37.5 
(22.2) 
6.0 – 76.0 
Not 
reported 
Cytogenetic 
DSM-III 
B-DAS
56
 
HBS
57
 
Not reported No 
Autistic disorder: 0.0
58
 
PDD-NOS: 17.4  
0.0 
(0) 
0.78    
   
Scambler et al., 2007 
   
17 88.2 24.0 – 47.0
59
 
Not 
reported 
DNA analysis 
ADOS-G 
ADI-R 
DSM-IV 
Clinician with 
expertise in 
ASD 
No Autism: 23.5  
23.5 
(4) 
0.89    
   
Shanahan et al., 2008 
   
25 100.0 
34.8
60
 
(2.2) 
30.0 – 37.0 
Not 
reported 
Not reported CARS Not reported No Mild/mod autism: 28.0 
28.0 
(7) 
0.33    
   
Shaw & Porter, 2013 
   
16 25.0 Not reported 64.0
61
 Genetic ABC N/A No Autism: 6.3  
6.3 
(1) 
0.67    
   
Simko et al., 1989 
   
20 90.0 < 7.5 100.0 
Chromosomal 
analysis 
Parental 
report 
N/A No 
Autistic-like behaviour: 
55.0 
55.0 
(11) 
0.44    
   
                                                 
56
 Brief Disability Assessment Scale 
57
 Handicaps, Behaviours and Skills Schedule 
58
 This longitudinal study presented ASD prevalence data for two time points; however, there were no differences in prevalence between the time points. 
59
 Age in months 
60
 Age in months 
61
 Mean IQ score 
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Quality 
Criteria 
Fragile X Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD Measure 
Professional
11
  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Smith et al., 2012 
   
136 84.6 > 12.0 
Not 
reported 
Genetic 
confirmation 
Parental 
report  
Case review 
SCQ 
Consensus 
review by 
authors 
Yes Autistic disorder: 22.0 
22.0 
(30) 
0.67    
   
Tawfik et al., 2009 
   
16 100.0 
10.8 
(3.6) 
6.0 – 18.0 
61.0
62
 
Molecular 
Genetic testing 
CARS Not reported No Mild/mod autism: 43.8 
43.8 
(7) 
0.56    
   
Turk & Graham, 1997 
   
49 100.0 4.0 – 16.0 
Not 
reported 
Cytogenetic HBS Researcher Yes 
Autism: 28.6 
PDD-NOS: 30.6   
28.6 
(14) 
0.56    
   
Warren et al., 2010 
   
55 80.0 11.0 – 48.0
63
 
Not 
reported 
Genetic CARS Examiners No 
Mild/mod autism: 
32.7
64
  
32.7 
(18) 
0.67    
   
Wheeler et al., 2010 
   
46 76.1 
61.6
65
 
(8.2) 
42.4 – 72.4 
Not 
reported 
Genetic CARS 
Consensus of  
two trained 
researchers 
No Mild/mod autism: 32.6 
32.6 
(15) 
0.67    
   
Wisniewski et al., 1985 
   
28 89.3 
21.3 
0.8 – 60.0 
100.0 
Participants 
had the 
‘Fragile X 
chromosome’ 
DSM-III Not reported No Infantile autism: 25.0  
25.0 
(7) 
0.56    
   
                                                 
62
 Mean IQ score 
63
 Age in months at first of three time points 
64
 Mean CARS scores were calculated by the authors based on the final two time points in the study.  
65
 Age in months 
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Quality 
Criteria 
Fragile X Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD Measure 
Professional
11
  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Wisniewski et al., 1991 
   
62 88.7 
23.1
66
    15.7 
(14.3)    (3.5) 
2-70    10-20 
100.0 Cytogenetic DSM-III-R Not reported No Autistic stigmata: 16.1  
16.1 
(10) 
0.33    
   
Wolff et al., 2013 
   
41 100.0 
4.6 
(0.8) 
55.7
67
 Genetic 
ADOS 
ADI-R 
Trained 
clinicians 
No Autism: 39.0 
39.0 
(16) 
0.89    
   
Zingerevich et al., 2009 
   
48 75.0 
41.3
68
 
(16.0) 
12.0 – 76.0 
Not 
reported 
DNA analysis 
ADOS 
ADI-R 
DSM-IV 
Experienced 
clinicians 
Team 
consensus 
No 
Autism: 27.1 
PDD-NOS: 33.3  
27.1 
(13) 
0.78    
   
                                                 
66
 Age presented for males (left) and females (right) separately 
67
 Mean IQ score 
68
 Age in months 
Chapter 1: A Meta-Analysis of ASD in Syndromes 
33 
 
Random and quality-effects pooled prevalence estimates were generated based on the 56 
papers that met the quality inclusion criteria. These are presented in Figures 1.1 and 
1.2.
Prev
0.80.60.40.20
Study 
Sabaratnam et al., 2003 
Mazzocco et al., 1997 
Bailey et al., 1998 
Bailey et al., 2001 
Bailey et al., 2008 
Cianchetti et al., 1991 
Shaw & Porter, 2013 
Demark  et al., 2003 
Maes et al., 1993 
Bregman et al., 1988 
Ke et al., 2005 
Einfeld et al., 1989 
Hall et al., 2010 
Clifford et al., 2007 
Fryns et al., 1984 
Harris et al., 2008 
Hall et al., 2008 
Hagerman et al., 1986 
Wisniewski et al., 1991 
Reiss & Freund, 1990 
Roberts et al., 2001 
Hatton et al., 2006 
Smith et al., 2012 
Scambler et al., 2007 
Ornstein et al., 2008 
Gabis et al., 2011 
Kaufmann et al., 2004 
Pierpont et al., 2011 
Wisniewski et al., 1985 
Overall 
Q=773.84, p=0.00, I2=93%
Zingerevich et al., 2009 
Baranek et al., 2005 
Shanahan et al., 2008 
Turk & Graham, 1997 
Cordeiro et al., 2011 
Alanay et al., 2007 
Borghgraef et al., 1987 
Roberts et al., 2009a 
Roberts et al., 2007 
Wheeler et al., 2010 
Warren et al., 2010 
Rogers et al., 2001 
Chonchaiya et al., 2010 
Roberts et al., 2009b 
Wolff et al., 2013 
Frankland et al., 2004 
Oliver et al., 2011 
Tawfik et al., 2009 
Philofsky et al., 2004 
McDuffie et al., 2010 
McDuffie et al., 2012 
Moss et al., 2013a 
Simko et al., 1989 
Flenthrope & Brady, 2010 
Hatton et al., 2003 
Largo & Schinzel, 1985 
McDuffie et al., 2014 
    Prev (95% CI)          % Weight
   0.00  (  0.00,  0.07)      1.69
   0.03  (  0.00,  0.14)      1.76
   0.04  (  0.00,  0.10)      1.89
   0.04  (  0.00,  0.11)      1.88
   0.05  (  0.04,  0.06)      2.05
   0.06  (  0.00,  0.16)      1.80
   0.06  (  0.00,  0.25)      1.57
   0.07  (  0.00,  0.26)      1.54
   0.07  (  0.02,  0.15)      1.89
   0.07  (  0.00,  0.28)      1.52
   0.08  (  0.00,  0.32)      1.46
   0.09  (  0.02,  0.19)      1.85
   0.13  (  0.08,  0.20)      1.97
   0.14  (  0.06,  0.24)      1.90
   0.14  (  0.02,  0.33)      1.66
   0.14  (  0.07,  0.24)      1.90
   0.15  (  0.07,  0.25)      1.89
   0.16  (  0.07,  0.28)      1.87
   0.16  (  0.08,  0.26)      1.90
   0.18  (  0.03,  0.40)      1.59
   0.21  (  0.09,  0.35)      1.82
   0.21  (  0.16,  0.28)      2.00
   0.22  (  0.15,  0.29)      1.98
   0.24  (  0.06,  0.47)      1.59
   0.24  (  0.12,  0.38)      1.83
   0.25  (  0.10,  0.43)      1.74
   0.25  (  0.14,  0.37)      1.88
   0.25  (  0.13,  0.39)      1.84
   0.25  (  0.10,  0.43)      1.74
   0.26  (  0.20,  0.31)    100.00
   0.27  (  0.15,  0.41)      1.86
   0.27  (  0.05,  0.58)      1.42
   0.28  (  0.12,  0.47)      1.71
   0.29  (  0.17,  0.42)      1.86
   0.29  (  0.20,  0.38)      1.95
   0.29  (  0.12,  0.49)      1.70
   0.30  (  0.13,  0.51)      1.69
   0.31  (  0.19,  0.44)      1.88
   0.33  (  0.23,  0.43)      1.94
   0.33  (  0.20,  0.47)      1.85
   0.33  (  0.21,  0.46)      1.88
   0.33  (  0.16,  0.54)      1.70
   0.34  (  0.26,  0.41)      1.99
   0.35  (  0.23,  0.49)      1.87
   0.39  (  0.25,  0.55)      1.83
   0.40  (  0.11,  0.72)      1.38
   0.43  (  0.36,  0.50)      2.00
   0.44  (  0.20,  0.69)      1.57
   0.44  (  0.22,  0.68)      1.61
   0.47  (  0.33,  0.61)      1.87
   0.47  (  0.30,  0.64)      1.79
   0.49  (  0.41,  0.56)      2.00
   0.55  (  0.33,  0.76)      1.64
   0.64  (  0.44,  0.82)      1.71
   0.64  (  0.53,  0.75)      1.92
   0.69  (  0.41,  0.92)      1.49
   0.82  (  0.69,  0.91)      1.86
 
Figure 1.1. Pooled prevalence estimates for ASD phenomenology in Fragile X syndrome 
using a random-effects model. 
p <.001, 
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Prev
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Roberts et al., 2009b 
Wolff et al., 2013 
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Tawfik et al., 2009 
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Moss et al., 2013a 
Simko et al., 1989 
Flenthrope & Brady, 2010 
Hatton et al., 2003 
Largo & Schinzel, 1985 
McDuffie et al., 2014 
    Prev (95% CI)          % Weight
   0.00  (  0.00,  0.07)      1.31
   0.03  (  0.00,  0.14)      1.03
   0.04  (  0.00,  0.10)      1.10
   0.04  (  0.00,  0.11)      1.64
   0.05  (  0.04,  0.06)     17.42
   0.06  (  0.00,  0.16)      1.55
   0.06  (  0.00,  0.25)      1.01
   0.07  (  0.00,  0.26)      0.83
   0.07  (  0.02,  0.15)      1.69
   0.07  (  0.00,  0.28)      0.81
   0.08  (  0.00,  0.32)      0.62
   0.09  (  0.02,  0.19)      1.48
   0.13  (  0.08,  0.20)      3.59
   0.14  (  0.06,  0.24)      2.08
   0.14  (  0.02,  0.33)      0.54
   0.14  (  0.07,  0.24)      1.77
   0.15  (  0.07,  0.25)      1.72
   0.16  (  0.07,  0.28)      1.30
   0.16  (  0.08,  0.26)      0.86
   0.18  (  0.03,  0.40)      0.86
   0.21  (  0.09,  0.35)      1.38
   0.21  (  0.16,  0.28)      3.06
   0.22  (  0.15,  0.30)    100.00
   0.22  (  0.15,  0.29)      2.96
   0.24  (  0.06,  0.47)      1.36
   0.24  (  0.12,  0.38)      1.20
   0.25  (  0.10,  0.43)      1.20
   0.25  (  0.14,  0.37)      1.93
   0.25  (  0.13,  0.39)      1.94
   0.25  (  0.10,  0.43)      1.00
   0.27  (  0.15,  0.41)      1.78
   0.27  (  0.05,  0.58)      0.77
   0.28  (  0.12,  0.47)      0.57
   0.29  (  0.17,  0.42)      1.29
   0.29  (  0.20,  0.38)      2.71
   0.29  (  0.12,  0.49)      0.95
   0.30  (  0.13,  0.51)      0.94
   0.31  (  0.19,  0.44)      1.37
   0.33  (  0.23,  0.43)      1.79
   0.33  (  0.20,  0.47)      1.50
   0.33  (  0.21,  0.46)      1.64
   0.33  (  0.16,  0.54)      1.51
   0.34  (  0.26,  0.41)      3.32
   0.35  (  0.23,  0.49)      1.58
   0.39  (  0.25,  0.55)      1.88
   0.40  (  0.11,  0.72)      0.45
   0.43  (  0.36,  0.50)      2.53
   0.44  (  0.20,  0.69)      0.84
   0.44  (  0.22,  0.68)      1.38
   0.47  (  0.33,  0.61)      1.84
   0.47  (  0.30,  0.64)      1.73
   0.49  (  0.41,  0.56)      2.38
   0.55  (  0.33,  0.76)      0.70
   0.64  (  0.44,  0.82)      0.57
   0.64  (  0.53,  0.75)      1.89
   0.69  (  0.41,  0.92)      0.80
   0.82  (  0.69,  0.91)      2.05
 
Figure 1.2. Pooled prevalence estimates for ASD phenomenology in Fragile X syndrome 
using a quality-effects model. 
p <.001, 
Chapter 1: A Meta-Analysis of ASD in Syndromes 
35 
 
The results revealed that the random-effects model generated a prevalence estimate for ASD 
phenomenology in Fragile X syndrome of 26% (CI 20 – 31%).  The quality-effects model 
generated a more conservative estimate of 22% (CI 15 – 30%).  
 
ASD phenomenology is reported to vary by gender in Fragile X syndrome (Moss & Howlin, 
2009). Therefore, additional prevalence estimates were generated from the 28 papers that 
reported on solely male samples. The forest plots for these analyses are presented in Appendix 
B. The results revealed that the random-effects model generated a prevalence estimate for 
males with Fragile X syndrome of 28% (CI 21 – 36%). The quality-effects model generated a 
less conservative estimate of 30% (CI 22 – 38%). In order to provide equivalent comparisons 
to the other syndrome groups, in which gender was not controlled for, the Fragile X male only 
prevalence estimates will not be used in between group comparisons. 
 
1.4.3 Tuberous Sclerosis Complex 
The literature search identified 26
69
 papers that reported the prevalence of ASD 
phenomenology in Tuberous Sclerosis Complex. These are presented in Table 1.7. The 
quality of the identified papers was variable, with quality weightings ranging from 0.33 to 
0.78. Only one study in Tuberous Sclerosis Complex achieved the highest quality rating for 
more than one criterion (Peters et al., 2013), and no studies obtained a quality rating of three 
in all three areas. One paper was excluded from the pooled prevalence estimate due to poor 
quality (Smalley, Smith & Tanguay, 1991). A total of two studies obtained the highest quality 
rating for sample identification, five for confirmation of Tuberous Sclerosis complex and 
eight for ASD assessment. Four studies presented data describing the profile of ASD in 
Tuberous Sclerosis Complex. 
 
The majority of the studies obtained small samples of less than 100 participants, however two 
large scale studies investigating ASD phenomenology in Tuberous Sclerosis Complex were 
identified (De Vries, Hunt & Bolton, 2007; Muzykewicz, Newberry, Danforth, Halpern & 
Thiele, 2007). These studies provide useful robust estimates of ASD phenomenology. 
However, both studies failed to reach an adequate rating of quality in all three areas, 
demonstrating the innate difficulties in conducting rigorous study of ASD phenomenology in 
large samples with rare syndromes.  
                                                 
69
 A further two papers met the initial screening criteria; however it was not possible to obtain these papers from 
either University of Birmingham Library or the British Library. 
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Table 1.7. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in Tuberous 
Sclerosis Complex. 
 
Quality 
Criteria 
Tuberous Sclerosis Complex Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N % Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Baker et al., 1998 
   
20 25.0 
13.8 
4.0 – 30.0 
Not 
reported 
for full 
sample 
Paediatric 
neuro-
radiologist 
ABC 
ADI 
DSM-IV 
Experienced 
psychiatrist 
No 
ABC autism: 60.0 
          ABC+ADI  
autism: 40.0 
            Consensus  
autism: 20.0 
20.0 
(4) 
0.67 
   
   
Bolton & Griffiths, 
1997 
   
18 
Not 
reported 
3.0 – 25.0 61.1 
Multi-
disciplinary 
experienced 
clinic 
ICD-10 Psychiatrist No 
Autism: 22.2 
Atypical autism: 27.8  
22.2 
(4) 
0.44    
   
Bolton et al., 2002 
   
60 
Not 
reported 
Not reported 
Not 
reported 
Participants 
met criteria 
for TSC 
ADI-R 
ADOS-G 
ICD-10 
Two 
Psychiatrists 
No 
Autism: 23.3 
Atypical autism: 6.7 
PDD-NOS: 1.7   
23.3 
(14) 
0.67    
   
Bruining et al., 2014 
   
50 38.0 
126.2
70
 
(74.0) 
69.3
71
 Cytogenetic ADI-R Not reported  Yes ASD: 44.0 
44.0 
(22) 
0.78    
   
Chopra et al., 2011 
   
45 48.9 
14.8 
0.5 – 47.0 
60.0 
Clinical, 
Radiological 
and Genetic 
Neuro-
psychologic
al tests
72
 
Neurologist  
Clinical 
Geneticist 
No ASD: 33.3 
33.3 
(15) 
0.56    
   
               
                                                 
70
 Age in months 
71
 Mean IQ score 
72
 Tests were only completed for some of the participants – the study does not report which tests, or for what proportion of the sample 
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Quality 
Criteria 
Tuberous Sclerosis Complex Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N % Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Chung et al., 2011 
   
62 56.5 
15.4 
(9.5) 
3.0 – 48.0 
69.4 
Clinical or 
genetic 
criteria by 
specialist 
DSM-IV Psychiatrist No ASD: 37.1 
37.1 
(23) 
0.44    
   
De Vries et al., 2007 
   
265 40.0 <18 56.6 
Parental 
report of 
diagnostic 
features 
Parental 
report of 
ICD-10 or 
DSM-IV
73
 
Diagnosis by 
a clinician 
No ASD: 44.9 
44.9 
(119) 
0.33    
   
Gillberg et al., 1994 
   
28 39.3 2.0 – 20.0 64.3 
Clinical 
criteria 
Psychiatric 
examination 
CARS 
ABC 
DSM-III-R 
Psychiatric 
examination 
No 
Autistic disorder: 60.7 
Autistic like 
conditions: 21.4 
Asperger syndrome: 
3.6   
60.7 
(17) 
0.56    
   
Granader et al., 2010 
   
21 57.1 
10.1 
(4.3) 
5.0 – 18.0 
73.6
74
 
Clinical 
criteria and 
chart review 
SRS
75
 
SCQ 
N/A No 
SRS ASD: 52.4 
SCQ ASD: 42.9 
52.4 
(11) 
0.33    
   
Gutierrez, 1998 
   
28 39.3 
Not reported 
for full 
sample 
60.7 
Medical 
geneticist 
ADI-R 
ADOS 
ICD-10 
DSM-IV 
Trained 
researchers 
Yes 
Autism: 28.6  
PDD-NOS: 14.3 
28.6 
(8) 
0.78    
   
                                                 
73
 The study further qualified these by establishing 90% agreement between ADOS/ADI-R diagnosis and parent report in a subset of 8% of the sample (N=21). Therefore, this 
study is given a quality rating of 1 for quality criterion 3. 
74
 Mean IQ score for 15 (71%) of participants 
75
 Social Responsiveness Scale 
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Quality 
Criteria 
Tuberous Sclerosis Complex Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N % Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Hunt, 1998 
   
23 43.5 18.0 –24.0 100.0 
Case note 
review 
HBS 
Screening 
questions
76
 
N/A No Autistic traits: 43.5  
43.5 
(10) 
0.44    
   
Hunt & Dennis, 1987 
   
90 
Not 
reported 
Not reported 
Not 
reported 
‘Confirmed 
diagnosis’ 
Case note 
review 
Rutter 
criteria
77
 
Screening 
questions
78
 
Authors No Autistic behaviour: 50.0  
50.0 
(45) 
0.44    
   
Hunt & Shephard, 
1993 
   
21 47.6 3.0 – 11.0 57.1 
At least one 
clinical 
feature 
HBS 
DSM-III-R 
Not reported No 
Autistic: 23.8  
PDD-NOS: 19.0  
23.8 
(5) 
0.44    
   
Jeste et al., 2008 
   
14 
Not 
reported 
60.0
79
 
Not 
reported 
‘Satisfied 
diagnostic 
criteria’ 
ADOS Not reported No 
Autism: 28.6 
ASD: 21.4 
28.6 
(4) 
0.33    
   
Jeste et al., 2013 
   
28 63.2
80
 
23.1
81
 
3.0 – 46.0 
Not 
reported 
Paediatric 
neuro-
radiologist 
ADOS or 
AOSI
82
 
Child 
neurologist 
No Autism: 35.7 
35.7 
(10) 
0.44    
   
                                                 
76
 Developed from Wing & Gould, 1979. 
77
 Developed from Rutter & Hersov, 1977 
78
 Criteria proposed by Rendle-Short (Bruce, 1967) 
79
 Age in months. This study was longitudinal and presents ADOS classifications at four time points. The oldest time point is reported here as the authors suggest that ASD 
phenomenology would be most stable at this point in development. 
80
 Gender only report for 19 (68%) of the sample 
81
 Age in months 
82
 Autism Observation Scale of Infancy; as not all children were assessed using a diagnostic assessment, the study was given a quality rating of ‘1’ for quality criterion ASD 
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Quality 
Criteria 
Tuberous Sclerosis Complex Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N % Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Lewis et al., 2013 
   
42 66.7 
9.9 
1.0 – 27.0 
Not 
reported 
Clinical 
criteria 
multi-
disciplinary 
team 
DSM-IV 
ADOS 
Paediatric 
neurologist 
No ASD: 28.6  
28.6 
(12) 
0.67    
   
Muzykewicz et al., 
2007 
   
241 49.0 
20.0 
0.8 – 63.4 
67.0
83
 
Clinical 
criteria 
Neurologist
84
 
Not reported 
Neuro-
psychologist 
or Neurologist 
No Autism: 35.7  
35.7 
(86) 
0.33    
   
Numis et al., 2011 
   
103 
Not 
reported 
3.0 – 55.0 
Not 
reported 
Clinical 
criteria and 
genetic 
DSM-IV 
GADS
85
 
CSI-4
86
 
BASC-2
87
 
Neuro-
psychologist 
No ASD: 9.1  
9.1 
(41) 
0.56    
   
Park & Bolton, 2001 
   
43 55.8 
110.0
88
 
(49.0) 
30.0 – 192.0 
Not 
reported 
Clinical 
criteria 
Child 
Psychiatrist 
ADOS-G 
ADI-R 
ICD-10 
Trained Child 
Psychiatrist 
Yes ASD: 32.6  
32.6 
(14) 
0.78    
   
                                                 
83
 Mean IQ score for 112 (46%) of sample 
84
 Mutational analysis was conducted for 191 (79%) of sample 
85
 Gilliam Asperger’s Disorder Scale 
86
 Child Symptom Inventory – 4 Parent Checklist 
87
 Behavioural Assessment System for Children - 2 
88
 Age in months 
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Quality 
Criteria 
Tuberous Sclerosis Complex Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N % Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Peters et al., 2012a 
   
40 60.0 
7.2 
0.5 – 25.0 
60.0 
Clinical 
criteria 
neurological 
examination 
Paediatric 
Neuro-
radiologist 
DSM-IV 
ADOS 
Paediatric 
neurologist 
No ASD: 20.0 
20.0 
(12) 
0.56    
   
Peters et al., 2013 
   
43 62.7 
6.9 
0.7 – 25.6 
Not 
reported 
Clinical 
criteria and 
genetic 
DSM-IV 
ADOS 
Paediatric 
neurologist 
Trained 
examiners 
No ASD: 32.6 
32.6 
(14) 
0.78    
   
Smalley et al., 1991 
   
24 
Not 
reported 
Not reported  
Not 
reported 
Not reported 
ABC 
DSM-III-R 
Author No Autism: 20.8 
20.8 
(5) 
0.11    
   
Smalley et al., 1992 
   
13 38.5 
10.1 
(7.4) 
53.8 
Medical 
geneticist 
ADI 
ICD-10 
Not reported Yes Autism: 53.8 
53.8 
(7) 
0.67    
   
van Eeghen et al., 
2013 
   
64 42.2 
22.0 
4.0 – 62.0 
46.9 
Genetic 
mutation 
analysis 
SRS N/A No 
Autism: 37.5  
ASD: 56.3 
37.5 
(24) 
0.56    
   
Walz et al., 2002 
   
50 54.0 Not reported 
Not 
reported 
Clinical 
criteria 
Paediatric 
Neuro-
radiologist 
DSM-IV 
Paediatric 
Neuro-
psychologist 
No Autism: 30.0 
30.0 
(15) 
0.44    
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Quality 
Criteria 
Tuberous Sclerosis Complex Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N % Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Wong & Khong, 2006 
   
22 45.5 Not reported 86.4 
Neuro-
radiologist 
DSM-IV 
ADI-R 
Not reported No Autism: 31.8  
 
31.8 
(7) 
0.67    
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The study conducted by Bruining and colleagues (2014) is notable, as a recent, 
methodologically robust study. The authors investigated ASD phenomenology using a 
diagnostic measure, across a variety of genetically confirmed syndromes. They then 
conducted novel statistical analysis to delineate the profiles of ASD phenomenology in each 
of the syndromes, relative to one another and relative to idiopathic ASD. This methodology 
could be usefully replicated and applied in other syndrome groups. 
 
Random and quality-effects pooled prevalence estimates were generated based on the 25 
papers that met the quality inclusion criteria. These are presented in Figures 1.3 and 1.4. The 
results revealed that the random-effects model generated a prevalence estimate for ASD 
phenomenology in Tuberous Sclerosis Complex of 37% (CI 33 – 40%). The quality-effects 
model generated a similar prevalence figure of 36% (CI 33 – 40%). There were no significant 
outliers in the data. 
 
Prev
0.80.70.60.50.40.30.20.1
Study 
Baker et al., 1998 
Bolton & Griffiths, 1997 
Bolton et al., 2002 
Hunt & Shephard, 1993 
Gutierrez, 1998 
Jeste et al., 2008 
Lewis et al., 2013 
Peters et al., 2012 
Walz et al., 2002 
Wong & Khong, 2006 
Park & Bolton, 2001 
Peters et al., 2013 
Chopra et al., 2011 
Muzykewicz et al., 2007 
Jeste et al., 2013 
Overall 
Q=40.29, p=0.02, I2=40%
Chung et al., 2011 
van Eeghen et al., 2013 
Numis et al., 2011 
Hunt, 1998 
Bruining et al., 2014 
De Vries et al., 2007 
Hunt & Dennis, 1987 
Granader et al., 2010 
Smalley et al., 1992 
Gillberg et al., 1994 
    Prev (95% CI)          % Weight
   0.20  (  0.05,  0.41)      2.31
   0.22  (  0.06,  0.45)      2.13
   0.23  (  0.13,  0.35)      4.89
   0.24  (  0.08,  0.45)      2.40
   0.29  (  0.13,  0.47)      2.98
   0.29  (  0.07,  0.55)      1.74
   0.29  (  0.16,  0.43)      3.94
   0.30  (  0.17,  0.45)      3.81
   0.30  (  0.18,  0.44)      4.39
   0.32  (  0.14,  0.53)      2.49
   0.33  (  0.19,  0.47)      4.00
   0.33  (  0.19,  0.47)      4.00
   0.33  (  0.20,  0.48)      4.12
   0.36  (  0.30,  0.42)      8.57
   0.36  (  0.19,  0.55)      2.98
   0.37  (  0.33,  0.40)    100.00
   0.37  (  0.25,  0.50)      4.98
   0.38  (  0.26,  0.50)      5.07
   0.40  (  0.31,  0.49)      6.42
   0.43  (  0.24,  0.64)      2.57
   0.44  (  0.30,  0.58)      4.39
   0.45  (  0.39,  0.51)      8.77
   0.50  (  0.40,  0.60)      6.04
   0.52  (  0.31,  0.74)      2.40
   0.54  (  0.26,  0.80)      1.63
   0.61  (  0.42,  0.78)      2.98
 
Figure 1.3. Pooled prevalence estimates for ASD phenomenology in Tuberous Sclerosis 
Complex using a random-effects model. 
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Prev
0.80.70.60.50.40.30.20.1
Study 
Baker et al., 1998 
Bolton & Griffiths, 1997 
Bolton et al., 2002 
Hunt & Shephard, 1993 
Gutierrez, 1998 
Jeste et al., 2008 
Lewis et al., 2013 
Peters et al., 2012 
Walz et al., 2002 
Wong & Khong, 2006 
Park & Bolton, 2001 
Peters et al., 2013 
Chopra et al., 2011 
Muzykewicz et al., 2007 
Jeste et al., 2013 
Overall 
Q=40.29, p=0.02, I2=40%
Chung et al., 2011 
van Eeghen et al., 2013 
Numis et al., 2011 
Hunt, 1998 
Bruining et al., 2014 
De Vries et al., 2007 
Hunt & Dennis, 1987 
Granader et al., 2010 
Smalley et al., 1992 
Gillberg et al., 1994 
    Prev (95% CI)          % Weight
   0.20  (  0.05,  0.41)      3.47
   0.22  (  0.06,  0.45)      2.22
   0.23  (  0.13,  0.35)      5.32
   0.24  (  0.08,  0.45)      2.31
   0.29  (  0.13,  0.47)      4.47
   0.29  (  0.07,  0.55)      1.57
   0.29  (  0.16,  0.43)      4.49
   0.30  (  0.17,  0.45)      3.67
   0.30  (  0.18,  0.44)      3.19
   0.32  (  0.14,  0.53)      3.56
   0.33  (  0.19,  0.47)      5.28
   0.33  (  0.19,  0.47)      5.28
   0.33  (  0.20,  0.48)      3.86
   0.36  (  0.30,  0.42)      6.75
   0.36  (  0.19,  0.55)      2.52
   0.36  (  0.33,  0.40)    100.00
   0.37  (  0.25,  0.50)      3.55
   0.38  (  0.26,  0.50)      4.60
   0.40  (  0.31,  0.49)      6.11
   0.43  (  0.24,  0.64)      2.37
   0.44  (  0.30,  0.58)      5.65
   0.45  (  0.39,  0.51)      7.30
   0.50  (  0.40,  0.60)      4.41
   0.52  (  0.31,  0.74)      1.73
   0.54  (  0.26,  0.80)      3.14
   0.61  (  0.42,  0.78)      3.21
 
Figure 1.4. Pooled prevalence estimates for ASD phenomenology in Tuberous Sclerosis 
Complex using a quality-effects model. 
 
1.4.4 22q11.2 Deletion Syndrome  
The literature search identified 14 papers that reported the prevalence of ASD 
phenomenology in 22q11.2 deletion syndrome. These are presented in Table 1.8. The papers 
were all of good quality, with quality weightings ranging from 0.44 to 0.89. All 14 papers 
received the maximum quality rating for confirmation of syndrome, six studies received the 
maximum quality rating for ASD assessment and three studies presented data on the profile of 
ASD phenomenology in the sample. No studies were excluded on the basis of quality and 11 
studies presented data on the proportion of their sample with an intellectual disability. The 
overall quality of the literature in 22q11.2 deletion syndrome suggests that the generated 
prevalence estimates will be robust. One notable limitation of the data is that the meta-
analysis may have inadvertently included individual samples multiple times, as studies by 
Niklasson and colleagues (2001; 2002; 2005; 2009) and Vorstman and colleagues (2006; 
2013) appear to have used similar samples across multiple studies; however, this was not 
definitively identifiable from the reporting in the papers.  
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Table 1.8. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in 22q11.2 
deletion syndrome. 
 
Quality 
Criteria 
22q11.2 Deletion Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Angkustsiri et al., 
2014 
   
100 55.0 
10.7 
(2.1) 
7.0 – 14.0 
74.6
89
 Molecular 
SCQ  
BASC-2 
ADOS 
 
Not reported Yes 
SCQ ASD: 6.9
90
 
BASC-2 ASD: 44.0 
ADOS ASD: 13.8 
ADOS autism: 3.4 
SCQ & ADOS: 0.0 
0.0 
(0) 
 
0.89 
    
   
Antshel et al., 2007 
   
41 52.5 
10.6 
(2.4) 
6.5 – 15.8 
Not 
reported 
Genetic  
ADI-R 
DSM-IV 
Research 
reliable 
clinician 
No 
Both autism: 19.5 
Both ASD: 41.5 
19.5 
(8) 
0.78    
   
Briegel et al., 2008 
   
77 55.8 
8.0 
4.0 –16.11 
61.0
91
 Genetic  VSK
92
 N/A 
Not 
reported 
ASD: 14.3 
14.3 
(11) 
0.67    
   
Bruining et al., 2014 
   
90 53.3 
162.5
93
 
33.6 
67.0
94
 Cytogenetic ADI-R Not reported  Yes ASD: 44.4  
44.4 
(40) 
0.78    
   
 
 
              
                                                 
89
 Mean IQ score 
90
 For SCQ and ADOS assessments, a smalls subsample of 29 were assessed. 
91
 Parents’ estimates of child’s intelligence as ‘below the average’, or ‘mentally disabled’. 
92
 A German adaption of the SCQ, titled the Behaviour and Social Communication Questionnaire 
93
 Age in months 
94
 Mean IQ score 
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Quality 
Criteria 
22q11.2 Deletion Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Fine et al., 2005 
   
98 57.1 22.0-153.0 
Mild 
global 
dev. 
delay
95
 
Molecular 
M-CHAT or 
SCQ
96
 
ADI-R 
Trained 
interviewer 
No 
Screening ASD: 22.4 
 
Consensus autism: 11.2  
Consensus ASD: 13.3  
11.2 
(11) 
0.78 
   
   
   
Ho et al., 2012 
   
63 47.6 
13.7  17.197 
(5.5)  (1.9) 
80.5  
74.598 
Genetic 
ADOS 
ADI-R 
AID-R and 
ADOS 
assessors 
Yes 
Both autistic disorder: 7.9  
Both ASD: 25.4 
7.9 
(5) 
0.89    
   
Niklasson et al., 2001 
   
32 40.6 5.0 – 33.0 53.1 
 
Clinical and 
genetic 
 
DSM-IV 
ASSQ 
Experienced 
Psychiatrists 
No 
Autistic disorder: 3.1  
PDD-NOS: 28.1 
3.1 
(1) 
0.56    
   
Niklasson et al., 2002 
   
20 40.0 5.0 – 33.0 50.0 Genetic 
DSM-IV 
ASSQ
99
 
 Two Neuro-
psychiatrists 
No 
Autistic syndrome: 30.0 
PDD-NOS: 5.0  
30.0 
(6) 
0.56    
   
Niklasson et al., 2005 
   
30 46.7 7.0 – 13.0  72.1
100
 
Clinical and 
genetic  
DSM-IV 
ASSQ 
Psychiatrists No 
Autistic disorder: 3.3 
PDD-NOS: 23.3  
3.3 
(1) 
0.56    
   
                                                 
95
 Average category obtained on the Vineland Adaptive Behavior Scales 
96
 Dependent upon age of child; M-CHAT = Modified Checklist for Autism in Toddlers, Revised 
97
 Data collected from two research sites; age data presented for both sites 
98
 Data collected from two research sites: mean IQ score presented for both sites 
99
 Asperger Syndrome Screening Questionnaire 
100
 Mean IQ score 
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Quality 
Criteria 
22q11.2 Deletion Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Niklasson et al., 2009 
   
100 42.0 1.0 – 35.0  51.0 Genetic 
DSM-IV 
ASSQ 
Neuro-
psychiatrists 
No 
Autistic disorder: 5.0 
PDD-NOS: 18.0  
5.0 
(5) 
0.56    
   
Ousley et al., 2013 
   
31 45.2 
19.3 
(4.1) 
14.0 –29.0 
Not 
reported 
Genetic 
ADI-R 
ADOS 
CPEA
101
 
DSM-IV 
Psychiatrist 
and 
Psychologist 
No 
CPEA ASD: 16.1 
DSM-IV only: 32.2 
16.1 
(5) 
0.78    
   
Van Campenhout et 
al., 2012 
   
11 54.5 3.0 – 13.0 63.7 Genetic 
CBC
102
 
Clinical 
assessment 
Not reported No 
             Severe autistic  
disorder: 9.1  
ASD: 9.1 
9.1 
(1) 
0.44    
   
Vorstman et al., 2013 
   
77 50.6 
5.9
103
    
6.4 
(2.0)  (2.0) 
69.7
104 
75.7 Genetic 
SRS 
SCQ 
N/A No 
SRS probable ASD: 
76.6
105
 16.9 
(13) 
0.56    
SCQ probable ASD: 16.9   
   
Vorstman et al., 2006 
   
60 38.3 
 
9.0 – 18.0 
 
65.2
106
 Genetic  
DSM-IV 
ADI-R 
Child 
Psychiatrist 
No 
Consensus autism: 5.0 
                 Consensus  
PDD-NOS: 45.0 
ADI-R autism: 33.3 
5.0 
(3) 
0.89    
   
                                                 
101
 Collaborative Program for Excellence in Autism criteria – scoring on both ADI-R, ADOS and meeting DSM-IV criteria 
102
 Child Behavior Checklist 
103
 Data collected from two subgroups; those with a history of psychosis (left) and those without (right) 
104
 Data collected from two subgroups; those with a history of psychosis (left) and those without (right) 
105
 Data were obtained retrospectively by parents, scoring the measures on behalf of their adult children 
106
 Mean IQ score 
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Random and quality-effects pooled prevalence estimates were generated based on the 14 
papers that met the quality inclusion criteria. These are presented in Figures 1.5 and 1.6.  
Prev
0.50.40.30.20.10
Study 
Angkustsiri et al., 2014 
Niklasson et al., 2001 
Niklasson et al., 2005 
Niklasson et al., 2009 
Vorstman et al., 2006 
Ho et al., 2012 
van Campenhout et al., 2012 
Fine et al., 2005 
Overall 
Q=112.20, p=0.00, I2=88%
Briegel et al., 2008 
Ousley et al., 2013 
Vorstman et al., 2013 
Antshel et al., 2007 
Niklasson et al., 2002 
Bruining et al., 2014 
    Prev (95% CI)          % Weight
   0.00  (  0.00,  0.02)      7.81
   0.03  (  0.00,  0.13)      6.80
   0.03  (  0.00,  0.14)      6.72
   0.05  (  0.01,  0.10)      7.81
   0.05  (  0.01,  0.12)      7.46
   0.08  (  0.02,  0.16)      7.50
   0.09  (  0.00,  0.35)      5.04
   0.11  (  0.06,  0.18)      7.80
   0.12  (  0.06,  0.19)    100.00
   0.14  (  0.07,  0.23)      7.65
   0.16  (  0.05,  0.31)      6.76
   0.17  (  0.09,  0.26)      7.65
   0.20  (  0.09,  0.33)      7.10
   0.30  (  0.12,  0.52)      6.12
   0.44  (  0.34,  0.55)      7.75
Figure 1.5. Pooled prevalence estimates for ASD phenomenology in 22q11.2 deletion 
syndrome using a random-effects model.  
 
Prev
0.50.40.30.20.10
Study 
Angkustsiri et al., 2014 
Niklasson et al., 2001 
Niklasson et al., 2005 
Niklasson et al., 2009 
Vorstman et al., 2006 
Ho et al., 2012 
van Campenhout et al., 2012 
Overall 
Q=112.20, p=0.00, I2=88%
Fine et al., 2005 
Briegel et al., 2008 
Ousley et al., 2013 
Vorstman et al., 2013 
Antshel et al., 2007 
Niklasson et al., 2002 
Bruining et al., 2014 
    Prev (95% CI)          % Weight
   0.00  (  0.00,  0.02)     13.20
   0.03  (  0.00,  0.13)      3.76
   0.03  (  0.00,  0.14)      3.62
   0.05  (  0.01,  0.10)      8.31
   0.05  (  0.01,  0.12)      8.95
   0.08  (  0.02,  0.16)      9.27
   0.09  (  0.00,  0.35)      1.85
   0.11  (  0.05,  0.19)    100.00
   0.11  (  0.06,  0.18)     11.38
   0.14  (  0.07,  0.23)      8.10
   0.16  (  0.05,  0.31)      5.14
   0.17  (  0.09,  0.26)      6.77
   0.20  (  0.09,  0.33)      6.07
   0.30  (  0.12,  0.52)      2.95
   0.44  (  0.34,  0.55)     10.64
 
Figure 1.6. Pooled prevalence estimates for ASD phenomenology in 22q11.2 deletion 
syndrome using a quality-effects model. 
 
 
The results revealed that the random-effects model generated a prevalence estimate for ASD 
phenomenology in 22q11.2 deletion syndrome of 12% (CI 6 – 19%).  The prevalence estimate 
generated by the quality-effects model of 11% (CI 5 – 19%) was very similar to that obtained 
through the random-effects model.  
p <.0 1, 
p <.001, 
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1.4.5 Cornelia de Lange Syndrome 
The literature search identified 12 papers that reported the prevalence of ASD 
phenomenology in Cornelia de Lange syndrome. These are presented in Table 1.9. All 12 
papers reached an adequate standard of quality for sample selection, confirmation of Cornelia 
de Lange diagnosis and assessment of ASD phenomenology. This is evidenced in the 
relatively homogeneous quality weightings, ranging from 0.44 to 0.78, indicating that the 
pooled prevalence estimates are generated from data of robust quality. Given the genetic 
heterogeneity in Cornelia de Lange syndrome, it is unsurprising that only one study included 
a genetic analysis of the Cornelia de Lange syndrome sample (Bhuiyan et al., 2006). Whilst 
only two studies received the highest quality rating for ASD assessment, five studies 
presented data on the profile of ASD phenomenology in the syndrome. Nine of the twelve 
studies reported the proportion of the sample with an intellectual disability.  
 
Similarly with other syndrome groups, it is possible that the meta-analysis may have included 
individual samples multiple times (e.g., Moss et al., 2013b & Oliver et al., 2011). Whilst 
papers reporting on identical samples were excluded from the meta-analysis, it was not 
possible to exclude or account for overlapping samples, as authors did not report the 
proportion of overlap between studies. The potential overlap between samples marginally 
limits confidence in the generated pooled prevalence estimates, as individual cases with 
Cornelia de Lange syndrome may be counted more than once within the meta-analysis.  
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Table 1.9. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in Cornelia 
de Lange syndrome. 
 
Quality 
Criteria 
Cornelia de Lange Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Basile et al., 2007 
   
56 51.8 
10.7 
(8.6) 
1.0 – 31.0 
96.4 
Expert 
Geneticist 
/Paediatrician 
ABC 
2 independent 
clinicians 
No 
Autism:22.0
107
 
7.3 
(3) 
0.56    
CARS 
Severe autism: 7.3  
Mild/mod autism: 29.3    
Berney et al., 1999 
   
49 42.9 
10.2 
(7.8) 
100.0 
General 
Clinician 
Modified 
ABC 
ICD-10 
1 clinician No Autistic disorder: 53.0 
53.0 
(26) 
0.44    
   
Bhuiyan et al., 2006 
   
39 48.7 Not reported 92.3 
2 Clinical 
Geneticists 
DBC
108
 
Not reported No 
Autism: 56.4  
61.5 
(24) 
0.78 
   
   
DISCO
109
 Autism: 61.5  
   
Moss et al., 2013a 
   
15 60.0 
12.4 
(3.7) 
6.1 – 18.5 
Not 
reported 
Physician/ 
Paediatrician/ 
Geneticist 
SCQ N/A Yes 
Autism: 46.2 
ASD: 100.0 
46.2 
(6) 
0.44    
   
Moss et al., 2012 
   
20 35.0 
11.34 
6.0 – 13.0 
43.45
110
 
(22.25) 
Physician/ 
Paediatrician/ 
Geneticist 
ADOS Not reported Yes 
Autism: 65.0 
ASD: 85.0 
65.0 
(13) 
0.56    
   
 
 
 
              
                                                 
107
 ABC and CARS data only available for 41 of the 56 participants 
108
 Developmental Behaviour Checklist (Dutch Version) 
109
 Diagnostic Interview for Social and Communication Disorders 
110
 British Picture Vocabulary Scales age equivalent score (SD) 
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Quality 
Criteria 
Cornelia de Lange Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Moss et al., 2013b 
   
103 41.8 
17.2 
(8.8) 
4.0 – 40.0 
Not 
reported 
Physician/ 
Paediatrician/ 
Geneticist 
SCQ N/A Yes 
Autism: 45.6  
ASD: 78.6  
45.6 
(47) 
0.44    
   
Moss et al., 2008 
   
34 47.2 
12.4 
(3.8) 
5.0 – 18.96 
100.0 
Paediatrician/ 
Geneticist 
SCQ N/A 
Yes 
SCQ Autism: 23.5 
 SCQ ASD: 41.2 
61.8 
(21) 
0.44    
ADOS 
Researcher 
Inter-rater 
reliability  
 ADOS Autism: 61.8 
ADOS ASD: 73.5     
Nakanishi et al., 2012 
   
49 47.0 
15.2 
4.0 – 44.0 
80.0 
Clinical 
Geneticist 
SCQ 
ADI-R 
Trained 
Investigators 
supervised by 
Psychologist 
No 
SCQ ASD: 49.0  
34.7 
(17) 
0.67    ADI-R Autism: 42.9  
   Both Autism: 34.7  
Oliver et al., 2008 
   
54 46.0 
13.9 
(8.6) 
3.2 – 37.9 
87.0
111
 
Medical 
Professional 
CARS Not reported No 
Severe autism 32.1 
Mild/Mod autism: 15.1 
32.1 
(17) 
0.44    
   
Oliver et al., 2011 
   
101 40.6 
17.5 
(9.87) 
4.0 – 40.0 
46.5
112
 
Physician/ 
Paediatrician/ 
Geneticist 
SCQ N/A Yes 
Autism: 45.9 
ASD: 78.8  
45.9 
(39) 
0.44    
   
Srivastava et al., 2014 
   
41 43.9 
11.4 
(3.8) 
5.0 – 18.0 
Not 
reported 
Clinical 
Geneticist 
CARS Not reported Yes 
Severe autism: 41.4 
Mild autism: 41.4 
41.4 
(17) 
0.56    
   
               
                                                 
111
 Defined as partly able/not able on the Wessex 
112
 Defined as not able on the Wessex 
Chapter 1: A Meta-Analysis of ASD in Syndromes 
51 
 
 
Quality 
Criteria 
Cornelia de Lange Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Wulffaert et al., 2009a 
   
37 56.8 
18.1 
(13.0) 
1.4 – 46.2 
97.3 
Clinical 
Geneticist 
DBC-P
113
 
DISCO 
Not reported No 
Autistic Disorder: 54.1 
    Possible autistic 
disorder: 16.2 
54.1 
(20) 
0.78    
   
 
                                                 
113
 Developmental Behaviour Checklist – Parent/carer  (Dutch version) 
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Random and quality-effects pooled prevalence estimates were generated based on the 12 
papers that met the quality inclusion criteria. These are presented in Figures 1.7 and 1.8.  
 
Prev
0.80.70.60.50.40.30.20.10
Study 
Basile et al., 2007 
Oliver et al., 2008 
Nakanishi et al., 2012 
Oliver et al., 2011 
Moss et al., 2013a 
Srivastava et al., 2014 
Overall 
Q=71.06, p=0.00, I2=85%
Moss et al., 2013b 
Berney et al., 1999 
Wulffaert et al.,2009a 
Bhuiyan et al., 2006 
Moss et al., 2008 
Moss et al.,2012 
    Prev (95% CI)          % Weight
   0.05  (  0.01,  0.13)      8.79
   0.31  (  0.20,  0.45)      8.74
   0.35  (  0.22,  0.49)      8.62
   0.39  (  0.29,  0.48)      9.36
   0.40  (  0.16,  0.66)      6.45
   0.41  (  0.27,  0.57)      8.37
   0.43  (  0.33,  0.54)    100.00
   0.46  (  0.36,  0.55)      9.37
   0.53  (  0.39,  0.67)      8.62
   0.54  (  0.38,  0.70)      8.22
   0.62  (  0.46,  0.76)      8.30
   0.62  (  0.45,  0.78)      8.08
   0.65  (  0.43,  0.85)      7.08
 
Figure 1.7. Pooled prevalence estimates for ASD phenomenology in Cornelia de Lange 
syndrome using a random-effects model. 
 
 
Prev
0.80.70.60.50.40.30.20.10
Study 
Basile et al., 2007 
Oliver et al., 2008 
Nakanishi et al., 2012 
Oliver et al., 2011 
Moss et al., 2013a 
Srivastava et al., 2014 
Overall 
Q=71.06, p=0.00, I2=85%
Moss et al., 2013b 
Berney et al., 1999 
Wulffaert et al.,2009a 
Bhuiyan et al., 2006 
Moss et al., 2008 
Moss et al.,2012 
    Prev (95% CI)          % Weight
   0.05  (  0.01,  0.13)      9.29
   0.31  (  0.20,  0.45)      7.16
   0.35  (  0.22,  0.49)     10.34
   0.39  (  0.29,  0.48)     10.58
   0.40  (  0.16,  0.66)      4.32
   0.41  (  0.27,  0.57)      7.90
   0.43  (  0.32,  0.53)    100.00
   0.46  (  0.36,  0.55)     10.73
   0.53  (  0.39,  0.67)      6.79
   0.54  (  0.38,  0.70)     10.49
   0.62  (  0.46,  0.76)     10.75
   0.62  (  0.45,  0.78)      5.70
   0.65  (  0.43,  0.85)      5.96
 
Figure 1.8. Pooled prevalence estimates for ASD phenomenology in Cornelia de Lange 
syndrome using a quality-effects model. 
 
 
The results revealed that both the random and quality-effects models generated a prevalence 
estimate for ASD phenomenology in Cornelia de Lange syndrome of 43%. The confidence 
intervals were similar in both the random and quality-effects models, ranging from 33 – 54% 
for random-effects and 32 – 53% for quality-effects. The study conducted by Basile, Villa, 
Selicorni & Molteni (2007) was an outlier, but removal of this study did not have a substantial 
impact upon the pooled prevalence estimates (both random and quality-effects estimates 
increased to 47%). Additionally, the study evidenced a good quality weighting of 0.56 and 
thus there is a pragmatic argument for including the data from this study.  
 
p <.001, 
p <.0 1, 
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1.4.6 Down Syndrome  
The literature search identified 11 papers that reported the prevalence of ASD 
phenomenology in Down syndrome. These are presented in Table 1.10. The quality of the 
identified papers was found to be variable, with quality weightings ranging from 0.11 to 1.00. 
All studies, apart from Skotko, Davidson and Weintraub (2013) provided an adequate 
assessment of ASD phenomenology; however, only one of the eleven studies assessed ASD 
phenomenology with sufficient rigour to obtain a quality rating of three (DiGuiseppi et al., 
2010). The study conducted by DiGuiseppi et al., (2010) was notable in that it obtained the 
highest quality rating for all three criteria. Additionally, the authors reported the prevalence 
data clearly, allowing for visual inspection of the differing prevalence data generated by each 
assessment method. Three of the eleven studies used total population recruitment strategies 
(DiGuiseppi et al., 2010; Kent, Evans, Paul & Sharp, 1999; Lowenthal, Paula, Schwartzman, 
Brunoni & Mercadante, 2007), which is unusual in comparison to the other syndrome groups 
where few population studies have been conducted. Seven of the studies also reported on the 
profile of ASD phenomenology in Down syndrome, in addition to reporting the prevalence.  
 
Despite the relatively clear clinical and genetic markers used for diagnosis in Down 
syndrome, five of the eleven papers did not report how Down syndrome diagnosis was 
established in their samples (Kent et al., 1999; Lowenthal et al., 2007; Povee, Roberts, 
Bourke & Leonard, 2012; Skotko et al., 2013; Starr, Berument, Tomlins, Papanikolaou & 
Rutter, 2005). In some cases, this was likely due to the competing demand of establishing 
large enough samples; however in other cases this was due to a lack of descriptive 
information in the paper. The lack of clarity regarding the diagnostic status of some of the 
samples does somewhat limit confidence in the generated pooled prevalence estimates. 
However, all eleven studies provided an adequate sampling strategy, and described this well 
in the papers. On the basis of quality, one paper (Skotko et al., 2013) was excluded from the 
quantitative analysis. 
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Table 1.10. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in Down 
syndrome. 
 
Quality 
Criteria 
Down Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N % Male 
Mean Age 
(SD) 
Range 
% with 
ID  
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Bruining et al., 2014 
   
21 23.8 
169.1
114
 
(32.6) 
49.5
115
 Cytogenetic ADI-R Not reported  Yes ASD: 28.6 
28.6 
(6) 
0.78    
   
DiGuiseppi et al., 2010 
   
123 65.0 
73.4
116
 
(28.0) 
31–142 
100.0 
Chromosomal 
analysis 
M-CHAT 
SCQ 
ADOS-G 
ADI-R 
DSM-IV 
Expert 
Psychologists  
No 
Autistic disorder: 6.4 
PDD-NOS:11.8 
SCQ/M-CHAT 
ASD: 42.3 
6.4 
(8) 
1.00    
   
Ji et al., 2011 
   
293 76.0 
Not 
reported 
Not 
reported 
Cytogenetic
117
 DSM-IV Not reported  Yes 
Autism: 27.3 
PDD-NOS: 11.6 
27.3 
(80) 
0.56    
   
Kent et al., 1999 
   
33 54.5 
7.2 
2.0-15.0 
Not 
reported 
Not reported 
ASSQ N/A Yes Aspergers: 18.2 
12.1 
(4) 
0.44    CARS Not reported No Atypical autism: 15.2 
   ICD-10 Not reported  No ASD: 12.1 
Lund, 1988 
   
44 
Not 
reported 
Not 
reported 
Not 
reported 
Clinical or 
chromosomal 
HBS Not reported  No Infantile autism: 11.4 
11.4 
(5) 
0.44    
   
                                                 
114
 Age in months 
115
 Mean IQ score 
116
 Age in months 
117
 Genetic confirmation was available for all except 8.5% of the sample who had clinical features consistent with Down syndromes 
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Quality 
Criteria 
Down Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N % Male 
Mean Age 
(SD) 
Range 
% with 
ID  
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Lowenthal et al., 2007  
   
180 41.3 
Not 
reported 
Not 
reported 
Not reported 
ASQ 
History Qs 
N/A  No 
Autism: 5.6 
PDD-NOS: 10.0 
5.6 
(10) 
0.44    
   
Moss et al., 2013c 
   
108 42.6 
22.16 
(12.51) 
4.0 – 62.0 
Not 
reported 
Physician/ 
Paediatrician/ 
Geneticist 
SCQ N/A Yes 
Autism: 8.3 
ASD: 19.4 
8.3 
(9) 
0.44    
   
Povee et al., 2012 
   
224 
Not 
reported 
4.0 – 25.0 
Not 
reported 
Not reported SCQ N/A  Yes ASD: 26.8
118
 
26.8 
(60) 
0.33    
   
Skotko et al., 2013 
   
105 63.8 
9.5 
(3.8) 
3.2 – 20.9 
Not 
reported 
Not reported 
Not 
reported 
N/A  
Not 
reported 
ASD: 10.5 
10.5 
(11) 
0.11    
   
Starr et al., 2005 
   
13 46.2 
14.6 
7.8 – 31.9 
100.0 N/A 
A-PL-
ADOS
119
 
ADI-R 
Not reported  Yes ASD: 38.5 
38.5 
(5) 
0.44    
   
Turk & Graham, 1997 
   
45 100.0 
Not 
reported 
Not 
reported 
Cytogenetic 
HBS 
ADDC
120
 
DSM-III 
Not reported  Yes 
Autism: 11.1 
PDD-NOS: 17.8 
11.1 
(5) 
0.56    
   
                                                 
118
 This study did not report the more stringent autism cut off for the SCQ. Thus the less conservative ASD cut off  is used. 
119
 Pre-linguistic ADOS 
120
 Autistic Disorders Diagnostic Checklist 
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Random and quality-effects pooled prevalence estimates were generated based on the ten 
papers that met the quality inclusion criteria. These are presented in Figures 1.9 and 1.10.  
Prev
0.60.50.40.30.20.10
Study 
Lowenthal et al., 2007 
DiGuiseppi et al., 2010 
Moss et al., 2013c 
Turk & Graham, 1997 
Lund, 1988 
Kent et al., 1999 
Overall 
Q=82.33, p=0.00, I2=89%
Povee et al., 2012 
Ji et al., 2011 
Bruining et al., 2014 
Starr et al., 2005 
    Prev (95% CI)          % Weight
   0.06  (  0.03,  0.09)     11.54
   0.07  (  0.03,  0.12)     11.21
   0.08  (  0.04,  0.14)     11.07
   0.11  (  0.03,  0.22)      9.70
   0.11  (  0.03,  0.23)      9.66
   0.12  (  0.03,  0.26)      9.01
   0.16  (  0.09,  0.23)    100.00
   0.27  (  0.21,  0.33)     11.69
   0.27  (  0.22,  0.33)     11.83
   0.29  (  0.11,  0.50)      7.84
   0.38  (  0.14,  0.67)      6.45
 
Figure 1.9. Pooled prevalence estimates for ASD phenomenology in Down syndrome 
using a random-effects model. 
 
Prev
0.60.50.40.30.20.10
Study 
Lowenthal et al., 2007 
DiGuiseppi et al., 2010 
Moss et al., 2013c 
Turk & Graham, 1997 
Lund, 1988 
Kent et al., 1999 
Overall 
Q=82.33, p=0.00, I2=89%
Povee et al., 2012 
Ji et al., 2011 
Bruining et al., 2014 
Starr et al., 2005 
    Prev (95% CI)          % Weight
   0.06  (  0.03,  0.09)     11.14
   0.07  (  0.03,  0.12)     20.09
   0.08  (  0.04,  0.14)      8.23
   0.11  (  0.03,  0.22)      7.24
   0.11  (  0.03,  0.23)      5.65
   0.12  (  0.03,  0.26)      5.20
   0.16  (  0.08,  0.24)    100.00
   0.27  (  0.21,  0.33)      9.69
   0.27  (  0.22,  0.33)     19.99
   0.29  (  0.11,  0.50)      8.36
   0.38  (  0.14,  0.67)      4.40
 
Figure 1.10. Pooled prevalence estimates for ASD phenomenology in Down syndrome 
using a quality-effects model. 
 
The results revealed that both the random and quality-effects models generated a prevalence 
estimate for ASD phenomenology in Down syndrome of 16%. The confidence intervals were 
similar in both the random and quality-effects models, ranging from 9 – 23% for random-
effects and 8 – 24% for quality-effects. There were no significant outliers in the data.
p <.001, 
p <.001, 
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1.4.7 Angelman Syndrome 
The literature search identified seven papers that reported the prevalence of ASD 
phenomenology in Angelman syndrome. These are presented in Table 1.11. Six of the seven 
papers reached an adequate standard of quality for sample selection, confirmation of 
Angelman diagnosis and assessment of ASD phenomenology. The only exception was Sahoo 
et al. (2006) who did not report how their sample were recruited, but did however report an 
interesting analysis of the associations between deletion size and ASD phenomenology. 
 
Confirmation of Angelman syndrome was well reported, with five of the seven studies 
utilising genetic analysis. Similarly, assessment of ASD phenomenology was good, with five 
studies using diagnostic measures. Importantly, five of the seven studies also progressed 
beyond simply reporting prevalence, and presented data describing the profile of ASD 
phenomenology in the syndrome. Overall, the quality weightings were good, ranging from 
0.44 to 0.89. However, it should be noted that the sample sizes across the studies were 
relatively small, with the exception of Oliver et al. (2011). 
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Table 1.11. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in 
Angelman syndrome. 
 
Quality 
Criteria 
Angelman Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Bonati et al., 2007 
   
23 60.9 2 - 37 
Not 
reported 
Molecular 
testing 
ADOS 
ADI-R 
Not reported Yes 
Autism: 34.8 
ASD: 26.1     
34.8 
(8) 
0.89    
   
Moss et al., 2013b 
   
19 52.6 
10.4 
(4.8) 
3.0 – 18.5 
Not 
reported 
Physician/ 
Paediatrician/ 
Geneticist 
SCQ N/A Yes 
Autism: 40.0 
ASD: 93.3 
40.0 
(6) 
0.44    
   
Oliver et al., 2011 
   
104 55.8 
13.4 
(8.0) 
4.0 – 45.0 
67.0
121
 
Physician/ 
Paediatrician/ 
Geneticist 
SCQ N/A Yes 
Autism: 17.8 
ASD: 66.3  
17.8 
(18) 
0.44    
   
Peters et al., 2004 
   
19 57.9 
3.8 
(2.5) 
Not 
reported 
Molecular 
testing 
ADOS 
ADI-R 
DSM-IV 
Reliability 
trained 
clinician 
No All autism: 42.1 
42.1 
(8) 
0.78    
   
Peters et al., 2012b 
   
42 57.1 
5.5 
(4.8) 
2.0 – 25.0 
Not 
reported 
Molecular 
testing 
ADOS 
Research 
reliable 
Psychologists 
Yes 
Autism: 28.6
122
  
ASD: 16.7 
28.6 
(12) 
0.78    
   
Sahoo et al., 2006 
   
22 59.1 1.5 – 17.0 
Not 
reported 
Molecular 
testing 
ADOS 
ADI-R 
Not reported No Autism: 45.5  
45.5 
(10) 
0.67    
   
                                                 
121
 Defined as not able on the Wessex 
122
 This is a longitudinal study and therefore data in the paper are presented at two time points. Only data from the first time point are reported here, 
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Quality 
Criteria 
Angelman Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Trillingsgaard & 
Østergaard, 2004 
   
16 43.8 5.0 – 15.0 
Not 
reported 
Molecular 
testing 
ADOS-G 
Trained 
psychologist 
Yes 
Autism: 62.5 
PDD-NOS: 18.8  
62.5 
(10) 
0.78    
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Random and quality-effects pooled prevalence estimates were generated based on the 7 
papers that met the quality inclusion criteria. These are presented in Figures 1.11 and 1.12.  
Prev
0.80.70.60.50.40.30.20.1
Study 
Oliver et al., 2011 
Peters et al.,2012 
Moss et al., 2013b 
Bonati et al., 2007 
Overall 
Q=19.92, p=0.00, I2=70%
Peters et al., 2004b 
Sahoo et al., 2006 
Trillingsgaard & Østergaard, 2004 
    Prev (95% CI)          % Weight
   0.17  (  0.11,  0.25)     19.12
   0.29  (  0.16,  0.43)     16.37
   0.32  (  0.12,  0.54)     12.74
   0.35  (  0.16,  0.56)     13.70
   0.35  (  0.24,  0.48)    100.00
   0.42  (  0.21,  0.65)     12.74
   0.45  (  0.25,  0.67)     13.48
   0.63  (  0.37,  0.85)     11.86
 
Figure 1.11. Pooled prevalence estimates for ASD phenomenology in Angelman 
syndrome using a random-effects model. 
 
 
Prev
0.80.70.60.50.40.30.20.1
Study 
Oliver et al., 2011 
Peters et al.,2012 
Moss et al., 2013b 
Overall 
Q=19.92, p=0.00, I2=70%
Bonati et al., 2007 
Peters et al., 2004b 
Sahoo et al., 2006 
Trillingsgaard & Østergaard, 2004 
    Prev (95% CI)          % Weight
   0.17  (  0.11,  0.25)     22.09
   0.29  (  0.16,  0.43)     19.69
   0.32  (  0.12,  0.54)      7.04
   0.34  (  0.23,  0.47)    100.00
   0.35  (  0.16,  0.56)     15.66
   0.42  (  0.21,  0.65)     12.47
   0.45  (  0.25,  0.67)     11.52
   0.63  (  0.37,  0.85)     11.53
 
Figure 1.12. Pooled prevalence estimates for ASD phenomenology in Angelman 
syndrome using a quality-effects model. 
 
The results revealed that the random-effects model generated a prevalence estimate of 35% 
(CI 24 – 48%). The quality-effects model generated a slightly more conservative estimate of 
34% (CI 23 – 47%). 
 
1.4.8 Neurofibromatosis Type 1 
The literature search identified six papers that reported the prevalence of ASD 
phenomenology in Neurofibromatosis Type 1
123
. These are presented in Table 1.12.  All of 
the papers reached an adequate standard of quality for sample selection, confirmation of 
Neurofibromatosis Type 1 diagnosis and assessment of ASD phenomenology.  
                                                 
123
 Although the literature search included terms for Neurofibromatosis Type 2, papers were only identified 
reporting the prevalence of ASD phenomenology in Neurofibromatosis Type 1. 
p <.001, 
p <.0 1, 
Chapter 1: A Meta-Analysis of ASD in Syndromes 
61 
 
Table 1.12. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in 
Neurofibromatosis Type 1. 
 
Quality 
Criteria 
Neurofibromatosis Type 1 Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N % Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Adviento et al., 2014 
   
66 39.4 
Not 
reported 
Not 
reported 
Medical 
geneticist or 
neurologist
124
 
SCQ N/A No SCQ ASD: 11.0 
10.6 
(~7) 
0.56    
   
Garg et al., 2013a 
   
47 
Not 
reported 
11.7 
(2.9) 
7.2 – 18.4 
95.7
125
 
Clinical 
features by 
geneticists 
ADI-R 
ADOS 
CPEA 
Blind inter-
rater 
reliability 
obtained 
Yes 
ASD: 29.8 
Broad ASD: 27.7 
29.8 
(14) 
0.89    
   
Garg et al., 2013b 
   
109 45.9 
9.11 
(3.3) 
Not 
reported 
Review of 
medical notes 
by specialists 
SRS N/A No 
Severe autism: 29.4 
Mild/mod autism: 26.6 
29.4 
(32) 
0.67    
   
van Eeghen et al., 
2013 
   
50 62.0 
25.0 
4.0 – 63.0 
6.0 
Clinical 
features by 
specialists 
SRS N/A No 
Autism: 18.0 
ASD: 40.0 
18.0 
(9) 
0.44    
   
Walsh et al., 2013 
   
66 63.6 
10.11 
(5.4) 
Not 
reported 
Clinical 
features by 
specialists 
SRS N/A No 
ASD: 10.6 
   Clinically raised 
symptoms: 48.4  
10.6 
(7) 
0.44    
   
 
 
              
                                                 
124
 Molecular confirmation reported for a subset of 11% 
125
 Mean verbal IQ 
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Quality 
Criteria 
Neurofibromatosis Type 1 Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N % Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Williams & Hersch, 
1998 
   
74 55.4 
9.6 
0.4 – 31.0 
Not 
reported 
Clinical 
features by 
geneticist 
DSM-III 
DSM-IV 
Not reported No Autism: 4.1  
4.1 
(3) 
0.44    
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The study by Garg et al., (2013a) is particularly notable as it is the only study that used 
diagnostic, rather than screening, measures for ASD phenomenology. The authors also 
conducted a population based epidemiological study in order to recruit their sample, resulting 
in a representative and robustly assessed group. It was also the only study to progress beyond 
reporting simple prevalence of ASD phenomenology, to describe the profile of ASD 
phenomenology in Neurofibromatosis Type 1. The quality weightings for all studies 
conducted in Neurofibromatosis Type 1 were relatively homogenous, ranging from 0.44 to 
0.89. This suggests that the generated pooled prevalence estimates are drawn from a robust 
data set.  
 
Random and quality-effects pooled prevalence estimates were generated based on the 6 
papers that met the quality inclusion criteria. These are presented in Figures 1.13 and 1.14.  
 
Prev
0.40.30.20.10
Study 
Williams & Hersch, 1998 
Adviento et al., 2007 
Walsh et al.,2013 
Overall 
Q=31.17, p=0.00, I2=84%
van Eeghen et al., 2013 
Garg et al., 2013b 
Garg et al., 2013a 
    Prev (95% CI)          % Weight
   0.04  (  0.01,  0.10)     17.03
   0.11  (  0.04,  0.19)     16.73
   0.11  (  0.04,  0.19)     16.73
   0.16  (  0.08,  0.26)    100.00
   0.18  (  0.08,  0.30)     15.91
   0.29  (  0.21,  0.38)     17.88
   0.30  (  0.17,  0.44)     15.71
Figure 1.13. Pooled prevalence estimates for ASD phenomenology in Neurofibromatosis 
Type 1 using a random-effects model. 
 
Prev
0.40.30.20.10
Study 
Williams & Hersch, 1998 
Adviento et al., 2007 
Walsh et al.,2013 
van Eeghen et al., 2013 
Overall 
Q=31.17, p=0.00, I2=84%
Garg et al., 2013b 
Garg et al., 2013a 
    Prev (95% CI)          % Weight
   0.04  (  0.01,  0.10)     13.38
   0.11  (  0.04,  0.19)     15.95
   0.11  (  0.04,  0.19)     12.53
   0.18  (  0.08,  0.30)     10.84
   0.18  (  0.09,  0.29)    100.00
   0.29  (  0.21,  0.38)     26.03
   0.30  (  0.17,  0.44)     21.27
 
Figure 1.14. Pooled prevalence estimates for ASD phenomenology in Neurofibromatosis 
Type 1 using a quality-effects model. 
 
p <.001, 
p <.0 1, 
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The results revealed that the random-effects model generated a prevalence estimate of 16% 
(CI 8 – 26%). The quality-effects model generated a less conservative estimate of 18% (CI 9 – 
29%). There were no significant outliers noted. 
 
1.4.9 Williams Syndrome  
The literature search identified six papers that reported the prevalence of ASD 
phenomenology in Williams syndrome. These are presented in Table 1.13. The quality 
weightings of the included studies were moderate to good, ranging from 0.33 to 0.78, and thus 
whilst the literature reporting the prevalence of ASD phenomenology in Williams syndrome 
is relatively small, it is also quite robust.  
 
One study was excluded from the statistical meta-analysis as it did not meet the pre-defined 
quality inclusion criteria (Van der Aa et al., 2009). Four of the five included studies 
confirmed the diagnosis of Williams syndrome with genetic testing. The paper published by 
Lincoln, Searcy, Jones and Lord (2007) is notable as both syndrome confirmation and ASD 
assessment received the highest quality weighting. In addition to reporting the prevalence of 
ASD phenomenology in Williams syndrome, three studies also reported on the profile of 
these behaviours (Klein-Tasman, Mervis, Lord & Phillips, 2007; Klein-Tasman, Phillips, 
Lord, Mervis & Gallo, 2009; Lincoln et al., 2007). As in other syndrome groups, it is possible 
that the two papers by Klein-Tasman and colleagues report on similar samples, and thus some 
individuals with Williams syndrome may be counted twice within the meta-analysis. 
However, it was not possible to obtain whether this was the case, or the proportion of 
overlapping samples from the papers, and thus both studies were included in the meta-
analysis. 
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Table 1.13. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in Williams 
syndrome. 
 
Quality 
Criteria 
Williams Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N % Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD Measure 
Professional 
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Klein-Tasman et al., 
2007 
   
29 
 
65.5 
 
41.6
126
 
(8.9) 
30.0 –63.0 
Not 
reported 
Genetically 
confirmed 
ADOS 
Certified 
examiners 
Yes 
Autism: 10.3 
ASD: 37.9 
10.3 
(3) 
0.78    
   
Klein-Tasman et al., 
2009 
   
30 63.3 
41.2
127
 
30.0 –63.0 
Not 
reported 
Genetically 
confirmed 
ADOS 
Certified 
examiners 
Yes 
Autism: 10.0 
ASD: 40.0  
10.0 
(3) 
0.78    
   
Lincoln et al., 2007 
   
20 45.0 
41.6
128
 
(11.3) 
27.0 –58.0 
60.5
129
 
Genetically 
confirmed
130
 
ADOS 
DSM-IV 
Trained reliable 
clinicians and  
Clinical 
Psychologist 
Yes 
Autistic disorder: 10.0  
PDD-NOS: 10.0  
10.0 
(2) 
0.78    
   
Saad et al., 2013 
   
16 62.5 
60.4 
(20.2) 
26.0– 100.0 
68.8 
Genetic 
analysis 
DSM-IV 
CARS 
Not reported No Autism: 6.3  
6.4 
(1) 
0.56    
   
Van der Aa et al., 2009 
   
14 
Not 
reported 
Not 
reported 
85.7 
Genetic 
analysis 
Not 
reported 
Not reported No 
Autism: 14.3 
Autistic features: 14.3  
14.3 
(2) 
0.33    
   
                                                 
126
 Age in months 
127
 Age reported in months 
128
 Age in months 
129
 Mean developmental quotient ratio 
130
 Confirmed genetically for 19 participants. The remaining 1 participant was diagnosed by a clinical geneticist. 
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Quality 
Criteria 
Williams Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N % Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD Measure 
Professional 
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Van der Fluit et al., 
2012 
   
24 50.0 
12.5 
(2.8) 
8.1 – 15.9 
65.7
131
 Not reported SCQ N/A No ASD: 29.2 
29.2 
(7) 
0.33    
   
                                                 
131
 Mean IQ score 
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Random and quality-effects pooled prevalence estimates were generated based on the five 
papers that met the quality inclusion criteria. These are presented in Figures 1.15 and 1.16.  
 
Prev
0.50.40.30.20.10
Study 
Saad et al., 2013 
Klein Tasman et al., 2009 
Lincoln et al., 2007 
Klein-Tasman et al., 2007 
Overall 
Q=4.70, p=0.32, I2=15%
Van der Fluit et al., 2012 
    Prev (95% CI)          % Weight
   0.06  (  0.00,  0.25)     14.35
   0.10  (  0.01,  0.24)     24.33
   0.10  (  0.00,  0.28)     17.38
   0.10  (  0.01,  0.25)     23.67
   0.14  (  0.08,  0.21)    100.00
   0.29  (  0.12,  0.49)     20.26
 
Figure 1.15. Pooled prevalence estimates for ASD phenomenology in Williams syndrome 
using a random-effects model. 
 
Prev
0.50.40.30.20.10
Study 
Saad et al., 2013 
Klein Tasman et al., 2009 
Lincoln et al., 2007 
Klein-Tasman et al., 2007 
Overall 
Q=4.70, p=0.32, I2=15%
Van der Fluit et al., 2012 
    Prev (95% CI)          % Weight
   0.06  (  0.00,  0.25)     13.51
   0.10  (  0.01,  0.24)     27.81
   0.10  (  0.00,  0.28)     21.39
   0.10  (  0.01,  0.25)     27.16
   0.12  (  0.06,  0.20)    100.00
   0.29  (  0.12,  0.49)     10.13
Figure 1.16. Pooled prevalence estimates for ASD phenomenology in Williams syndrome 
using a quality-effects model. 
 
The results revealed that the random-effects model generated a prevalence estimate of 14% 
(CI 8 – 21%). The quality-effects model generated a more conservative estimate of 12% (CI 6 
– 20%). 
 
1.4.10 Rett syndrome 
The literature search identified five
132
 papers that reported the prevalence of ASD 
phenomenology in Rett syndrome. These are presented in Table 1.14. The overall quality of 
research conducted in Rett syndrome was relatively poor, with only one study obtaining a 
quality weighting greater than 0.56 (range 0.44 – 0.78). Two studies confirmed the presence 
of Rett syndrome with genetic testing, but no studies undertook sufficiently robust ASD 
assessments to obtain the highest quality rating. Two studies did however present data on the 
profile of ASD phenomenology in the syndrome.  
                                                 
132
 A further paper met the initial screening criteria; however it was not possible to obtain this paper from either 
University of Birmingham Library or the British Library. 
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Table 1.14. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in Rett 
syndrome. 
 
Quality 
Criteria 
Rett Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Coleman et al., 1988 
   
63 0.0 2.0 – 20.0 
Not 
reported 
Experienced 
Paediatricians 
Paediatric 
neurologists 
Parental 
report 
N/A No 
               Autistic  
withdrawal: 73.0 
73.0 
(46) 
0.44    
   
Hagberg et al., 1983 
   
35 0.0 Not reported 
Not 
reported 
Child 
neurologists 
and authors of 
paper 
Not 
reported 
Not reported No 
Pronounced autistic 
behaviour:80.0  
80.0 
(28) 
0.44    
   
Mount et al., 2003 
   
15 0.0 
13.6 
(2.1) 
Not 
reported 
Experienced 
paediatrician 
ABC N/A Yes 
  High probability 
autism: 40.0  
40.0 
(6) 
0.44    
   
Renieri et al., 2009 
   
29 0.0 5.0 – 37.0 
Not 
reported 
for full 
sample 
Genetic and 
Child Neuro-
psychiatrist 
DSM-IV 
ABC
133
 
Child Neuro-
psychiatrist 
No Autism: 44.8  
44.8 
(13) 
0.56    
   
Wulffaert et al., 2009b 
   
52 0.0 
16.5 
(11.8) 
2.4 – 49.3 
100.0 
Genetic 
testing and 
clinical 
features 
DBC 
Trained 
interviewers 
Yes 
       DBC Autistic  
disorder: 42.3  57.8 
(30) 
0.78 
   
   
DISCO 
     DISCO autistic 
disorder: 57.8     
 
                                                 
133
 Only used in some cases – study does not report the proportion of cases where this was used. 
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The overall lower quality of evidence obtained in Rett syndrome does somewhat limit the 
validity of the generated pooled prevalence estimates. However, all studies obtained a good 
rating for confirmation of Rett syndrome and an adequate rating for sample identification, so 
key aspects of internal and external validity were appropriately controlled.  
 
Random and quality-effects pooled prevalence estimates were generated based on the five 
papers that met the quality inclusion criteria. These are presented in Figures 1.17 and 1.18. 
  
Prev
0.90.80.70.60.50.40.30.2
Study 
Mount et al., 2003 
Renieri et al., 2009 
Wulffaert et al., 2009b 
Overall 
Q=15.02, p=0.00, I2=73%
Coleman et al., 1988 
Hagberg et al., 1983 
    Prev (95% CI)          % Weight
   0.40  (  0.16,  0.66)     14.97
   0.45  (  0.27,  0.63)     19.24
   0.58  (  0.44,  0.71)     22.32
   0.61  (  0.47,  0.75)    100.00
   0.73  (  0.61,  0.83)     23.15
   0.80  (  0.65,  0.92)     20.32
Figure 1.17. Pooled prevalence estimates for ASD phenomenology in Rett syndrome 
using a random-effects model. 
 
Prev
0.90.80.70.60.50.40.30.2
Study 
Mount et al., 2003 
Renieri et al., 2009 
Wulffaert et al., 2009b 
Overall 
Q=15.02, p=0.00, I2=73%
Coleman et al., 1988 
Hagberg et al., 1983 
    Prev (95% CI)          % Weight
   0.40  (  0.16,  0.66)     11.76
   0.45  (  0.27,  0.63)     18.96
   0.58  (  0.44,  0.71)     30.53
   0.61  (  0.46,  0.74)    100.00
   0.73  (  0.61,  0.83)     22.51
   0.80  (  0.65,  0.92)     16.24
 
Figure 1.18. Pooled prevalence estimates for ASD phenomenology in Rett syndrome 
using a quality-effects model. 
 
The results revealed that both the random and quality-effects models generated a prevalence 
estimate for ASD phenomenology in Rett syndrome of 61%. The confidence intervals were 
similar in both the random and quality-effects models, ranging from 47– 75% for random-
effects and 46 – 74% for quality-effects.  
 
1.4.11 CHARGE Syndrome 
The literature search identified five papers that reported the prevalence of ASD 
phenomenology in CHARGE syndrome. These are presented in Table 1.15.  
p <.0 1, 
p <.0 1, 
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Table 1.15. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in 
CHARGE syndrome. 
 
Quality 
Criteria 
CHARGE syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N % Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Hartshorne et al., 2005 
   
160 53.1 
10.9 
(5.6) 
3.0 – 33.0 
Not 
reported 
Not reported ABC N/A Yes Autism: 27.5 
27.5 
(44) 
0.33    
   
Johansson et al., 2006 
   
28 48.4
134
 8.11
135
 78.6 
Multi-
disciplinary  
specialist team 
Clinical features 
ADI-R 
CARS 
ABC 
DSM-III 
DSM-IV 
Independent 
investigators 
Yes Autism: 60.7 
60.7 
(17) 
0.78    
   
Miller et al., 2004 
   
31 
Not 
reported 
Not 
reported 
38.7
136
 
Multi-
disciplinary  
specialist team 
Clinical features 
ADI-R 
CARS 
ABC 
DSM-IV 
Not reported No 
Autistic disorder: 16.1  
ASD: 16.1  
16.1 
(5) 
0.78    
   
Smith et al., 2005 
   
13 61.5 
9.0 
2.9 – 24.0 
Not 
reported 
Multi-
disciplinary  
specialist team 
Clinical features 
SCQ N/A No 
Autism: 15.4 
ASD: 23.1  
15.4 
(2) 
0.67    
   
Wachtel et al., 2007 
   
87 59.3 
11.1 
(3.7) 
6.0 – 18.0 
Not 
reported 
Parental report 
Parental 
report 
N/A No 
Autism: 9.2 
Asperger’s: 2.3 
PDD: 6.9   
9.2 
(8) 
0.11    
   
                                                 
134
 Percentage of males presented for total sample of 31; however only 28 participants completed the ASD assessments 
135
 Mean age presented for total sample of 31; however, only 28 participants completed the ASD assessments 
136
 Severe developmental delay 
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The quality of the studies was varied, with quality ratings ranging from 0.33 to 0.78. One 
study (Wachtel, Hartshorne & Dailor, 2007) was excluded as it did not meet the pre-defined 
quality inclusion criteria. Of the four included studies, two papers assessed ASD very 
robustly, using consensus of a diagnostic measure and an additional ASD assessment 
(Johansson et al., 2006; Miller, Stromland, Ventura, Johansson, Bandim & Gillberg, 2004), 
and two studies presented data on the profile of ASD phenomenology in the syndrome 
(Hartshorne, Grialou & Parker, 2005; Johansson et al., 2006). The paper conducted by 
Hartshorne and colleagues (2005) was notable, as they recruited a large sample with 
CHARGE syndrome, although they did not report how the syndrome was confirmed. All 
three other studies reported ‘expert’ clinical confirmation of CHARGE syndrome.  
 
Random and quality-effects pooled prevalence estimates were generated based on the four 
papers that met the quality inclusion criteria. These are presented in Figures 1.19 and 1.20.  
 
Prev
0.80.70.60.50.40.30.20.10
Study 
Smith et al., 2005 
Miller et al., 2004 
Hartshorne et al., 2005 
Overall 
Q=15.39, p=0.00, I2=81%
Johansson et al., 2006 
    Prev (95% CI)          % Weight
   0.15  (  0.00,  0.41)     19.32
   0.16  (  0.05,  0.31)     25.20
   0.28  (  0.21,  0.35)     30.87
   0.29  (  0.14,  0.48)    100.00
   0.61  (  0.42,  0.78)     24.61
Figure 1.19. Pooled prevalence estimates for ASD phenomenology in CHARGE 
syndrome using a random-effects model. 
 
 
Prev
0.80.70.60.50.40.30.20.10
Study 
Smith et al., 2005 
Miller et al., 2004 
Hartshorne et al., 2005 
Overall 
Q=15.39, p=0.00, I2=81%
Johansson et al., 2006 
    Prev (95% CI)          % Weight
   0.15  (  0.00,  0.41)     17.87
   0.16  (  0.05,  0.31)     26.80
   0.28  (  0.21,  0.35)     29.53
   0.30  (  0.14,  0.48)    100.00
   0.61  (  0.42,  0.78)     25.80
Figure 1.20. Pooled prevalence estimates for ASD phenomenology in CHARGE 
syndrome using a quality-effects model 
 
 
The results revealed that the random-effects model generated a prevalence estimate of 29% 
(CI 14 – 48%). The quality-effects model generated a similar estimate of 30% (CI 14 – 48%). 
p <.001, 
p <.001, 
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1.4.12 Moebuis Syndrome 
The literature search identified four papers that reported the prevalence of ASD 
phenomenology in Moebuis syndrome. These are presented in Table 1.16. All four papers 
reached an adequate standard of quality for sample selection, confirmation of Moebuis 
diagnosis and assessment of ASD phenomenology. This is evidenced in the relatively 
homogeneous quality weightings, ranging from 0.44 to 0.67, indicating that the pooled 
prevalence estimates are generated from data of robust quality. As no specific genetic cause 
has been identified for Moebuis syndrome, it is unsurprising that none of the studies 
employed genetic testing to confirm the diagnosis; however, only one study utilised ‘experts’ 
to confirm a clinical diagnosis of Moebuis, with the remaining three studies utilising 
‘generalists’. Two papers provided very robust assessment of ASD phenomenology, and one 
study presented data on the profile of ASD in Moebuis as well as the prevalence. Whilst the 
key indicators for the quality ratings were well reported across the studies, two of the studies 
did not report the sample characteristics of their participants very clearly (Gillberg & 
Steffenburg, 1989; Miller et al., 2004). Additionally, although the quality weightings of the 
studies were robust, the generated pooled prevalence estimates may be biased by the 
inadvertent inclusion of participants in multiple studies (Briegel et al., 2009; Briegel et al., 
2010). Similarly to other syndrome groups, it was not possible to confirm the proportion of 
overlapping samples from the papers, and thus both studies were included in the meta-
analysis. 
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Table 1.16. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in Moebuis 
syndrome. 
 
Quality 
Criteria 
Moebuis Syndrome  Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N % Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Briegel et al., 2010 
   
22 54.5 
11.3 
6.0 – 16.0 
9.1 
Geneticist or 
paediatrician 
VSK 
MBAS
137
 
Clinical 
consensus 
conference 
No 
Possibly autistic: 13.6  
0.0 
(0) 
0.67 
   
ADI-R 
ADOS 
Kinder-
DIPS 
Autistic: 0.0 
   
Briegel et al., 2009 
   
27 44.4 
11.6 
(2.11) 
6.9 – 17.0 
0.0 
Geneticist or 
paediatrician 
VSK 
MBAS 
Not reported Yes 
Possibly autistic: 7.4  
0.0 
(0) 
0.67 
   ADI-R 
ADOS 
Kinder-
DIPS 
Autistic: 0.0 
   
Gillberg & 
Steffenburg, 1989 
   
17 
Not 
reported 
2.0 – 34.0  
Not 
reported 
Clinical criteria 
Medical case 
records 
Paediatrician or 
Child Psychiatrist 
DSM-III-
R 
Authors No Autistic disorder: 29.4  
 
29.4 
(5) 
0.44    
   
Miller et al., 2004 
   
28 
Not 
reported 
Not 
reported 
Not 
reported 
Multi-
disciplinary  
specialist team 
Clinical features 
CARS 
DSM-IV 
Not reported No 
Autistic disorder: 17.9  
          Autistic-like  
condition: 7.1  
17.9 
(5) 
0.56    
   
                                                 
137
 Marburger Asperger’s Syndrome Rating Scale 
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Random and quality-effects pooled prevalence estimates were generated based on the four 
papers that met the quality inclusion criteria. These are presented in Figures 1.21 and 1.22.  
 
Prev
0.50.40.30.20.10
Study 
Briegel et al., 2010 
Briegel et al., 2009 
Overall 
Q=16.29, p=0.00, I2=82%
Miller et al., 2004 
Gillberg & Steffenburg, 1989 
    Prev (95% CI)          % Weight
   0.00  (  0.00,  0.08)     24.84
   0.00  (  0.00,  0.06)     25.74
   0.09  (  0.00,  0.25)    100.00
   0.18  (  0.06,  0.35)     25.88
   0.29  (  0.10,  0.54)     23.54
Figure 1.21. Pooled prevalence estimates for ASD phenomenology in Moebuis syndrome 
using a random-effects model. 
 
 
Prev
0.50.40.30.20.10
Study 
Briegel et al., 2010 
Briegel et al., 2009 
Overall 
Q=16.29, p=0.00, I2=82%
Miller et al., 2004 
Gillberg & Steffenburg, 1989 
    Prev (95% CI)          % Weight
   0.00  (  0.00,  0.08)     27.29
   0.00  (  0.00,  0.06)     30.78
   0.07  (  0.00,  0.22)    100.00
   0.18  (  0.06,  0.35)     26.31
   0.29  (  0.10,  0.54)     15.63
Figure 1.22. Pooled prevalence estimates for ASD phenomenology in Moebuis syndrome 
using a quality-effects model. 
 
The results revealed that the random-effects model generated a prevalence estimate of 9% (CI 
0 – 25%). The quality-effects model generated a more conservative estimate of 7% (CI 0 – 
22%). However, given the heterogeneity between the prevalence estimates in the papers, the 
pooled prevalence estimates need to be interpreted with caution. This caution is supported by 
the confidence intervals for both the random and quality-effects models’ including zero. 
Therefore, the pooled prevalence estimates for Moebuis syndrome are not included in any 
further between syndrome comparisons.  
 
1.4.13 Phenylketonuria 
The literature search identified four papers that reported the prevalence of ASD 
phenomenology in Phenylketonuria. These are presented in Table 1.17. Three of the four 
papers reached an adequate standard of quality for sample selection, confirmation of 
Phenylketonuria diagnosis and assessment of ASD phenomenology.  
p <.001, 
p <.001  
Chapter 1: A Meta-Analysis of ASD in Syndromes 
75 
 
Table 1.17. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in 
Phenylketonuria. 
 
Quality 
Criteria 
Phenylketonuria Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N % Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Baieli et al., 2003 
   
97
138
 
63.9 
5.7
139
 18.5 
(2.5)  (2.4) 
2-10  12-24 
94.4
140
 
45.5 
Metabolic 
testing 
ADI-R 
CARS 
Not reported No Autism: 2.1
141
  
2.1 
(2) 
0.78    
   
Hackney et al., 1968 
   
22
142
 
Not 
reported 
Not 
reported 
100.0 Various
143
 
Not 
reported 
Psychologist No 
Autistic behaviour 
patterns: 40.9 
40.9 
(9) 
0.22    
   
Sadek et al., 2013 
   
24
144
 
62.5 
3.4 
(3) 
0.08 –11.0 
66.7 
Metabolic 
testing 
CARS 
DSM-IV 
Not reported No Autistic features: 33.3 
33.3 
(8) 
0.56    
   
Yalaz et al., 2006 
   
146
145
 
Not 
reported 
Not 
reported 
89.0 
Paediatric 
neurologist
146
 
CARS 
ABC 
Not reported No Autism: 10.3
147
  
10.3 
(15) 
0.44    
   
                                                 
138
 Includes 62 diagnosed by neonatal screening and 35 were identified later as they were born after the introduction of screening, and thus had gone untreated 
139
 Data presented separately for the early diagnosed (left) and late diagnosed groups (right) 
140
 Mean IQ score – early diagnosed group top, late diagnosed group bottom 
141
 Both cases were identified in the late diagnosed group 
142
 All untreated cases 
143
 Some underwent metabolic testing, or screening, but not all 
144
 This sample were untreated as they were newly diagnosed 
145
 This sample were untreated as they were recruited from rural areas where screening had not taken place; all participants were then commenced upon treatment and some 
results in the study are presented stratified based upon the length of treatment the participant had received. 
146
 Genotyping conducted for 84.2% of cases 
147
 All cases were identified in the late treated sample 
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The study by Hackney, Hanley, Davidson and Lindsao (1968) is the earliest study identified 
in the literature search, across all of the syndromes, and as such should be highlighted as one 
of the first attempts to quantify and describe the phenomenology of ASD in a syndrome. 
However, the assessment of ASD phenomenology in this study was inadequate, and as the 
quality rating of the other two criteria was low, the study was not included in the statistical 
pooled prevalence estimation.  
 
Of the remaining three papers reporting the prevalence of ASD phenomenology in 
Phenylketonuria, the quality was broadly good, with quality weightings ranging from 0.44 to 
0.78. Importantly, all three studies clearly reported the proportion of their samples that 
evidenced untreated Phenylketonuria, which is an important moderating variable when 
interpreting the prevalence estimates in this syndrome (Baieli, Pavone, Meli, Fiumara & 
Coleman, 2003, 36% untreated; Sadek, Emam & Alhaggagy, 2013, 100% untreated; Yalaz, 
Vanli, Yilmaz, Tokatli & Anlar, 2006, 100% untreated). Similarly, all four studies provided 
information on the proportion of their sample with an intellectual disability, enabling further 
understanding of the nature of ASD phenomenology in the group. However, none of the three 
included studies provided any analysis on the profile of ASD behaviours in the syndrome, and 
thus would not be possible to ascertain how similar or different the profile is from idiopathic 
ASD. Two of the studies provided metabolic confirmation of Phenylketonuria, and one 
provided a very robust assessment of ASD phenomenology and obtained the highest quality 
rating on this criteria.  
 
Random and quality-effects pooled prevalence estimates were generated based on the three 
papers that met the quality inclusion criteria. These are presented in Figures 1.23 and 1.24.  
 
Prev
0.50.40.30.20.10
Study 
Baieli et al., 2003 
Yalaz et al., 2006 
Overall 
Q=18.40, p=0.00, I2=89%
Sadek et al., 2013 
    Prev (95% CI)          % Weight
   0.02  (  0.00,  0.06)     35.40
   0.10  (  0.06,  0.16)     36.45
   0.10  (  0.01,  0.27)    100.00
   0.33  (  0.16,  0.54)     28.16
 
Figure 1.23. Pooled prevalence estimates for ASD phenomenology in Phenylketonuria 
using a random-effects model. 
p <.001, 
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Prev
0.50.40.30.20.10
Study 
Baieli et al., 2003 
Overall 
Q=18.40, p=0.00, I2=89%
Yalaz et al., 2006 
Sadek et al., 2013 
    Prev (95% CI)          % Weight
   0.02  (  0.00,  0.06)     46.97
   0.09  (  0.00,  0.23)    100.00
   0.10  (  0.06,  0.16)     34.53
   0.33  (  0.16,  0.54)     18.50
 
Figure 1.24. Pooled prevalence estimates for ASD phenomenology in Phenylketonuria 
using a quality-effects model. 
 
The results revealed that the random-effects model generated a prevalence estimate of 10% 
(CI 1 – 27%). The quality-effects model generated a more conservative estimate of 9% (CI 0 
– 23%).  
 
However, given the small number of papers and significant heterogeneity between the 
prevalence estimates in the papers, the pooled prevalence estimates need to be interpreted 
with caution. This caution is supported by the confidence intervals for the quality-effects 
model including zero. Therefore, the pooled prevalence estimates for Phenylketonuria are not 
included in any further between syndrome comparisons.  
 
1.4.14 Cohen syndrome 
The literature search identified two
148
 papers that reported the prevalence of ASD 
phenomenology in Cohen syndrome. These are presented in Table 1.18. The quality of the 
identified papers was good, with both obtaining quality weightings of 0.67. Both studies 
provided excellent assessment of ASD phenomenology (Howlin & Karpf, 2004; Howlin, 
Karpf & Turk, 2005), with one study progressing beyond prevalence data to report the profile 
of ASD phenomenology in the syndrome (Howlin et al., 2005). However, whilst the 
generated pooled prevalence data are likely to be robust, they are limited by the small number 
of identified papers and the relatively limited confirmation of Cohen syndrome by 
‘generalists’ in each study. 
                                                 
148
 A further paper met the initial screening criteria; however it was not possible to obtain this paper from either 
University of Birmingham Library or the British Library. 
p <.0 1, 
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Table 1.18. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in Cohen 
syndrome 
 
Quality 
Criteria 
Cohen Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% 
with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Howlin & Karpf, 2004 
   
51 ~43.1 
16.7 
(8.9) 
4.8 – 49.0 
80.4 
 
Geneticist, 
Paediatrician or 
Ophthamologist 
SCQ 
ADI-R 
ADOS 
Trained 
examiner 
attending 
consensus 
meetings 
No 
SCQ ASD: 49.0 
ADOS autism: 58.8 
ADOS ASD: 15.7 
ADI-R autism: 78.4 
Consensus ASD: 58.8  
58.8 
(30) 
0.67    
   
Howlin et al., 2005  
   
45 42.2 
16.5 
(9.3) 
4.8 – 48.9 
80.0 
Geneticist, 
Paediatrician or 
Ophthamologist 
ADOS 
ADI-R 
Trained 
examiner 
attending 
consensus 
meetings 
Yes 
ADOS autism: 51.1 
ADOS ASD: 75.5  
ADI-R autism: 75.5  
Consensus autism: 48.9 
Consensus ASD: 68.9   
 
48.9 
(22) 
0.67    
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Random and quality-effects pooled prevalence estimates were generated based on the two 
papers that met the quality inclusion criteria. These are presented in Figures 1.25 and 1.26.  
 
Prev
0.70.650.60.550.50.450.40.35
Study 
Howlin et al., 2005 
Overall 
Q=0.93, p=0.34, I2=0%
Howlin & Karpf, 2004 
    Prev (95% CI)          % Weight
   0.49  (  0.34,  0.64)     46.91
   0.54  (  0.44,  0.64)    100.00
   0.59  (  0.45,  0.72)     53.09
Figure 1.25. Pooled prevalence estimates for ASD phenomenology in Cohen syndrome 
using a random-effects model. 
 
 
Prev
0.70.650.60.550.50.450.40.35
Study 
Howlin et al., 2005 
Overall 
Q=0.93, p=0.34, I2=0%
Howlin & Karpf, 2004 
    Prev (95% CI)          % Weight
   0.49  (  0.34,  0.64)     47.93
   0.54  (  0.44,  0.64)    100.00
   0.59  (  0.45,  0.72)     52.07
Figure 1.26. Pooled prevalence estimates for ASD phenomenology in Cohen syndrome 
using a quality-effects model. 
 
The results revealed that the random and quality-effects models generated the same 
prevalence estimate of 54% (CIs 44 – 64%).  
 
1.4.15 Noonan syndrome  
Following the literature search, two recent papers were identified that reported the prevalence 
of ASD phenomenology in Noonan syndrome. These are presented in Table 1.19. Both papers 
reached an adequate standard of quality for sample selection, confirmation of Noonan 
diagnosis and assessment of ASD phenomenology, although both studies are limited by 
reliance upon screening tools to assess ASD phenomenology. Whilst the quality weightings 
for both studies were good, as only two studies were included in the meta-analysis, the pooled 
prevalence estimates should be interpreted with caution.  
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Table 1.19. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in Noonan 
syndrome. 
 
Quality 
Criteria 
Noonan Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional 
ASD 
Profile  
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Adviento et al., 2014 
   
48 54.2 Not reported 
Not 
reported 
Clinical 
criteria by 
Geneticist
149
 
SCQ N/A No SCQ ASD: 21 
20.8 
(~10) 
0.56    
   
Alfieri et al., 2014 
   
38 57.9 
9.5
150
 
2.9 – 21.9 
85.5
151
 
Genetic 
confirmation 
SCQ or 
M-CHAT 
N/A 
No ASD: 10.5 
10.5 
(4) 
0.67    
   DSM-IV Not reported 
 
 
 
 
 
 
                                                 
149
 Molecular confirmation occurred for 56% of cases 
150
 Median age 
151
 Median IQ score 
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Random and quality-effects pooled prevalence estimates were generated based on the 2 
papers that met the quality inclusion criteria. These are presented in Figures 1.27 and 1.28.  
Prev
0.350.30.250.20.150.10.05
Study 
Alfieri et al., 2014 
Overall 
Q=1.57, p=0.21, I2=36%
Adviento et al., 2014 
    Prev (95% CI)          % Weight
   0.11  (  0.02,  0.23)     46.33
   0.16  (  0.07,  0.27)    100.00
   0.21  (  0.10,  0.34)     53.67
Figure 1.27. Pooled prevalence estimates for ASD phenomenology in Noonan syndrome 
using a random-effects model. 
 
 
Prev
0.350.30.250.20.150.10.05
Study 
Alfieri et al., 2014 
Overall 
Q=1.57, p=0.21, I2=36%
Adviento et al., 2014 
    Prev (95% CI)          % Weight
   0.11  (  0.02,  0.23)     50.97
   0.15  (  0.07,  0.26)    100.00
   0.21  (  0.10,  0.34)     49.03
Figure 1.28. Pooled prevalence estimates for ASD phenomenology in Noonan syndrome 
using a quality-effects model. 
 
The results revealed that the random-effects model generated a prevalence estimate of 16% 
(CI 7 – 27%). The quality-effects model generated a slightly more conservative estimate of 
15% (CI 7 – 26%).  
 
1.4.16 Joubert syndrome 
Following the literature search, two papers were identified that reported the prevalence of 
ASD phenomenology in Joubert syndrome. These are presented in Table 1.20 Both papers 
reached an adequate standard of quality for sample selection, confirmation of Joubert 
diagnosis and assessment of ASD phenomenology. The study by Ozonoff, Williams, Gale 
and Miller (1995) is notable as the authors included multiple diagnostic measures of ASD 
phenomenology; however, the study did not obtain the highest quality rating for ASD 
assessment, as no consensus was derived from the multiple measures. Additionally, the 
sample size for the study was small. Whilst the quality weightings for both studies were good, 
as only two studies were included in the meta-analysis, the pooled prevalence estimates 
should be interpreted with caution.  
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Table 1.20. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in Joubert 
syndrome. 
 
Quality 
Criteria 
Joubert Syndrome Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Ozonoff et al., 1995 
   
11 63.6 
7.9 
(4.0) 
2.3 – 15.1 
Not 
reported 
Neurologist or 
geneticist 
ADI-R 
ADOS-G 
DSM-
IV
152
 
Independent 
raters 
Yes 
Autistic disorder: 27.3 
PDD-NOS: 9.1 
27.3 
(3) 
0.67    
   
Takahashi et al., 2005 
   
43 67.4 
6.6 
(5.3) 
0.4 – 16.2 
Not 
reported 
Medical 
ABC 
Family 
history 
interview 
Authors of 
paper 
No 
Autism: 0.0 
  Borderline autism 
symptoms: 9.3 
0.0 
(0) 
0.44    
   
 
 
 
 
 
 
                                                 
152
 Although the study used multiple diagnostic tools, they did not obtain a consensus from the tools. Therefore the study can only obtain a rating of 2 on the third quality 
criterion. 
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Random and quality-effects pooled prevalence estimates were generated based on the 2 
papers that met the quality inclusion criteria. These are presented in Figures 1.29 and 1.30.  
 
Prev
0.60.50.40.30.20.10
Study 
Takahashi et al., 2005 
Overall 
Q=8.87, p=0.00, I2=89%
Ozonoff et al., 1995 
    Prev (95% CI)          % Weight
   0.00  (  0.00,  0.04)     53.28
   0.09  (  0.00,  0.50)    100.00
   0.27  (  0.05,  0.58)     46.72
Figure 1.29. Pooled prevalence estimates for ASD phenomenology in Joubert syndrome 
using a random-effects model. 
 
Prev
0.60.50.40.30.20.10
Study 
Takahashi et al., 2005 
Overall 
Q=8.87, p=0.00, I2=89%
Ozonoff et al., 1995 
    Prev (95% CI)          % Weight
   0.00  (  0.00,  0.04)     55.09
   0.09  (  0.00,  0.49)    100.00
   0.27  (  0.05,  0.58)     44.91
Figure 1.30. Pooled prevalence estimates for ASD phenomenology in Joubert syndrome 
using a quality-effects model. 
 
The results revealed that both the random and quality-effects models generated a prevalence 
estimate of 9%. The confidence intervals were similar in both the random and quality-effects 
models, ranging from 0 – 50% for random-effects and 0 – 49% for quality-effects. However, 
given the significant heterogeneity between the prevalence estimates in the papers, the pooled 
prevalence estimates need to be interpreted with caution. This caution is supported by the 
confidence intervals for the random-effects and quality-effects models’ including zero. 
Therefore, the pooled prevalence estimates for Joubert syndrome are not included in any 
further between syndrome comparisons. 
 
 
p < 001
p <.001, 
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1.4.17 Hypomelanosis of Ito 
The literature search identified three papers that reported the prevalence of ASD 
phenomenology in Hypomelanosis of Ito. These are presented in Table 1.21.  
 
Whilst all three of these papers provided an estimation of the prevalence of ASD 
phenomenology in Hypomelanosis of Ito, two of them were judged not to be of sufficient 
quality to include in the meta-analysis (Pascual-Castroviejo et al., 1988; Pascual-Castroviejo 
et al., 1998). Importantly, neither study provided any information about how ASD 
phenomenology was assessed or confirmed. Thus, as there was only one paper from which to 
generate a prevalence estimate for Hypomelanosis of Ito, no calculations were made and the 
syndrome was not included in any further between syndrome comparisons.  
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Table 1.21. Quality criteria, study and sample characteristics and outcome data for studies reporting the prevalence of ASD in 
Hypomelanosis of Ito. 
 
Quality 
Criteria 
Hypomelanosis of Ito Study and Sample Characteristics Outcome Data 
Authors 
S
a
m
p
le
 
S
y
n
d
ro
m
e
 
A
S
D
 
N 
% 
Male 
Mean Age 
(SD) 
Range 
% with 
ID 
Syndrome 
Diagnosis 
ASD 
Measure 
ASD 
Measure 
Professional  
ASD 
Profile 
%ASD categories 
% 
ASD 
(N) 
Quality 
Weighting 
Pascual-Castroviejo et 
al., 1998 
   
76 46.1 
Newborn - 
10 
56.6 
Clinical 
confirmation 
Not reported Not reported No Autism: ~5.3 
5.3 
(~4) 
0.22    
   
Pascual-Castroviejo et 
al., 1988 
   
34 58.8 0.2 – 10.0 64.7 
Clinical 
confirmation 
Not reported Not reported No 
Autistic 
behaviour:11.8 
11.8 
(4) 
0.22    
   
Zappella, 1992 
   
25 64.0 2.0 – 17.0 96.0 
Clinical 
features 
ABC 
DSM-III-R 
Not reported No 
Autistic disorder: 40.0 
          Autistic like 
conditions:12.0  
40.0 
(10) 
0.33    
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1.4.18 Comparisons across syndromes 
In order to explore the second aim of the meta-analysis, comparisons between the prevalence 
estimates of ASD phenomenology in each syndrome were made. Syndromes were only 
included in these analyses if the pooled prevalence estimates were robust (i.e., confidence 
intervals > 0) and the quality of the papers met the minimum inclusion criteria. Thus, the 
random-effects and quality-effects pooled prevalence estimates for 12 of the 16 syndromes 
are presented below in Figure 1.31.  The data revealed that ASD phenomenology was most 
prevalent in Rett syndrome (random-effects and quality-effects 61%) and least prevalent in 
22q11.2 deletion syndrome (random-effects 12%, quality-effects 11%).  
 
These comparisons were explored further by conducting relative risks analyses between each 
syndrome. Table 1.22 presents the relative risk statistics and 99% confidence intervals. The 
results revealed that ASD phenomenology was significantly more likely in Rett and Cohen 
syndrome compared to nearly all other syndromes. The associations for Tuberous Sclerosis 
Complex, Cornelia de Lange, CHARGE and Angelman syndrome were mixed; ASD 
phenomenology was significantly more likely in each of these groups, in comparison to four 
to six other syndromes, but ASD phenomenology was also significantly less likely in 
comparison to one or two other syndromes.  ASD phenomenology was significantly less 
likely in Fragile X syndrome and Neurofibramatosis Type 1 compared to three or four other 
syndromes. ASD phenomenology was significantly less likely in Noonan, 22q11.2 deletion, 
William and Down syndromes in comparison to five or six other groups.  
 
 
 
Chapter 1: A Meta-Analysis of ASD in Syndromes 
87 
 
 
 
Figure 1.31. Pooled prevalence estimates, with 95% confidence intervals for each group (filled = random-effects; unfilled = quality-
effects); N = Number of papers used to generate pooled prevalence estimates; QW = mean quality weighting for syndrome. 
N=25 
Q=0.55 
N=14 
Q=0.69 
N=10 
Q=0.54 
N=12 
Q=0.55 N=7 
Q=0.68 
N=5 
Q=0.65 
N=4 
Q=0.64 
N=6 
Q=0.57 
N=2 
Q=0.62 
N=56 
Q=0.63 
N=5 
Q=0.51 
N=2 
Q=0.67 
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Table 1.22. Relative risk statistics, with 99% confidence intervals for the prevalence of ASD phenomenology in each syndrome in 
comparison to all other syndromes. Significant differences between syndromes are highlighted in bold, + = ASD phenomenology 
prevalence is significantly more likely than in one other syndrome ; - = ASD phenomenology is significantly less likely than in one other 
syndrome. 
 
   Test Syndrome 
 
FraX 
 
- - - 
TSC 
+++++ 
- 
22q11.2 
 
- - - - - - 
CdLS 
++++++ 
 
DS 
 
- - - - - 
AS 
++++ 
- - 
NF1 
 
- - - - 
WS 
 
- - - - - -  
Rett 
+++++ 
++++ 
CHARGE 
++ 
- - 
Cohen 
+++++ 
+++ 
Noonan 
 
- - - - - 
FraX - 
1.64 
(0.90-2.97) 
0.50 
(0.21-1.21) 
1.95 
(1.11-3.45) 
0.73 
(0.34-1.56) 
1.55 
(0.84-2.83) 
0.82 
(0.39-1.71) 
0.55 
(0.23-1.28) 
2.77 
(1.64-4.70) 
1.36 
(0.73-2.55) 
2.45 
(1.43-4.22) 
0.68 
(0.31-1.49) 
TSC 
0.61 
(0.34-1.11) 
- 
0.31 
(0.14-0.69) 
1.19 
(0.76-1.88) 
0.44 
(0.22-0.88) 
0.94 
(0.57-1.55) 
0.50 
(0.26-0.96) 
0.33 
(0.15-0.73) 
1.69 
(1.13-2.53) 
0.83 
(0.49-1.41) 
1.50 
(0.99-2.28) 
0.42 
(0.21-0.84) 
22q11.2 
2.00 
(0.83-4.82) 
3.27 
(1.46-7.36) 
- 
3.91 
(1.77-8.63) 
1.45 
(0.57-3.73) 
3.09 
(1.37-7.00) 
1.64 
(0.65-4.10) 
1.09 
(0.40-3.00) 
5.55 
(2.59-11.89) 
2.73 
(1.19-6.27) 
4.91 
(2.27-10.62) 
1.36 
(0.52-3.55) 
CdLS 
0.51 
(0.29-0.90) 
0.84 
(0.53-1.32) 
0.26 
(0.12-0.56) 
- 
0.37 
(0.19-0.72) 
0.79 
(0.50-1.26) 
0.42 
(0.22-0.78) 
0.28 
(0.13-0.60) 
1.42 
(0.99-2.04) 
0.70 
(0.43-1.14) 
1.26 
(0.86-1.84) 
0.35 
(0.18-0.69) 
DS 
1.38 
(0.64-2.96) 
2.25 
(1.14-4.46) 
0.69 
(0.27-1.76) 
2.69 
(1.39-5.21) 
- 
2.13 
(1.06-4.24) 
1.13 
(0.50-2.52) 
0.75 
(0.30-1.87) 
3.81 
(2.04-7.13) 
1.88 
(0.92-3.82) 
3.38 
(1.78-6.38) 
0.94 
(0.40-2.20) 
AS 
0.65 
(0.35-1.18) 
1.06 
(0.64-1.74) 
0.32 
(0.14-0.73) 
1.26 
(0.79-2.02) 
0.47 
(0.24-0.94) 
- 
0.53 
(0.27-1.02) 
0.35 
(0.16-0.77) 
1.79 
(1.19-2.72) 
0.88 
(0.52-1.50) 
1.59 
(1.03-2.44) 
0.44 
(0.22-0.90) 
NF1 
1.22 
(0.59-2.55) 
2.00 
(1.04-3.83) 
0.61 
(0.24-1.53) 
2.39 
(1.28-4.47) 
0.89 
(0.40-1.99) 
1.89 
(0.98-3.65) 
- 0.67 
(0.27-1.62) 
3.39 
(1.88-6.10) 
1.67 
(0.85-3.28) 
3.00 
(1.65-5.47) 
0.83 
(0.37-1.90) 
WS 
1.83 
(0.78-4.29) 
3.00 
(1.38-6.54) 
0.92 
(0.33-2.53) 
3.58 
(1.68-7.66) 
1.33 
(0.53-3.33) 
2.83 
(1.29-6.22) 
1.50 
(0.62-3.65) 
- 
5.08 
(2.45-10.53) 
2.50 
(1.12-5.58) 
4.50 
(2.15-9.41) 
1.25 
(0.49-3.17) 
Rett 
0.36 
(0.21-0.61) 
0.59 
(0.40-0.88) 
0.18 
(0.08-0.39) 
0.70 
(0.49-1.01) 
0.26 
(0.14-0.49) 
0.56 
(0.37-0.84) 
0.30 
(0.16-0.53) 
0.20 
(0.09-0.41) 
- 
0.49 
(0.32-0.77) 
0.89 
(0.65-1.21) 
0.25 
(0.13-0.47) 
CHARGE 
0.73 
(0.39-1.37) 
1.20 
(0.71-2.02) 
0.37 
(0.16-0.84) 
1.43 
(0.88-2.35) 
0.53 
(0.26-1.09) 
1.13 
(0.66-1.93) 
0.60 
(0.30-1.18) 
0.40 
(0.18-0.89) 
2.03 
(1.30-3.17) 
- 
1.80 
(1.14-2.85) 
0.50 
(0.24-1.04) 
Cohen 
0.41 
(0.24-0.70) 
0.67 
(0.44-1.01) 
0.20 
(0.09-0.44) 
0.80 
(0.54-1.17) 
0.30 
(0.16-0.56) 
0.63 
(0.41-0.97) 
0.33 
(0.18-0.61) 
0.22 
(0.11-0.46) 
1.13 
(0.82-1.55) 
0.56 
(0.35-0.88) 
- 0.28 
(0.14-0.54) 
Noonan 
1.47 
(0.67-3.21) 
2.40 
(1.19-4.85) 
0.73 
(0.28-1.91) 
2.87 
(1.45-5.67) 
1.07 
(0.45-2.50) 
2.27 
(1.11-4.62) 
1.20 
(0.53-2.74) 
0.80 
(0.32-2.03) 
4.07 
(2.13-7.77) 
2.00 
(0.96-4.15) 
3.60 
(1.86-6.96) 
- 
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1.4.19 Comparisons to General Population Estimates 
In order to explore the final aim of the meta-analysis, odds ratios with 95% confidence 
intervals were generated, comparing each syndrome with the most recent Centre for Disease 
Control (2014) estimates for ASD diagnoses in the general population. Figure 1.32 presents 
the results and reveals that ASD phenomenology was significantly more likely in all of the 
syndromes, compared to the general population. Odds ratios ranged from 8.3 for 22q11.2 
deletion syndrome to 104.8 for Rett syndrome. Calculations also revealed that ASD 
phenomenology was significantly more likely for males with Fragile X syndrome, compared 
to the general population (OR 28.71, CI 3.81 – 216.54). 
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Figure 1.32. Odds ratios and 95% confidence intervals comparing the likelihood of ASD phenomenology in each syndrome to the general 
population
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1.5 Discussion 
The prevalence of ASD phenomenology in rare genetic and metabolic syndromes was 
detailed in this meta-analysis. Pooled prevalence estimates were generated, including 
estimates weighted by the quality of the identified research. Statistical cross-syndrome 
comparisons and contrasts to the prevalence of ASD in the general population were also 
conducted. This was the first meta-analysis of the prevalence of ASD phenomenology in 
syndromes, and thus extended findings from previous systematic reviews (Moss & Howlin, 
2009, Moss et al., 2011, Zafeiriou et al., 2007, Zafeiriou et al., 2013). The study employed 
wide search criteria, and was strengthened by screening both abstracts and titles during the 
initial search stages, thus allowing for the identification and inclusion of a greater number of 
studies than previous systematic reviews. The creation of a unique quality rating scheme to 
evaluate and weight the prevalence data further strengthened the findings of the meta-
analysis. The inclusion of multiple syndromes and the application of novel statistical 
comparisons between syndromes and the general population provided useful and robust data 
that could be transferred to an understanding of the gene, brain, cognition, behaviour 
pathways implicated in idiopathic ASD, and to the development of clinical services for 
individuals with syndromes. The results demonstrated that ASD phenomenology was highly 
prevalent in Cohen and Rett syndrome and in Tuberous Sclerosis Complex, Cornelia de 
Lange, Angelman and CHARGE syndromes. ASD phenomenology was moderately prevalent 
in Neurofibromatosis Type 1, Fragile X, Noonan, 22q11.2 deletion, Williams and Down 
syndromes. However, despite cross-syndrome differences, the presence of ASD 
phenomenology was found to range between eight and one hundred and five times more 
likely in all syndromes compared to general population estimates.   
 
The pooled prevalence estimates revealed that ASD phenomenology ranged in prevalence 
across 12 syndromes, from 61% in individuals with Rett syndrome to 11% in individuals with 
22q11.2 deletion syndrome. Prevalence estimates were also generated for Moebuis syndrome, 
Phenylketonuria and Joubert syndromes (7%, 9%, 9% respectively) but these data were not 
deemed to be robust. Overall, the generated prevalence figures were similar to previous 
prevalence range estimates cited in systematic reviews (Moss & Howlin, 2009, Moss et al., 
2011, Zafeiriou et al., 2007, Zafeiriou et al., 2013). However, a number of differing results 
were identified. First, the prevalence figure of 22% generated for Fragile X syndrome was at 
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the very low end of the range indicated by Moss and Howlin (2009; 21-50%) and Zafeiriou et 
al. (2013; 22-33%). It is likely that the more conservative prevalence estimate proposed in 
this meta-analysis was due to the inclusion of samples with both males and females with 
Fragile X syndrome. The prevalence estimate generated for solely male samples of 30% was 
in line with previous reviews. However, in order to maintain parity with other syndromes, the 
generated prevalence estimate including data from mixed gender samples was used to conduct 
cross syndrome comparisons. Secondly, the generated prevalence estimates for Cornelia de 
Lange syndrome, Angelman, Down and 22q11.2 deletion syndrome were slightly more 
conservative than some of the ranges reported in previous systematic reviews (Cornelia de 
Lange syndrome: 50-67%, Moss et al., 2011, 46-67% Zafeiriou et al., 2013; Angelman 
syndrome: 50-81% Moss et al., 2011, 50-61% Zafeiriou et al., 2013; 22q11.2 deletion 
syndrome: 20-31% Zafeiriou et al., 2007, 14-50% Zafeiriou et al., 2013). In all cases, the 
prevalence estimates in the systematic reviews were based upon far fewer studies than the 
prevalence estimate for this meta-analysis. Additionally, this review aimed to improve the 
quality of prevalence estimates for each of the syndromes, by including quality review and 
weighting the estimates more heavily by the most robust papers. Thus, whilst the reported 
prevalence data may be more conservative in some cases, it is likely to also be more robust.  
 
A key strength of this meta-analysis has been to provide between syndrome comparisons and 
comparisons to a general population estimate. These statistics revealed that the syndromes 
appeared to cluster into groups; those where ASD phenomenology was highly likely (Rett and 
Cohen syndrome), moderately likely (Tuberous Sclerosis Complex, Cornelia de Lange, 
CHARGE and Angelman syndrome), less likely (Fragile X syndrome and Neurofibramatosis 
Type 1) and least likely (22q11.2 deletion, Noonan William and Down syndromes). In 
combination with the data comparing prevalence rates to the general population, these data 
provide useful evidence for research investigating the gene, brain, cognition, behaviour 
pathways implicated in idiopathic ASD. The results demonstrate that even within a group of 
very high risk syndromes, in which prevalence rates for ASD phenomenology are 
significantly higher than in the general population, there is still significant variation, and 
cluster of syndromes in which ASD phenomenology is more or less likely. These data can be 
used to focus further research into underlying pathways of idiopathic ASD. Studies directed 
towards delineating the profile of ASD behaviour in the syndromes where ASD 
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phenomenology has been demonstrated to be highly likely would allow for an exploration of 
the cognitive and genetic explanations for idiopathic ASD. Some researchers have begun to 
reject unified explanations of ASD phenomenology and instead suggest a fractionation of the 
social communicative and repetitive impairments present in idiopathic ASD (Happé, Ronald 
& Plomin, 2006). However, research in idiopathic ASD is limited by circularity in recruitment 
strategy; individuals are included in studies by virtue of an ASD diagnosis which necessitates 
impairments in all areas of the triad, and then these same individuals are assessed to 
investigate the unitary coherence of the triad. Investigation of the convergence or divergence 
of the triad in these ‘high risk’ syndromes would progress unitary or fractionated models of 
the triad of impairments, whilst removing the inclusion bias present in studies of individuals 
with idiopathic ASD.   
 
The results of this study have important implications for clinical and educational services for 
individuals with syndromes. Despite between syndrome differences in the likelihood of ASD 
phenomenology, the results indicate that an individual with any of these syndromes is at 
greater risk of displaying ASD-type behaviours than individuals in the general population. 
Regardless of empirical questions about whether these behaviours are commensurate with 
idiopathic ASD, the presence of ASD-like difficulties in communication, social interaction 
and restrictive and repetitive behaviours should lead to the tailored support for individuals 
with these syndromes that is proposed for those with idiopathic ASD. Additionally, detailed 
assessments of ASD impairments should be undertaken in order to ascertain whether an 
additional diagnosis of ASD would be beneficial.  Assessments should also include an 
exploration of the impact of any identified ASD impairments upon the individual’s quality of 
life, and that of their families and carers. It may be that in some cases, ASD specific 
educational placements are of benefit, or that ASD specific clinical interventions to support 
communication and/or social skills development could be useful. Most importantly, these 
results demonstrate the importance of reducing diagnostic overshadowing and the necessity of 
assessing and identifying concurrent ASD impairments, rather than attributing any identified 
difficulties to the syndrome itself (Moss & Howlin, 2009).  
 
The meta-analysis has also afforded the opportunity to evaluate and compare research 
methodologies for assessing the prevalence of ASD phenomenology within and between 
syndromes. A key issue that was present in a number of different syndromes was a propensity 
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for research groups to publish data which appeared to have been collected in a similar, but not 
identical sample, in multiple papers. Whilst there may be legitimate reasons for doing this, 
specifically publishing data regarding different aspects of the same syndrome, it is imperative 
for authors to fully describe their sample, and whether the whole sample or a proportion of the 
sample have been reported previously. If authors had specified the proportion of their sample 
that overlapped with other published data, it would have been possible to perform statistical 
calculations to control for this, and thus the likelihood of an individual participant being 
counted more than once within the meta-analysis would have been reduced. This is a key area 
for methodological improvement in future research.  
 
Significant variability was also noted in the reporting of intellectual disability and the 
reporting of the professional involved in interpreting the ASD assessments. Where ASD 
assessments require clinical interpretation (e.g., CARS) or significant pre-assessment training 
(e.g., ADI-R or ADOS), it is critical that studies report these data clearly in their papers. For 
the purposes of this review, it was imperative to include as many studies as possible in order 
to evaluate the current state of the literature. However, future reviews should seek to 
determine more stringent inclusion criteria, requiring adequate description of the delivery and 
interpretation of ASD assessment tools, in order to improve the internal validity of any future 
prevalence estimates. This type of inclusion criteria would have resulted in a significant 
reduction of papers in the present meta-analysis. The quality of description of intellectual 
disability within the studies was also variable. Intellectual disability is associated with ASD, 
and it has been suggested that degree of disability may more fully account for the prevalence 
of ASD phenomenology within syndromes, rather than the presence of the syndrome itself 
(Skuse, 2007). Only half of the studies (54%) reported the proportion of their sample that had 
an intellectual disability, and there was great variability in the depth of assessment used to 
determine this (ranging from an individual question delivered to parents/carers to a full 
psychometrically robust cognitive assessment). Future studies to evaluate the prevalence and 
phenomenology of ASD in syndromes must appropriately assess intellectual disability, and 
conduct analysis to determine how far intellectual disability can account for the prevalence of 
ASD phenomenology in the syndrome.  
 
A number of limitations of the present meta-analysis were also identified. Firstly, due to the 
large number of included papers, it was not possible to provide more detailed analysis or 
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review of individual papers. Whilst attempts were made to highlight notable studies and 
patterns across and within syndromes, inevitably, some interesting findings or patterns may 
not have been discussed. However, this limitation is a direct consequence of the size and 
scope of the literature identified within the meta-analysis. This study was unique in capturing 
a large literature and providing robust, quality weighted prevalence estimates for 16 
syndromes. Future reviews may seek to provide a more in-depth analysis of the literature in 
individual syndromes, particularly those with a large combined dataset (e.g., Fragile X 
syndrome and Tuberous Sclerosis Complex). A second limitation of the meta-analysis is that 
it was not possible to provide an evaluation of the profile of ASD within and between 
syndromes. Whilst robust prevalence data were generated, there is emerging evidence to 
suggest that the profile of ASD impairments within syndromes may be qualitatively different 
in phenomenology to that of idiopathic ASD (Moss et al., 2011; Moss & Howlin, 2009). 
Thus, the generated prevalence data may not be indicative of the prevalence of diagnosable 
ASD. However, this limitation was noted from the outset, and the meta-analysis has afforded 
some progress, through identifying those syndromes in which the data are accumulating on 
the profile of ASD (e.g., Fragile X, Cornelia de Lange, Down and Angelman syndrome) and 
by exclusion, those syndromes in which this is still under-researched. As further robust 
research evaluating the profile of ASD in syndromes is undertaken, it may soon be possible to 
conduct a similar meta-analytic review, detailing the profile of ASD within and between 
syndromes.   
 
The results and limitations identified in this meta-analysis also serve to highlight areas for 
future research. Firstly, five syndromes were excluded from the meta-analysis on the basis of 
a paucity of research delineating the prevalence of ASD phenomenology in these groups 
(Goldernhar, Soto, Ehlers-Danlos, Lujan-Fryns and Leber’s Amaurosis syndromes). 
Hypomelanosis of Ito was later excluded from the statistical meta-analysis, due to the poor 
quality of the research conducted in this population. In addition, generated pooled prevalence 
estimates for Phenylketonuria, Joubert, and Moebuis were not deemed sufficiently robust to 
allow for further interpretation or cross-syndrome comparison. Thus, given the putative 
associations between each of these syndromes and ASD phenomenology, there is a need for 
future robust research in each of these groups, to detail the prevalence and profile of ASD 
phenomenology. Secondly, given the wide variety of ASD assessments and reported 
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differences in the sensitivity and specificity of these instruments (e.g., Charman & Gotham, 
2013), it would be useful to evaluate the psychometric properties of ASD assessments in 
marginal populations such as those with syndromes and intellectual disability, and to evidence 
the differing prevalence data that these assessments generate. Johansson, Gillberg and Rastam 
(2010) present a useful methodology for conducting this type of research, by contrasting the 
utility of the ADI-R, CARS and ABC to identify ASD phenomenology in Moebuis, 
CHARGE and Goldenhar syndrome. This method could be usefully applied across all other 
groups, in order to reach a more unified consensus on the most appropriate ASD assessments 
for use in syndromes, in both research and clinical practice.  
 
A final and key area for future research is to more robustly detail the profile of ASD 
phenomenology in each syndrome. Whilst some syndromes within the meta-analysis had a 
significant body of evidence regarding the profile of ASD impairments, the quality and 
breadth of this analysis was variable. Genetic or metabolic confirmation of syndromes, where 
appropriate, should be conducted, in order to make more precise links between aetiology and 
ASD profile. Gold standard assessments of the profile of ASD phenomenology should 
necessarily include comparison to other syndrome groups, to afford control of degree of 
intellectual disability, and comparisons to idiopathic ASD to evaluate the similarities and 
differences in the profile of behaviour. Subscale or item level analyses of ASD measures 
between groups would allow for greater specificity in the delineation of the profile. The 
generation of these data would allow for improved delineation of the psychological constructs 
associated with ASD in each of these syndromes, specifically the cognitive and social profiles 
and their developmental trajectories. As detailed assessment of the behavioural phenomenon 
in each syndrome develops, it is likely that differences in ASD phenomenology may emerge 
and that these differences may align or disassociate with the hypothesised cognitive 
underpinnings of idiopathic ASD (e.g., Theory of Mind deficits, Weak Central Coherence, 
Deficits in Executive Functioning).  
 
In summary, the meta-analysis has generated robust estimates of the prevalence of ASD 
phenomenology for 16 genetic and metabolic syndromes. Despite between syndrome 
variations in these prevalence data, ASD phenomenology was significantly more likely in all 
of the syndromes, compared to the general population.  
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CHAPTER 2 
 
Autism Spectrum Disorder Phenomenology in 
Phelan-McDermid Syndrome 
______________________________________________________________________ 
 
2.1 Abstract 
Background: The behavioural phenotype of Phelan-McDermid syndrome (PMS) is relatively 
unknown. Research has indicated atypically high levels of activity, impulsivity and autism 
spectrum disorder (ASD) behaviours. Divergent profiles of ASD in PMS are reported, with 
some studies demonstrating similarities to idiopathic ASD and others indicating an uneven 
profile of the triad of impairments. An evaluation of the behavioural phenotype of PMS and 
the prevalence and phenomenology of ASD is warranted, particularly given the putative 
causal involvement of the SHANK3 gene in the aetiology of PMS.  
Methods: Carers of individuals with PMS, (N = 30; mean age = 10.55, SD = 7.08) completed 
questionnaires relating to impulsivity, overactivity, mood, interest and pleasure, repetitive 
behaviour and ASD phenomenology. These data were compared to data from matched 
samples of individuals with Fragile X and Down syndromes, and idiopathic ASD.  In order to 
evaluate the profile of ASD phenomenology in PMS, two comparisons were made; first, 
including the total sample with PMS and second, including only those who met clinical 
threshold for autism on the screening measure.   
Results: The results revealed lower mood in individuals with PMS, but no difference in 
impulsivity and overactivity compared to the comparison groups. Compulsive and routine 
driven repetitive behaviours were less common in the total sample with PMS; however, motor 
based stereotyped behaviours were more common. ASD phenomenology was highly 
prevalent, with 87% of the sample meeting criteria for ASD and 57% meeting criteria for 
autism. The profile of ASD phenomenology in the total sample with PMS was heterogeneous 
across the triad of impairments. However, the profile of those who met clinical threshold for 
autism was homogenous, and analogous to those with idiopathic ASD.  
Conclusions: ASD phenomenology is common within PMS. Whilst the total sample may 
display an atypical profile of ASD behaviour, the profile in those who meet clinical thresholds 
for autism is very similar to those with idiopathic ASD. These results are discussed in relation 
to the wider behavioural phenotype.   
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2.2 Introduction 
Phelan-McDermid syndrome (PMS) is a micro-deletion syndrome caused by loss or 
disruption of chromosome 22q13.3 (Phelan, 2008). The incidence of PMS is unknown, with 
under-diagnosis suspected due to the subtlety of the deletion (Phelan et al., 2001). 
Approximately 80% of people with PMS have de novo, simple terminal deletions and the 
remaining 20% typically result from unbalanced translocations and ring chromosomes 
(Phelan, 2008). The 22q13 region contains the SHANK3 gene; haploinsufficiency of the 
SHANK3 gene is proposed to cause the major features of PMS (Durand et al., 2006; Phelan & 
McDermid, 2011; Wilson et al., 2003). Dysmorphic physical features associated with PMS 
are subtle and include hypotonia, normal to accelerated growth, long eye lashes, large ears, 
full brow, dolicocephaly, full cheeks, bulbous nose and pointed chin (Luciani et al., 2003; 
Phelan, 2008; Phelan & McDermid, 2011). The most characteristic clinical features of PMS 
are moderate to profound intellectual disability and absent to severely delayed speech 
(Havens, Visootsak, Phelan & Graham, 2004; Luciani et al., 2003; Phelan, 2008; Phelan et 
al., 2001). Preliminary research suggests that the physical features and severity of intellectual 
disability correlate with the size of the genetic deletion; however, expressive speech deficits 
are not associated with the size or type of deletion (Luciani et al., 2003). Research 
investigating the behavioural phenotype of PMS has recently developed due to improvements 
in cytogenetic testing, specifically the introduction of subtelomeric fluorescence in-situ 
hybridization (FISH) analysis (Havens et al., 2004). These advances have allowed for more 
robust detection of the deletion in PMS and thus, better delineation of the genotype- 
phenotype association within the syndrome.  
 
A number of behavioural characteristics have been reported in PMS. Hyperactivity, 
impulsivity and difficulties in sustaining attention have been identified. Shaw, Rahman & 
Sharma (2011) reported that 34% of their sample of 35 children had existing diagnoses of 
Attention Deficit Hyperactivity Disorder (ADHD). When assessed using the Parent Form of 
the Children’s Interview for Psychiatric Symptoms (PChIPS; Weller, Weller, Fristad,  Rooney 
& Schecter, 2000), a high proportion of parents endorsed items indicative of impulsivity and 
inattention; similarly the mean Attention Deficit score of the Reiss Scales for Children’s Dual 
Diagnosis (Reiss & Valenti-Hein, 1990) was above clinical cut off. Jeffries et al., (2005) 
identified convergent results, with 36% of a sample of 31 children with PMS scoring above 
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the clinical cut off for ADHD on the Strengths and Difficulties Questionnaire (PSDQ; 
Goodman, 1997). Taken together, these findings suggest a potential association between PMS 
and ADHD phenomenology. However, only the Reiss Scale was designed for individuals with 
intellectual disabilities, and none of the studies compared the results for the PMS group to 
control groups. Thus, it is unclear whether the presence of ADHD symptoms should be 
attributed to the behavioural phenotype of PMS, or to the severity of intellectual disability, 
age of the children assessed or the measures used. Similar threats to validity weaken results 
associating atypical affect with the behavioural phenotype of PMS. Cohort and case studies 
have identified behaviours indicative of depression and psychosis/atypical bipolar disorder in 
PMS (Shaw et al., 2011; Verhoeven, Egger, Willemsen, Leijer, Kleefstra, 2012). However, 
given deficits in expressive language, it is unclear how internal experiences of positive 
symptoms of psychosis have been reported and assessed. Nonetheless, given the clinical 
implications of mood disturbances, these findings warrant further investigation. Finally, there 
is emerging robust evidence of a heightened prevalence of self-injurious behaviour and 
destruction of property in PMS (Powis, Richards, Moss & Oliver, In Review). Importantly, 
these data have been established using measures validated for individuals with intellectual 
disability, and in comparison to matched contrast groups and can therefore be identified as 
components of the behavioural phenotype of PMS (Powis et al., In Review). However, further 
investigation of hyperactivity, impulsivity and affect in PMS is required, utilising robust 
measures validated for individuals with intellectual disability, and contrasting findings with 
appropriate comparison groups.  
 
A final characteristic, frequently identified in PMS, is that of autism spectrum disorder
153
 
(ASD; Jeffries et al., 2005; Phelan et al., 2001; Shaw et al., 2011; Soorya et al., 2013). The 
putative association between ASD and PMS is of particular interest as the SHANK3 gene is 
one of many genes implicated in the aetiology of idiopathic ASD (Bill & Geschwind, 2009; 
Durand et al., 2006; Uchino & Waga, 2013). Thus, delineation of the prevalence and 
phenomenology of ASD in PMS may have clinical implications for individuals with PMS and 
individuals with idiopathic ASD. Results from screening instruments have demonstrated 
convergent results: mean autism/Pervasive Developmental Disorders scale scores for children 
on the Reiss Scales were above clinical cut off (Shaw et al., 2011); 94% of children with PMS 
                                                 
153
 As in Chapter 1, ASD is used as an umbrella term for the range of neurodevelopmental disorders specified as 
Pervasive Developmental Disorders in DSM-IV, DSM-V and ICD-10 
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scored in the mild-moderate range for ASD and 67% in the severe range for ASD using the 
Childhood Autism Rating Scale (CARS; Phelan et al., 2001); 85%  of children with PMS met 
the ASD criteria on the Social Communication Questionnaire, and 67% met the more 
stringent cut off for autism (SCQ; Jeffries et al., 2005). More robust evidence is found in 
studies employing ‘gold standard’ diagnostic measures of ASD. Soorya et al., (2013) utilised 
both the Autism Diagnostic Observation Schedule (ADOS; Lord et al., 2000) and Autism 
Diagnostic Interview-Revised (ADI-R; Rutter, Le Couteur & Lord, 2003), and found that 
84% of the sample with PMS met criteria for ASD and 75% met criteria for a more stringent 
classification of autistic disorder. However, whilst there appears to be a strong association 
between ASD phenomenology and PMS, no studies have employed contrast or comparison 
groups to evaluate whether ASD phenomenology can be identified as a component of the 
behavioural phenotype of PMS
154
. This is particularly important given the degree of 
intellectual disability and expressive speech deficits in PMS, and the potential for over 
estimating ASD when these comorbities are present (Skuse, 2007).  
 
Whilst there is a purportedly high prevalence of ASD phenomenology in PMS, the profile of 
the triad of ASD impairments in the syndrome is less well described. This profile is known to 
vary across genetic syndromes (Moss & Howlin, 2009). For example, ASD phenomenology is 
common in Cornelia de Lange (Section 1.4.5) and Fragile X syndromes (Section 1.4.2). 
Detailed item-level analysis of screening (Moss, Oliver, Nelson, Richards & Hall, 2013) and 
diagnostic measures (Moss, Howlin, Magiati & Oliver, 2012) reveal that both syndromes 
evidence an atypical profile of ASD. Those with Cornelia de Lange evidence greater 
impairments in communication domains, whereas those with Fragile X evidence more 
impairment in repetitive behaviour, and a profile consistent with social anxiety (Hall, 
deBernardis, & Reiss, 2006). Phillipe et al. (2008) reported that whilst children with PMS 
attained high ADI-R scores, these only reached clinical thresholds in social interaction, play, 
and communication domains. They argue that the relative lack of repetitive behaviours 
distinguishes PMS from idiopathic ASD. However, the study was limited by not including an 
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 Behavioural phenotypes can be defined as “…the heightened probability or likelihood that people with a 
given syndrome exhibit certain behavioural and developmental sequelae relative to those without the syndrome.” 
(Dykens, 1995, p.523) Thus, in order for ASD characteristics to be deemed part of the behavioural phenotype of 
PMS, ASD phenomenology must be: 1) equally as likely in PMS as in syndromes where ASD phenomenology is 
a known characteristic of the behavioural phenotype and/or 2) more likely in PMS compared to syndromes 
where ASD phenomenology is known to not be a characteristic of the behavioural phenotype. 
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idiopathic ASD comparison group and relying upon visual inspection of data. Additionally, a 
number of sub-threshold items in the repetitive behaviour domains necessitated expressive 
language, which is often delayed or absent in individuals with PMS (e.g., delayed echolalia, 
verbal rituals). Interestingly Soorya et al., (2013) also found that interpretation of the ADI-R 
algorithm alone indicated that many children with PMS presented with sub-threshold levels of 
repetitive behaviour. However, when they included statistical analysis of all items, including a 
two factor algorithm of repetitive behaviour identified in research on the ADI-R, they found 
that repetitive and sensory-motor behaviours were present in the majority of the participants, 
and were similar in range to those reported in idiopathic ASD.  
 
Finally, authors have suggested that behaviours indicative of psychopathology (psychosis and 
low mood) may be misinterpreted as ASD phenomenology in PMS (Shaw et al., 2011). Shaw 
and colleagues (2011) report that some endorsed items could indicate both ASD and mental 
health problems e.g., “Does not seem to listen when spoken to directly,” “Random and 
inappropriate speech,” “Appears confused”. Additionally, they suggest that other items such 
as “Maintains a rigid posture”, “Appears to be in a stupor, as if intoxicated” and “Laughs or 
appears angry for no apparent reason” may be more indicative of psychosis than ASD. 
However, it could be argued equally that these behaviours are indicative of repetitive 
behaviour, sensory difficulties or problems with emotional regulation, all of which are 
commonly reported in idiopathic ASD. Thus, there is a need to evaluate further the profile of 
ASD in PMS, utilising measures appropriate for individuals with intellectual disability, and 
with sufficient specificity and psychometric properties to allow for item-level statistical 
analysis. Additionally, these analyses need to be made in comparison to contrast groups, 
necessarily including individuals with idiopathic ASD, and ideally including groups with 
other genetic syndromes with known ASD profiles, in order to determine the relative position 
of the ASD profile in PMS.  
 
A final point of interest is that the investigation of the profile of ASD impairments in PMS 
appears to have been largely driven by the hypothesised genetic links between PMS and 
idiopathic ASD. This has resulted in studies analysing the ASD profile of all participants in 
the PMS samples (Phillipe et al., 2008; Shaw et al., 2011; Soorya et al., 2013) in order to 
establish whether the profile in the syndrome is similar to individuals with idiopathic ASD. 
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These data could support or weaken the hypothesised genetic SHANK3 link. A 
complementary analysis approach would be to restrict analyses to those who score above 
thresholds on measures of ASD. These data would answer a second question about whether 
individuals with PMS meet criteria for ASD for the same reasons as individuals with 
idiopathic ASD. Answers to this question would inform discussion of the specific clinical 
needs for individuals with PMS who evidence ASD behaviours, thus increasing the specificity 
of clinical provision and interventions for individuals with PMS.    
 
In summary, there is emerging evidence of attentional differences and differences of affect in 
individuals with PMS (Jeffries et al., 2005; Shaw et al., 2011), however these findings require 
further investigation utilising measures appropriate for individuals with intellectual 
disabilities, allowing for statistical comparisons with contrast groups. Additionally, there is 
evidence of a heightened prevalence of ASD phenomenology in PMS (Jeffries et al., 2005; 
Phelan et al., 2001; Shaw et al., 2011; Soorya et al., 2013). The prevalence and profile of 
these ASD behaviours requires further investigation with particular attention to the profile of 
repetitive behaviours in the syndrome. There is a need to delineate the profile of ASD 
phenomenology in PMS in contrast to individuals with idiopathic ASD, and individuals with 
genetic syndromes with known ASD profiles. Fragile X and Down syndromes may provide a 
useful comparison as they evidence divergent prevalence of ASD phenomenology (30% in 
males with Fragile X syndrome, see 1.4.2; 16% in Down syndrome, see 1.4.6) and well 
known profiles of ASD behaviour. Finally, given tentative hypotheses regarding diagnostic 
overlap between ASD phenomenology and mental health problems (Shaw et al., 2011), an 
evaluation of the associations between ASD phenomenology and the broader behavioural 
phenotype in PMS may prove useful. Therefore, this study has the following aims: 
i) To describe the behavioural phenotype of PMS; specifically the profile of 
overactivity/impulsivity, mood and repetitive behaviour. This will be achieved by 
comparing a sample with PMS to matched comparison groups with Fragile X 
syndrome, Down syndrome and idiopathic ASD. 
ii) To delineate the prevalence of ASD behaviours, as measured by an ASD screening 
tool, in PMS in comparison to matched samples with Fragile X syndrome, Down 
syndrome and idiopathic ASD.  
iii) To delineate the profile of ASD phenomenology in PMS, through analysis of 
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subscales and items on the ASD screening tool, in comparison to matched samples 
with Fragile X syndrome, Down syndrome and idiopathic ASD. 
iv) To investigate whether individuals with PMS reach clinical threshold on the ASD 
screening measure for the same reasons as matched individuals with idiopathic 
ASD. 
v) To investigate associations between scores on the ASD screening measure and the 
profile of repetitive behaviour, impulsivity/overactivity and mood in individuals 
with PMS, compared to the matched samples with Fragile X syndrome, Down 
syndrome and idiopathic ASD.  
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2.3 Methods 
2.3.1 Recruitment 
Participants with PMS were contacted via UNIQUE, the UK syndrome support group for rare 
genetic disorders, and were invited to participate in the study. 85 parents and carers were 
contacted and 36 completed and returned the questionnaires (return rate 42%).  
 
Participants for the comparison groups with idiopathic ASD, Fragile X syndrome and Down 
syndrome were recruited via the National Autistic Society, Fragile X Society and the Down’s 
Syndrome Association respectively. 288 carers of individuals with ASD (return rate 19.63%), 
144 carers of individuals with Down syndrome (return rate 28.80%) and 212 carers of 
individuals with Fragile X syndrome (return rate 44%) completed the questionnaire pack. 
Data from a subsection of these comparison groups have been reported previously (Richards, 
Oliver, Nelson & Moss, 2012)
155
. 
 
2.3.2 Procedure 
All carers received an information sheet, cover letter, consent form, demographic 
questionnaire and questionnaire pack (see Appendix C). To avoid priming, the study was 
described as ‘Understanding behaviour in people with neurodevelopmental disorders’. Carers 
returned completed questionnaires and consent forms in a prepaid envelope. Ethical approval 
for this study was obtained from the University of Birmingham’s Science, Technology, 
Engineering and Mathematics Ethical Review Committee (see Appendix D). 
  
2.3.3 Participants 
Participants from all groups were excluded from the study if: 
1) They were under the age of four, as some measures were not appropriate for young 
children 
2) A large proportion of the data was missing or incomplete (25% or more across the 
questionnaire pack) 
3) They did not have a confirmed diagnosis of the respective syndrome from an 
appropriate professional. For individuals with PMS, Fragile X syndrome and Down 
syndrome, the diagnosis professionals included General Practitioners, Clinical 
                                                 
155
 93.3% (N=28) of the Fragile X sample, 100% (N=30) of the ASD sample and 90% (N=27) of the Down 
syndrome sample were previously reported on by Richards et al., (2012). 
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Geneticist, Paediatricians and Neurologists
156
. For individuals with ASD, the 
professionals additionally included Psychiatrists, Clinical Psychologists and 
Educational Psychologists. 
 
These exclusions resulted in a total of 30 participants with PMS. Matched groups with ASD, 
Fragile X syndrome and Down syndrome were then selected from the comparison samples. 
These groups were matched on chronological age (+/- 3 years) and self-help score (+/- 3) 
derived from the Wessex Scale (Kushlick, Blunden & Cox, 1973). Self-help scores were 
utilised as a proxy measures of degree of disability. Table 2.1 presents the demographic 
characteristics of the groups. The mean age of the total sample was 10.80 years (SD=7.06; 
Range= 4-39 years), 83 (69.2%) were male and 60 (50.0%) were able/partly able (score above 
six on the self-help subscale of the Wessex Scale). 91 (75.8%) were mobile, 89 (74.2%) 
verbal, 100 (83.3%) had normal hearing and 94 (78.3%) had normal vision. After matching, 
significant differences were still found between the groups for gender
157
, self-help score, 
hearing and speech. 
                                                 
156
 21 (70%) of the PMS diagnoses were given by Clinical Geneticists; 8 (27%) by Paediatricians. The remaining 
diagnosis (3%) was confirmed by FISH test; however the parent did not stipulate which professional group had 
given the diagnosis. 
157
 The difference for gender was expected as only males were recruited in the Fragile X syndrome comparison 
group. 
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Table 2.1 Mean age (standard deviation) and range, percentage of males, mean self-help score (standard deviation), percentage of participants 
who were mobile, verbal, had normal hearing and normal vision for all groups. 
Groups: PMS = Phelan McDermid syndrome; ASD = Autism Spectrum Disorder; FraX = Fragile X syndrome; DS = Down syndrome 
a 
In years (decimal); 
b
 data derived from the Wessex Scale (Kushlick et al. 1973) 
c
 According to Item 1 on the SCQ “Is he/she now able to talk using short phrases or 
sentences” 
* 
Kruskal Wallis Test for continuous non-normally distributed data 
** 
Fishers exact T calculated
  Syndrome group Chi –square  Post Hoc <.01 
 PMS ASD FraX DS df Χ
2
  P value  
N  30 30 30 30     
Age
a 
Mean (SD) 10.55 (7.08) 10.60 (7.46)  11.37 (7.02) 10.67 (7.00) 3 1.29
⃰
 .732 - 
 Range 4.00 – 37.00 4.00 – 39.00 6.00 – 39.00 4.00 – 36.00     
Gender Male 
(%) 
13 
(43.33) 
26 
(86.67) 
30 
(100.00) 
14 
(46.67) 
3 34.19
 
<.01 ASD, FraX>PMS,DS  
Self help
b 
Mean (SD) 4.77 (1.14) 5.33 (1.24) 5.33 (1.09) 6.20 (1.06) 3 20.47
⃰
 <.001 DS>PMS,ASD,FraX 
Mobility
b 
Fully mobile 
(%) 
22 
(73.33) 
23 
(76.67) 
20 
(66.67) 
26 
(86.67) 
3 34.10 .33 - 
Vision
b 
Normal 
(%) 
24 
(80.00) 
27 
(90.0) 
24 
(80.0) 
19 
(63.33) 
3 6.89 .08 - 
Hearing
b 
Normal 
(%) 
26 
(86.67) 
27 
(90.00) 
29 
(96.67) 
18 
(60.00) 
3 15.23
⃰ ⃰ 
.001 PMS,ASD,FraX>DS 
Speech
c
 Verbal 
(%) 
5 
(16.77) 
20 
(66.77) 
24 
(80.00) 
24 
(80.00) 
3 33.96 <.001 ASD,DS,FraX>PMS 
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2.3.3.1 Idiopathic ASD Comparison Group 
To confirm the validity of the idiopathic ASD comparison sample as a reference group, Social 
Communication Questionnaire (SCQ; Berument, Rutter, Lord, Pickles & Bailey 1999) data 
were compared to that of the normative sample reported in the SCQ manual (Rutter, Bailey, 
Lord, & Berument, 2003). This method for validating an ASD reference group has been 
utilised previously in a study investigating the profile of autism phenomenology in genetic 
syndromes (Moss et al., 2013a). The manual reports the percentage of individuals in the SCQ 
normative sample who displayed “impairments” for each item. Data were extracted based on 
calculations from these percentages and the total sample size. These data were then used to 
calculate odds ratios at item level, using 99% confidence intervals. Odds ratio analyses 
revealed no significant differences between the idiopathic ASD comparison sample in the 
present study and the normative SCQ sample on 34 of 39 items. The idiopathic ASD 
comparison group in the present study was more likely to score as ‘‘impaired’’ on four SCQ 
items including three algorithm items: social chat, neologisms and unusual sensory interests, 
and one non-algorithm item: unusual attachments to objects. The idiopathic ASD comparison 
sample in the present study was less likely to score as ‘‘impaired’’ on seeking to share 
enjoyment. Overall, these findings validate the matched sample selected in this study, 
demonstrating that they are very similar to the normative sample reported in the SCQ. See 
Appendix E for odds ratio data. 
 
2.3.4 Measures 
The questionnaire pack included the following informant based questionnaire measures which 
are all appropriate for children and adults with intellectual disabilities. The order of the 
measures in the questionnaire pack was counterbalanced across the group to reduce order 
effects. 
 
A demographic questionnaire that required information on date of birth, gender, mobility, 
verbal ability and diagnosis was included. The Wessex (Kushlick et al., 1973) was used to 
assess ability. It comprises five subscales including: continence, mobility, self help skills, 
speech and literacy. For this study, the self help subscale was used to estimate degree of 
ability, and responses to items on mobility, vision and hearing were used to further describe 
the groups. The Wessex Scale has modest inter-rater reliability at subscale level for both 
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children and adults (mean Kappa value of .62 and .54 for overall classification and item level 
reliability respectively; Kushlick et al., 1973; Palmer & Jenkins, 1982). The Wessex has been 
argued to be an effective tool for large-scale questionnaire studies (Palmer & Jenkins, 1982). 
 
The Mood Interest and Pleasure Questionnaire – Short form (MIPQ-S; Ross & Oliver, 2003) 
was used to assess affect and comprises twelve items, forming two subscales: Mood, and 
Interest and Pleasure. The measure has good internal consistency (Cronbach’s alpha 
coefficients: total = .88, Mood = .79, Interest and Pleasure = .87), test-retest (.97) and inter-
rater reliability (.85).  Internal consistency for subscales is good (alpha coefficient range for 
subscales .84 - .94). Concurrent validity between the MIPQ and the Aberrant Behavior 
Checklists (ABC) ranged from medium to strong (0.36 – 0.73; p<.001). 
 
The Activity Questionnaire (TAQ; Burbidge et al., 2010) was included to assess behaviours 
indicative of overactivity and impulsivity. The measure has eighteen items which form three 
subscales of Overactivity, Impulsivity and Impulsive Speech. Item level inter-rater reliability 
ranges from .31 to .75 (mean .56) and test-retest reliability ranges from .60 to .90 (mean .75). 
Inter-rater and test-retest reliability indices for subscales and total score exceed .70. Internal 
consistency for the subscales is good (alpha coefficient range for subscales .67 - .94). 
 
The Repetitive Behaviour Questionnaire (RBQ; Moss, Oliver, Arron, Burbidge & Berg, 2009) 
was used to assess repetitive behaviours and comprises five subscales: Stereotyped behaviour, 
Compulsive behaviour, Insistence on Sameness, Restricted Preferences and Repetitive 
Speech. Previous examination of the psychometric properties of the RBQ (Moss et al., 2009) 
reveals good inter-rater reliability coefficients (range .46 - .80), test-retest reliability (range 
.61 - .93; Moss et al., 2009) and internal consistency (alpha coefficient range for subscales .50 
- .78). Concurrent validity and content validity between the RBQ and the repetitive behaviour 
subscale of the ASQ is good (0.6; p<.001). 
 
The Social Communication Questionnaire – Lifetime version (SCQ; Berument et al., 1999) 
was included to assess ASD behaviours. The SCQ was developed as a tool for screening for 
ASD in children and adults and is based on the Autism Diagnostic Interview (Rutter et al., 
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2003). The measure consists of 40 items which are scored to indicate the presence (a score of 
1) or absence (a score of 0) of autistic impairments. These items are grouped into three 
subscales which correspond to the triad of impairments: Communication; Social Interaction 
and Repetitive and Stereotyped patterns of behaviours. The authors identify a cut off score of 
15 as indicative of Autistic Spectrum Disorder and a higher cut off of 22 to differentiate 
between individuals with autism and those with other Pervasive Developmental Disorders.  
The SCQ shows good concurrent validity with the Autism Diagnostic Interview and the 
Autism Diagnostic Observation Schedule (Howlin & Karpf, 2004). Importantly, the SCQ 
demonstrates higher precision in samples with low IQ than other screening tools, including 
the Children’s Communication Checklist and the Social Responsiveness Scale (Charman et 
al., 2007).  Internal consistency is also good (α = .90 for the total scale). The SCQ has good 
item level validity, with 33 out of 39 items differentiating between those with ASD and those 
without ASD (Rutter et al., 2003). The Fragile X and Down syndrome groups completed an 
earlier version of the SCQ (Autism Screening Questionnaire; ASQ). One item differed 
between the ASQ and SCQ for non-verbal individuals for subscale scoring (Item 20: Social 
chat). Following the approach taken by Moss et al., (2013a), to ensure consistency across the 
groups, this item was treated as missing and pro-rated for all non-verbal participants.
158
 Item 
20 was not included in item-level analysis. 
 
Internal consistency for the PMS group on the self-help scale of the Wessex (0.68) was 
moderate. Internal consistency was good for the Interest and Pleasure (0.88) subscale of the 
MIPQ, and the Total Score of the MIPQ (0.81). However, internal consistency of the Mood 
subscale of the MIPQ was poor (0.23).  Internal consistency was good for the Overactivity 
(0.86) and Impulsivity (0.83) subscales of the TAQ, and the Total Score of the TAQ (0.90). 
Internal consistency was moderate for the Stereotyped Behaviour (0.54) subscale of the RBQ, 
and good for the Compulsive behaviour (0.84) and Insistence on Sameness (0.76) subscales of 
the RBQ, and the Total Score of the RBQ (0.84).  Finally, internal consistency of the 
Communication (0.88) and Social Interaction (0.81) subscales of the SCQ and the SCQ Total 
Score (0.86) were all good. The internal consistency of the Repetitive and Restricted 
Behaviour (0.55) subscale of the SCQ was moderate. 
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 The prorated score was calculated as the mean item score, based on other completed items within the 
communication domain. 
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2.3.5 Data analysis 
Data were tested for normality using Kolmogorov–Smirnov tests. Where data were not 
normally distributed (p<.05), non-parametric techniques were employed. To control for 
multiple comparisons, alpha levels were set at a conservative value of p <.01. 
 
In order to describe the behavioural phenotype of PMS relative to the comparison groups, 
subscale scores were derived to describe mood (taken from the MIPQ), activity levels (taken 
from the TAQ) and repetitive behaviour (taken from the RBQ). A series of Kruskal Wallis 
tests were performed to test for differences in the subscales between the groups. 
 
To investigate the prevalence of ASD phenomenology in each group, the percentage of each 
group scoring above the cut off for ASD (score > 15) and autism (score > 22) were derived 
from the SCQ. Differences between the proportions of each group scoring above these 
thresholds were compared using Chi-Square tests.  
  
The profile of ASD phenomenology in PMS was explored by comparing subscale scores from 
the SCQ between the groups, and testing for differences using Kruskal Wallis tests. In order 
to allow for the high proportion of individuals with PMS who were non-verbal, subscale 
scores excluding verbal items were also generated, and differences between the groups were 
evaluated using Kruskal Wallis tests. In order to further explore the profile of ASD 
phenomenology in PMS relative to the other groups, the proportion of individuals in each 
group who scored as ‘impaired’ on all non-verbal items of the SCQ was generated. Chi-square 
tests were used to test for item level differences between all groups. 
 
In order to explore whether individuals with PMS reach threshold on the SCQ for similar 
reasons as individuals with idiopathic ASD, item level comparisons were conducted, 
comparing those with PMS who scored over the threshold for autism (> 22) to the idiopathic 
ASD group. The number of individuals in the PMS group scoring as ‘impaired’ on each item 
was compared to the number of individuals in the idiopathic ASD comparison group scoring 
as impaired on each item, using odds ratio analyses.  
 
Finally, to investigate the association between ASD phenomenology and behavioural 
phenotype, a series of Spearman’s Rank Correlations were performed between SCQ total 
score and: chronological age; self-help score; subscale scores on the MIPQ, RBQ and TAQ.  
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2.4 Results 
2.4.1 Behavioural Phenotype of PMS 
In order to investigate the first aim of the study, delineating the behavioural phenotype of 
PMS, subscale and total scores on the MIPQ, TAQ and RBQ were generated for each group. 
Table 2.2 displays the subscale, total scores and Kruskal Wallis statistics.  
 
The results in Table 2.2 reveal that individuals with PMS had significantly higher total mood 
scores than individuals with idiopathic ASD
159
, although they also demonstrated significantly 
lower total mood scores than individuals with Down syndrome. The PMS group evidenced 
significantly higher levels of stereotyped behaviour than individuals with Down syndrome. 
However, they also had significantly lower scores for compulsive behaviour than the 
idiopathic ASD group. Additionally, individuals with PMS obtained significantly lower 
scores for insistence on sameness and total repetitive behaviour than both the Fragile X and 
idiopathic ASD groups. Individuals with PMS did not differ from individuals with idiopathic 
ASD, Fragile X or Down syndrome on measures of activity level.  
 
In summary, individuals with PMS evidenced higher mood, but lower levels of repetitive 
behaviour than those with idiopathic ASD. The PMS group had lower mood scores than those 
with Down syndrome. The activity levels in individuals with PMS did not differ to those 
identified in any of the contrast groups.  
 
 
 
 
 
 
 
 
 
 
 
                                                 
159
 For brevity and to prevent duplication of results from previously published data, this paper will only describe 
the differences between the PMS group and other comparison groups, rather than also describing inter-
comparison group differences. 
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Table 2.2 MIPQ, RBQ and TAQ subscale and total score medians and interquartile ranges for each group. Kruskal Wallis statistics to evaluate 
differences between the groups. Significant differences (p<.01) are indicated in bold. 
 
Measure Median scores  
(interquartile range) 
Kruskal Wallis Test Post Hoc <.01 
  PMS FraX DS Idiopathic ASD df k P value   
MIPQ-S         
Mood 
20.00 
(17.75 – 21.25) 
21.00 
(19.75 – 21.18) 
22.00 
(19.75 – 22.25) 
17.00 
(16.00 – 21.00) 
3 22.26 <.001 FraX,DS>ASD 
Interest and Pleasure 
16.00 
(12.88 – 20.00) 
18.00 
(13.00 – 19.25) 
20.00 
(17.75 – 22.00) 
12.00 
(8.75 – 15.25) 
3 27.53 <.001 DS>ASD 
Total Score 
36.00 
(31.75 – 41.00) 
39.00 
(31.75 – 42.00) 
41.00 
(38.75 – 44.00) 
29.50 
(25.00 – 35.25) 
3 30.34 <.001 
PMS,DS,FraX>ASD 
DS>PMS 
RBQ
160
         
Stereotyped behaviour 
7.50 
(5.75 – 12.00) 
9.00 
(7.37 – 12.00) 
0.50 
(0.00 – 6.50) 
9.50 
(6.00 – 12.00) 
3 24.84 <.001 PMS,ASD,FraX>DS 
Compulsive behaviour 
0.00 
(0.00 – 4.50) 
6.00 
(0.00 – 9.00) 
0.00 
(0.00 – 3.25) 
6.00 
(3.50 – 15.25) 
3 21.81 <.001 ASD>DS,PMS 
Insistence on sameness 
0.00 
(0.00 – 2.50) 
4.00 
(3.00 – 7.25) 
0.00 
(0.00 – 2.25) 
4.00 
(2.00 – 6.00) 
3 30.45 <.001 ASD,FRaX>DS,PMS 
Total Score 
12.00 
(7.75 – 19.75) 
29.50 
(22.50 – 36.25) 
10.50 
(4.00 – 15.25) 
25.00 
(16.00 – 32.50) 
3 39.44 <.001 ASD,FRaX>DS,PMS 
 
 
  
  
    
                                                 
160
 The RBQ contains two subscales scored only for verbal individuals (Restricted Preferences and Repetitive Language). The TAQ also contains a subscale scored only for 
verbal individuals (Impulsive Speech). As only 5 of the PMS sample were classified as verbal, these subscales were not analysed in the present study. 
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Measure Median scores  
(interquartile range) 
Kruskal Wallis Test Post Hoc <.01 
  PMS FraX DS Idiopathic ASD df k P value   
TAQ 
Impulsivity  
16.50 
(12.00 – 20.25) 
20.72 
(15.75 – 23.25) 
12.00 
(7.75 – 18.25) 
20.00 
(16.50 – 23.00) 
3 18.22 <.001 ASD,FraX>DS 
Overactivity 
19.00 
(12.75 – 25.25) 
24.00 
(12.75 – 32) 
9.50 
(6.00 – 23.25) 
20.50 
(15.75 – 30.00) 
3 14.54 .002 ASD,FraX>DS 
Total Score 
37.00 
(26.50 – 45.25) 
48.50 
(32.00 – 59.25) 
23.00 
(17.00 – 41.75) 
50.00 
(33.25 – 53.75) 
3 17.45 .001 ASD,FraX>DS 
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2.4.2 Prevalence of ASD phenomenology in PMS 
In order to investigate the second aim of the study, prevalence data were calculated to 
compare the proportion of each group scoring above the ASD and autism thresholds on the 
SCQ. Table 2.3 displays the results. 
 
Table 2.3 Percentage of individuals scoring above the ASD cut off and autism cut off on the 
SCQ in each group  
Group % scoring above ASD cut off 
(N) 
% scoring above autism cut off 
(N) 
PMS 86.7 
(26) 
56.7 
(17) 
FraX 80.0 
(24) 
51.9 
(14) 
DS 23.3 
(7) 
22.2 
(6) 
Idiopathic ASD  100.0 
(30) 
76.7 
(23) 
 
The results revealed that 86.7% of individuals with PMS scored above the threshold for ASD 
and 56.7% scored above the threshold for autism. There was a significant difference between 
the proportion of individuals in each group scoring above the cut off for ASD (
2 
(3) = 51.38, 
p <.001; ASD, FraX, PMS> DS). There was also a significant difference between the 
proportion of individuals in each group scoring above the cut off for autism (
2
(3) = 17.17, p 
= .001; ASD, FraX, PMS>DS). 
 
In summary, the proportion of individuals with PMS who scored above the SCQ thresholds 
for ASD and autism was higher than the Down syndrome group, but did not differ from those 
with idiopathic ASD or Fragile X syndrome.  
 
2.4.3 Profile of ASD phenomenology in PMS 
In order to investigate the third aim of the study, subscale scores for Communication, 
Repetitive Behaviour and Reciprocal Social Interaction domains were derived from the SCQ 
for each group. In addition to calculating the subscales and total score according to the SCQ 
manual, subscales and totals scores were also derived excluding all verbal items for each 
group. These subscale and total scores are presented in Table 2.4 with Kruskal Wallis test 
results to evaluate differences between the groups. 
Chapter 2: ASD in Phelan-McDermid Syndrome 
115 
 
Table 2.4 SCQ subscale and total score medians and interquartile ranges for each group, calculated according to the SCQ manual and calculated 
with all verbal items removed. Kruskal Wallis statistics to evaluate differences between the groups. Significant differences (p<.01) are indicated 
in bold. 
 
Domain 
Median scores all items 
(interquartile range) 
Kruskal Wallis Test Post Hoc <.01 
PMS FraX DS Idiopathic ASD df k 
P 
value 
 
Communication 
(SCQ Manual Scoring) 
8.00 
(6.86 – 8.00) 
7.40 
(5.00 – 9.00) 
4.00 
(3.00 – 7.69) 
8.00 
(6.97 – 10.25) 
3 20.10 <.001 ASD>DS 
Communication 
(Verbal Items Removed) 
7.00 
(4.00 – 7.00) 
4.00 
(3.00 – 5.80) 
1.00 
(0.00 – 4.00) 
6.00 
(4.00 – 7.00) 
3 29.97 <.001 ASD,PMS>DS 
Repetitive Behaviour 
(SCQ Manual Scoring) 
4.00 
(2.82 – 5.00) 
5.85 
(4.00 – 7.00) 
2.00 
(1.00 – 4.00) 
6.00 
(4.75 – 7.00) 
3 33.83 <.001 ASD, FraX>DS 
ASD>PMS 
Repetitive Behaviour 
(Verbal Items Removed) 
4.00 
(2.75 – 5.00) 
5.00 
(3.00 – 6.00) 
1.00 
(0.00 – 4.00) 
5.50 
(4.00 – 7.00) 
3 32.72 <.001 ASD,FraX>DS 
Reciprocal Social 
Interaction 
10.00 
(7.75 – 13.00) 
9.00 
(6.00- 11.00) 
3.00 
(1.00 – 8.00) 
11.25 
(9.00 – 13.00) 
3 28.04 <.001 ASD,PMS>DS 
Total Score 
(SCQ Manual Scoring) 
22.57 
(19.82 – 26.00) 
23.00 
(18.28 – 28.00) 
9.29 
(7.00 – 24.69) 
27.50 
(23.39 – 32.00) 
3 22.63 <.001 ASD>DS 
Total Score 
(Verbal Items Removed) 
21.50 
(18.75 – 25.00) 
18.50 
(12.00 – 23.25) 
5.00 
(2.00 – 12.50) 
23.40 
(19.00 – 27.00) 
3 35.66 <.001 ASD,PMS>DS 
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The results in Table 2.4 reveal that the PMS group did not significantly differ from the 
comparison groups on communication impairments when calculated according to the SCQ 
manual. However, when verbal items were removed, the PMS group showed significantly 
more ‘ASD-like’ communication impairments than the Down syndrome group. When 
calculated according to the SCQ manual, the PMS group showed significantly fewer ‘ASD 
like’ repetitive behaviours than the idiopathic ASD comparison group. However this 
difference was no longer significant when verbal items were removed. The PMS group 
evidenced significantly more ‘ASD like’ reciprocal social interaction impairments than 
individuals with Down syndrome. When calculated according to the SCQ manual, the PMS 
group did not differ from any of the comparison groups in total scores for ‘ASD like’ 
impairments. However, when verbal items were removed, the PMS group were significantly 
more impaired than those with Down syndrome. 
 
In order to further evaluate the profile of ASD phenomenology in PMS, the percentage of 
individuals in each group scoring as ‘impaired’ (score of 1) for each non-verbal item of the 
SCQ was calculated. Differences between the groups for each item were evaluated using Chi-
Square tests. Table 2.5 presents the results.  
 
The results revealed that significantly more of the PMS group than the Down syndrome group 
scored as impaired on five of the seven items in the Communication subscale. Additionally, 
for the item describing ‘nodding to say no’, significantly more individuals with PMS were 
identified as impaired than individuals with Fragile X syndrome and Down syndrome. 
Significantly more of the PMS group than the Down syndrome group scored as impaired on 
four of the seven items in the Repetitive Behaviour subscale. However, significantly fewer 
individuals with PMS were identified as showing ritualistic repetitive behaviours, relative to 
individuals with idiopathic ASD and Fragile X syndrome. Significantly more of the PMS 
group than the Down syndrome group scored as impaired on eight of the fifteen items in the 
Reciprocal Social Interaction subscale. Importantly, significantly more individuals with PMS 
showed impairments in ‘showing and directing attention’ than individuals with idiopathic 
ASD or Down syndrome. Conversely, significantly fewer individuals with PMS showed 
impairments in items regarding interest in other children, and responding to other children’s 
approaches, than individuals with idiopathic ASD. 
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Table 2.5 Percentage of individuals in each group that scored as ‘impaired’ on each non-verbal algorithm item of the SCQ. Chi-square statistics 
to test for differences between the groups, significant differences are highlighted in bold (p<.01). ‘+’ indicates that significantly more individuals 
in the PMS group scored as impaired than individuals in one of the comparison groups; ‘-’ indicates that significantly fewer individuals in the 
PMS group scored as impaired than individuals in one of the comparison groups; N/A indicates no differences between any of the groups. 
 
  % Impairment Chi Square   
Domain Item PMS FraX DS ASD df Χ
2
 P value Post Hoc <.01 
Communication 
Imitation 76.7 46.7 33.3 83.3 3 15.53 .001 ASD>FraX,DS; PMS>DS + 
Pointing  86.7 56.7 33.3 70.0 3 15.87 .001 PMS>DS + 
Gestures  70.0 46.7 36.7 60.0 3 5.53 .137 N/A N/A 
Nodding to mean yes  86.7 46.7 23.3 83.3 3 31.50 <.001 ASD,PMS>FraX,DS + + 
Head shaking to mean no 73.3 36.7 23.3 76.7 3 21.22 <.001 ASD>FraX,DS; PMS>DS + 
Imitative social play 80.0 60.0 16.7 76.7 3 28.22 <.001 ASD,PMS,FraX>DS + 
Imaginative play  83.3 80.0 36.7 80.0 3 21.05 <.001 ASD,PMS,FraX>DS + 
Repetitive 
Behaviour 
Rituals 40.0 73.3 46.7 83.3 3 17.18 .001 ASD>PMS,DS; FraX>PMS - - 
Unusual preoccupations 60.0 63.3 20.0 70.0 3 19.44
 
<.001 ASD,PMS,FraX>DS + 
Stereotyped play  66.7 60.0 30.0 76.7 3 13.97 .003 ASD,PMS>DS + 
Circumscribed interests 30.0 56.7 36.7 60.0 3 7.40 .060 N/A N/A 
Sensory interests 53.3 43.3 13.3 83.3 3 29.15 <.001 ASD>FRaX,DS; PMS>DS + 
Hand stereotypies  70.0 86.7 33.3 90.0 3 27.40 <.001 ASD,PMS,FRaX>DS + 
Body stereotypies  56.7 60.0 23.3 66.7 3 12.64 .005 ASD,FraX>DS N/A 
Reciprocal 
Social 
Interaction 
Inappropriate facial expressions 40.0 23.3 6.7 40.0 3 11.49 .009 ASD,PMS>DS + 
Use of other’s body to communicate 83.3 56.7 40.0 86.7 3 20.10 <.001 ASD,PMS>DS + 
Friends 70.0 80.0 30.0 76.7 3 19.72 <.001 ASD,PMS,FRaX>DS + 
Eye contact 56.7 53.3 23.3 56.7 3 8.57 .036 N/A N/A 
Social smiling  40.0 36.7 16.7 66.7 3 13.66 .003 ASD>DS N/A 
Showing and directing attention  70.0 46.7 16.7 36.7 3 15.69 .001 PMS>ASD,DS ++ 
Offering to share 80.0 63.3 33.3 76.7 3 15.41 .001 ASD, PMS>DS + 
Seeking to share enjoyment 43.3 26.7 23.3 36.7 3 2.27 .519 N/A N/A 
Offering comfort  83.3 56.7 20.0 86.7 3 32.27 <.001 ASD,PMS,FraX>DS + 
Quality of social overtures  56.7 26.7 13.3 46.7 3 12.67 .005 ASD,PMS>DS + 
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  % Impairment Chi Square   
Domain Item PMS FraX DS ASD df Χ
2
 P value Post Hoc <.01 
Range of facial expression 63.3 56.7 23.3 80.0 3 17.82 <.001 ASD,PMS,FRaX>DS + 
Interest in children 60.0 56.7 26.7 90.0 3 21.91 <.001 ASD>PMS,DS - 
Response to other children’s approaches 53.3 63.3 23.3 86.7 3 23.64 <.001 ASD>PMS,DS; FraX>DS - 
Imaginative play with peers 90.0 86.7 60.0 100.0 3 14.12
* 
.001 ASD>DS N/A 
Group play 86.7 73.3 46.7 86.7 3 12.64 .005 ASD,PMS>DS + 
* Fishers exact T calculated as multiple cells had expected count < 5. 
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In summary, the PMS group did not differ from the idiopathic ASD or Fragile X syndrome 
groups in levels of ‘ASD like’ communication impairments. When verbal items were 
removed, they evidenced significantly more communication impairments than those with 
Down syndrome. At item level, individuals with PMS evidenced specific impairments in 
using nodding to communicate with others. The PMS group did not differ from the Fragile X 
or Down syndrome groups in levels of ‘ASD like’ repetitive behaviour, but did evidence 
significantly less impairment than the idiopathic ASD group when verbal items were included 
in analysis. At item level, the PMS group demonstrated significantly less ritualistic behaviour. 
The PMS group evidenced significantly more impairment in social interaction than the Down 
syndrome group, and did not differ from the idiopathic ASD or Fragile X syndrome groups. 
At item level, those with PMS evidenced significant impairment in showing and directing 
attention, but relative preservation of interest in, and responses to, other children compared to 
those with idiopathic ASD. 
 
2.4.4 Analysis of items associated with meeting threshold for autism in PMS 
In order to meet the fourth aim of the study, odds ratios were generated with 99% confidence 
intervals, to compare the likelihood of individuals with PMS who scored above the autism 
threshold on the SCQ displaying impairments on individual SCQ items, compared to those 
with idiopathic ASD. The results in Figure 2.1 reveal that individuals with PMS who met 
criteria for autism on the SCQ were no more or less likely to evidence impairments in the 
Communication or Repetitive Behaviour items than individuals with idiopathic ASD. 
However, they were significantly more likely to score as impaired on the ‘Showing and 
directing attention’ item in the Reciprocal Social Interaction domain.  
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Figure 2.1. Odds ratios for SCQ items included in the domain algorithms comparing individuals with PMS who score over the autism threshold to the idiopathic 
ASD group. Error bars indicate 99% confidence intervals, significant differences are indicated with ‘*’. Y axis scales differ between subscales.  
Communication 
Repetitive Behaviour 
Reciprocal Social Interaction 
* 
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2.4.5 Association between behavioural phenotype and ASD phenomenology in PMS 
In order to investigate the final aim of the study, a series of correlations were conducted for 
each group, evaluating associations between total SCQ score and demographic characteristics 
(self-help score and chronological age) and behavioural characteristics (affect, activity and 
repetitive behaviour). Table 2.6 reveals that higher scores on the SCQ were significantly 
correlated with lower scores for interest and pleasure for individuals with PMS. The 
correlation between SCQ score and mood score approached significance (rs(28) = -.37, P = 
.043).  
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Table 2.6 Correlation coefficients for Spearman’s Rank Correlations between total SCQ score 
and: Self-help score; Chronological age; MIPQ subscales (mood, interest and pleasure); RBQ 
subscales (stereotyped behaviour, compulsive behaviour, insistence on sameness); TAQ 
subscales (impulsivity, overactivity). Significant correlations (p<.01) and highlighted in bold. 
 
Demographic/ 
Behavioural 
Characteristic 
PMS FraX DS Idiopathic ASD 
Self-help -0.20 -0.07 -0.21 -0.02 
Age 0.35 0.28 0.24 -0.11 
Mood -0.28 -0.06 0.07 -0.40 
Interest and 
pleasure 
-0.50 -0.20 -0.38 -0.14 
Stereotyped 
behaviour 
0.36 0.34 0.63 0.12 
Compulsive 
behaviour 
-0.08 -0.21 0.22 0.39 
Insistence on 
sameness 
-0.04 -0.32 0.13 0.04 
Impulsivity 0.21 0.22 0.32 0.25 
Overactivity 0.32 0.25 0.19 0.23 
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2.5 Discussion 
The behavioural characteristics, prevalence and profile of ASD phenomenology in PMS were 
delineated in this study. The relationship between ASD phenomenology and broader 
behavioural and demographic characteristics was also evaluated. Importantly, the recruitment 
of comparison groups with Fragile X and Down syndrome, in which the profile of ASD 
phenomenology is well described, strengthens the validity of the study. The inclusion of a 
matched idiopathic ASD comparison group allows for robust delineation of the profile of 
ASD phenomenology in PMS. The utilisation of validated measures, with appropriate 
psychometric properties established in populations with intellectual disabilities further 
improves the validity and reliability. The majority of these measures exhibited good internal 
consistency in the PMS group. The results revealed that the PMS group evidenced lower 
levels of affect than the Down syndrome group, but higher affect than the idiopathic ASD 
group. The PMS group also evidenced higher levels of stereotyped repetitive behaviours, but 
lower levels of other topographies of repetitive behaviour. No evidence was found for 
heightened overactivity or impulsivity in PMS. The results identified a high prevalence of 
ASD phenomenology in PMS. The profile of ASD behaviours was similar to those with 
Fragile X syndrome and idiopathic ASD, and when compensation was made for verbal 
ability, those with PMS evidenced significantly more impairments in communication and 
social interaction than those with Down syndrome. Item level analyses revealed lower levels 
of some ASD repetitive behaviours in the total sample with PMS. Interestingly, analyses also 
revealed significant impairments in behaviours indicative of social skill, but relative 
preservation in behaviours indicative of social motivation.  Analysis of those with PMS who 
met clinical threshold for autism revealed a very similar profile of ASD phenomenology 
compared to those with idiopathic ASD, including a similar profile of repetitive behaviours. 
This suggests that individuals with PMS meet criteria for ASD for similar reasons to those 
with idiopathic ASD. Finally, higher total levels of ASD phenomenology in PMS were found 
to be associated with lower levels of mood in the group, which is of clinical significance.  
 
The results of the behavioural phenotype analyses revealed that individuals with PMS 
evidenced higher total mood scores than those with idiopathic ASD, but lower total mood 
scores than those with Down syndrome.  Importantly, this finding was established using a  
measure designed specifically for individuals with intellectual disability, and good internal 
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consistency was established for the total mood score for the PMS group. Despite the 
differences at the total score level, there were no identified differences on the Mood or 
Interest and Pleasure subscales between the PMS and comparison groups, although it should 
be noted that internal consistency was poor for the Mood subscale. These findings support 
previous research identifying low mood in individuals with PMS (Shaw et al., 2011), but also 
demonstrate the utility of including multiple comparison groups in order to position the 
behavioural phenotype in PMS relative to other syndromes. The PMS group achieved higher 
total mood scores than those with idiopathic ASD and comparable total mood scores to those 
with Fragile X syndrome, suggesting that whilst lower mood is present in PMS it may not be 
significantly atypical, given the degree of intellectual disability in the group. The use of a 
carefully designed and detailed assessment of repetitive behaviour (Moss et al., 2009) 
revealed a mixed profile in individuals with PMS. The group evidenced similar levels of 
stereotyped behaviour, but lower levels of compulsive behaviour, insistence on sameness and 
total repetitive behaviour than both the Fragile X syndrome and idiopathic ASD groups. This 
finding supports and synthesises divergent results demonstrating low levels of repetitive 
behaviour in PMS (Phillippe et al., 2008) and the presence of repetitive and sensory-motor 
behaviours in the group (Soorya et al., 2013). Individuals with PMS appear to evidence a 
dissociation between motor driven repetitive behaviours, which are common in the sample, 
and more compulsive and routine driven behaviours, which are less evident in the group. It is 
important to note that this finding is at the level of the total sample, including those who meet 
threshold for autism and those who do not. Finally, the results revealed no significant 
differences in levels of overactivity or impulsivity between the PMS and comparison groups. 
This finding differs from those previously reported, where high levels of ADHD type 
behaviours were identified (Jeffries et al., 2005; Shaw et al., 2011). However, previous 
research did not compare individuals with PMS to matched comparison groups, and thus the 
high levels of activity and impulsivity may be more appropriately associated with the degree 
of intellectual disability in PMS rather than the behavioural phenotype of PMS per se.  
 
The results demonstrated a high prevalence of ASD phenomenology in PMS, with 87% 
meeting threshold for ASD and 57% meeting the more stringent criteria for autism. These 
findings support the prevalence figures identified in previous studies using screening 
measures (94% mild-moderate ASD, 67% severe ASD, Phelen et al., 2011; 85% ASD, 67% 
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autism, Jeffries et al., 2005) and diagnostic tools (84% ASD, 75% autistic disorder, Soorya et 
al., 2013). The results of this study extend findings by demonstrating that a similar proportion 
of individuals with PMS meet threshold for ASD and autism as males with Fragile X 
syndrome, in whom ASD phenomenology is characteristically common. Importantly, the 
proportion of individuals in the PMS group meeting clinical thresholds on the SCQ was 
significantly higher than the Down syndrome group, suggesting that a high prevalence of 
ASD phenomenology can be associated with the behavioural phenotype of PMS. It is 
important to note that whilst this study has demonstrated a high prevalence of ASD 
phenomenology in PMS, this does not directly equate to a high prevalence of ASD diagnoses 
in PMS, given the necessity of thorough, multimodal assessment in the clinical diagnoses of 
ASD. 
 
Analyses to evaluate the profile of ASD phenomenology in the total PMS sample provided 
heterogeneous results across the triad of impairments. Firstly, at subscale level the group did 
not differ from the idiopathic ASD or Fragile X syndrome groups in ‘ASD-like’ 
communication impairments. When verbal items were removed from the analysis, the PMS 
group evidenced more impairments than those with Down syndrome. This finding supports 
previous results highlighting ‘ASD-like’ impairments in communication in PMS (Phillipe et 
al., 2008; Soorya et al., 2013). Item-level analyses extended these findings to reveal that the 
PMS group evidenced specific impairments in ‘nodding to communicate yes’, with a higher 
proportion of the PMS sample scoring as impaired on this item than all three comparison 
groups, although this did not reach statistical significance when compared to the idiopathic 
ASD group. The PMS group did not significantly differ from the idiopathic ASD group on 
any item in the communication domain, suggesting that the profile of ‘ASD-like’ 
communication impairments is similar in the total PMS and idiopathic ASD groups.  
 
Secondly, the PMS group did not differ from the Fragile X or Down syndrome groups in 
‘ASD-like’ repetitive behaviours. However, when verbal items were included in the subscale 
analysis, the PMS group evidenced significantly lower repetitive behaviour scores than the 
idiopathic ASD group. This finding mirrors those previously reported (Phillipe et al., 2008) 
and highlights the need to evaluate the specificity of measures when assessing ASD 
phenomenology in groups with intellectual disabilities and communication impairments. 
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When verbal items were excluded from the subscale analysis, the PMS group did not differ 
from the idiopathic ASD group. This suggests the perceived profile of reduced ASD repetitive 
behaviour in PMS is, in part, due to the group being unable to score on some verbal items of 
measures. However, item-level analysis also revealed that the PMS group was significantly 
less likely to engage in non-verbal ritualistic behaviours than those with Fragile X syndrome 
or idiopathic ASD. Thus, the profile of repetitive behaviour is still somewhat unclear in PMS. 
Fine-grained observational analysis of repetitive behaviours would be beneficial, in order to 
detail topography, frequency and any potential management difficulties of repetitive 
behaviour in the syndrome.   
 
Finally, at subscale level, the PMS group evidenced significantly more impairments in social 
interaction than the Down syndrome group and showed comparable levels of impairment to 
the idiopathic ASD and Fragile X syndrome groups. This finding supports data demonstrating 
‘ASD-like’ social interaction impairments in PMS (Phillipe et al., 2008; Soorya et al., 2013). 
An interesting dissociation in social interaction was revealed at item level; the PMS group 
showed significantly more impairments in ‘Showing and directing attention’ than both the 
Down syndrome and idiopathic ASD groups, but significantly less impairment in items 
assessing interest in, and responses to, other children. One interpretation of this finding is that 
there is a divergence in social skills and social motivation in PMS, with relatively preserved 
social motivation in contrast to deficits in social competence, potentially due to low levels of 
expressive speech. Alternatively, the result may represent a specific impairment in initiating 
interaction, with relatively preserved abilities to respond to interactions initiated by others. 
This finding warrants further investigation, including attempts to replicate the results in larger 
samples with PMS, using both indirect and direct assessments of social competence and 
motivation. 
 
Whilst the profile of ASD impairments across the triad was varied within the total PMS 
sample, the results within the subgroup that scored above the autism threshold were 
homogenous. The results in this subgroup revealed that individuals with PMS were no more 
or less likely to score on items in any area of the triad, including the repetitive behaviour 
domain, than those with idiopathic ASD. This was true for all items except for ‘Showing and 
directing attention’, where the PMS group were approximately 30 times more likely to score 
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as impaired than the idiopathic ASD group. This finding extends previous research, affording 
a more refined understanding of the nature ASD impairments in affected individuals with 
PMS. The result suggests that when individuals with PMS meet criteria for autism, they do so 
for similar reasons to those with idiopathic ASD. Clinically, this may indicate that 
interventions to support individuals with idiopathic ASD could be usefully applied to 
individuals with PMS who meet diagnostic criteria, for example, Reciprocal Imitation 
Training (RIT; e.g., Ingersoll & Schreibman, 2006). The result also replicates the specific 
deficit noted in the total sample in showing and directing attention. Interventions to extend the 
behavioural repertoires of individuals with PMS, focused on behaviour to recruit and maintain 
others’ attention may be warranted in this population, particularly given the high levels of 
functional challenging behaviour identified in the group (Powis et al., In Review).   
 
The final results of this study demonstrated that across all demographic and behavioural 
scores, only ‘Interest and pleasure’ was (negatively) correlated with SCQ score in the PMS 
group. The correlation between ‘Mood’ and total SCQ score approached significance; 
however this result should be interpreted with caution due to the poor internal consistency of 
the Mood subscale in the PMS group. These findings lend tangential support to previous 
research indicating an association between the presentation of mood disorders and ASD 
phenomenology in the syndrome (Shaw et al., 2011). However, given the strength of evidence 
of behaviours indicative of ASD in PMS, the correlation between interest and pleasure and 
SCQ score is not interpreted as substantiation of mood disorders being wholly explanatory for 
ASD phenomenology in PMS. Instead, it is possible that behaviours indicative of low mood 
are associated with ASD impairments in PMS, similarly to the association reported in 
idiopathic ASD (Stewart, Barnard, Pearson, Hasan, O’Brien, 2006). Alternatively, it may be 
that mood disorders and ASD impairments co-exist within PMS due to similar genetic 
underpinnings, perhaps with greater severity of mood disorder being associated with more 
significant genetic deletion, as ASD phenomenology is hypothesised to (Luciani et al., 2003). 
These hypotheses are tentative and further research is required to delineate the association 
between mood and ASD phenomenology in PMS, including any causal links between the two 
phenomena. 
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A number of caveats must be considered when interpreting the findings in this study. Firstly, 
the assessment of ASD phenomenology is somewhat limited, due to the utilisation of a 
screening measure rather than a diagnostic measure; the ‘gold standard’ for assessment of 
ASD in individuals with intellectual disability is a combination of ADOS (Lord et al., 2000) 
and ADI-R (Rutter et al., 2003). However, utilising a brief parent screening measure reduced 
time and assessment demands, and conferred the advantage of assessing multiple comparison 
groups in order to position the profile of ASD phenomenology in PMS relative to other 
syndromes (Oliver, Berg, Moss, Arron & Burbidge, 2011). Additionally, the SCQ is 
recognised as more appropriate for assessing ASD phenomenology in samples with 
intellectual disabilities than other ASD screening tools (Charman et al., 2007). Similarly, the 
Wessex adaptive behaviour scores were utilised as a proxy measure for intellectual disability. 
Whilst it would have been beneficial to conduct full cognitive assessments of all of the 
participants, it would not have been possible within the scope of this study. Thus, a brief 
assessment of adaptive behaviour was chosen in order to balance the need to assess 
intellectual disability, and the need to maximise participants in all four groups. Secondly, 
despite careful matching of the groups, it was not possible to reduce all differences in 
adaptive behaviour. Therefore, the Down syndrome group were significantly more able than 
the PMS, Fragile X syndrome and idiopathic ASD samples. Previous researchers have argued 
that delineating the behavioural phenotype of a given genetic syndrome in relation to multiple 
other syndromes reduces the need for chronological or mental age matched comparison 
groups (Oliver et al., 2011). Additionally, the PMS, Fragile X syndrome and idiopathic ASD 
groups were well matched for chronological age and adaptive ability. Nonetheless, the results 
should be interpreted with this caveat in mind. Finally, due to the relatively small PMS 
sample, there was insufficient statistical power to test causal associations between expressive 
speech, adaptive behaviour and ASD scores. Previous research has highlighted that it is 
important to explore these associations in samples with genetic syndromes (Moss & Howlin, 
2009). Correlational evidence from this study indicates that adaptive behaviour was not 
associated with SCQ score; however this still warrants further exploration in larger sample 
sizes, where causal statistical modelling is possible.  
 
The results of this study have a number of important clinical implications. Firstly, the 
similarity in ASD profile between those with PMS who reach the autism threshold and those 
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with idiopathic ASD suggests that interventions utilised in those with idiopathic ASD could 
be usefully applied to individuals with PMS. Secondly, the results indicate that assessment of 
behaviours indicative of low mood should be routine in individuals with PMS. Research in 
individuals with severe intellectual disabilities has revealed that low mood scores may 
indicate pain and undiagnosed health conditions (Breau, Camfield, McGrath & Finley, 2003; 
Carr & Owen-Deschryver, 2007; Luzzani, Macchini, Valade, Milani & Selicorni, 2003). 
There are reports of gastro-oesophageal reflux and other painful conditions in PMS (Phelan, 
2008). Therefore, thorough health assessments should routinely be conducted for individuals 
with PMS. Finally, the results of this study have implications for research investigating the 
genetic underpinnings of idiopathic ASD. The results demonstrate that those with high levels 
of ASD impairment evidence a profile of ASD impairments similar to that of idiopathic ASD. 
However, the wider PMS sample presents a more heterogeneous pattern with fewer 
impairments in repetitive behaviours. This may suggest that social and communicative 
impairments would be a useful autism endophenytpe to be investigated in relation to 22q13.3 
deletions (Bill & Geschwind, 2009). 
 
In summary, this study has demonstrated that differences in affect and repetitive behaviour 
are common in PMS. Additionally, autism spectrum disorder phenomenology is prevalent 
within the syndrome. The profile of ASD impairments in the total sample with PMS is 
heterogeneous; the profile within those who meet clinical threshold for autism is more 
homogenous and analogous to those with idiopathic ASD. The presence of ASD 
phenomenology is associated with lower mood in those with PMS. 
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CHAPTER 3 
 
Executive Summary 
_____________________________________________ 
 
3.1. Literature Review 
3.1.1. Background 
Autism spectrum disorder (ASD) is a term used to describe a neurodevelopmental disorder in 
which three key areas of impairment are seen; difficulties in communication, difficulties in 
social interaction, and difficulties in flexibility of thought and imagination, with 
accompanying restricted and repetitive behaviours.  ASD is very common, with recent 
estimates suggesting that 1 in 68 individuals has a diagnosis of ASD. ASD is also known to 
be hereditable, although the precise genetic pathway for this is still unclear. 
 
There is emerging evidence that ASD behaviours are more common in individuals with rare 
genetic or metabolic syndromes, compared to other syndromes and/or compared to the general 
population. This is important for two key reasons. First, it is possible that knowing the 
specific genetic cause of a rare syndrome and knowing that ASD behaviours are very 
common in that syndrome could help researchers to understand the pathway from genetics, to 
brain development, to cognition (or the style and type of thinking processes) that leads to 
ASD behaviour. The development of this understanding would be important for individuals 
and families with these rare syndromes, and to individuals and families with ASD that is not 
associated with a syndrome. Second, having robust estimates of how common ASD behaviour 
is in each rare syndrome would help to improve the provision of clinical and educational 
services for individuals with those syndromes.  
 
There has been a lot of published scientific research in individual rare syndromes, detailing 
how common ASD behaviours are in these syndromes (for an accessible overview of this 
research see Moss & Oliver, 2012). However, there has not yet been a systematic review of all 
of these studies, which brings together the estimates of how common ASD behaviour is in 
each syndrome, summarises these estimates, compares them between syndromes and 
compares them to the general population.  
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3.1.2. What did the review do? 
A large literature search was conducted to find all of the research papers that detailed how 
common ASD behaviours were in 21 rare genetic and metabolic syndromes. A system for 
reviewing the quality of each individual research paper was devised, and overall estimates 
were generated for how common ASD behaviour was in each syndrome. These overall 
estimates were influenced more heavily by the highest quality research papers, and least 
heavily by the poorest quality papers.  
 
3.1.3 What did the review find? 
After poor quality papers had been removed, it was possible to generate robust estimates of 
how common ASD behaviours were for 12 syndromes. Figure 3.1 presents the results of this, 
showing that ASD behaviour was most common in Rett syndrome (with estimates suggesting 
that 61 in 100 individuals with Rett syndrome may show ASD behaviour) and least common 
in 22q11.2 deletion syndrome (with estimates suggesting that only 11 in 100 individuals with 
22q.11.2 deletion syndrome may show ASD behaviour). 
 
 
Figure 3.1 Generated estimates of how common ASD behaviour is in syndromes. 
 
For each syndrome, it was also possible to estimate how many times more likely ASD 
behaviour was, compared to the general population. Figure 3.2 presents the results of this. The 
results revealed that ASD behaviour was significantly more common in each of the 
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syndromes, compared to the general population. In Rett syndrome, the odds of showing ASD 
behaviour were almost 105 times greater than in the general population. In 22q11.2 deletion 
syndrome, the odds of showing ASD behaviour were 8 times greater than in the general 
population. 
 
 
Figure 3.2 Generated estimates of how likely ASD behaviour is in each syndrome 
compared to the general population. 
 
3.1.4 What do these findings really mean? 
These findings give us important robust estimates of how common ASD behaviour is in lots 
of rare syndromes. This can help us to plan clinical and educational services more 
appropriately for individuals with these syndromes. These estimates can also be used to focus 
future research into the underpinnings of ASD and the precise nature of ASD type difficulties 
in people with rare syndromes. 
 
3.2. Empirical Paper 
3.2.1. Background 
Phelan McDermid syndrome (PMS) is a rare genetic syndrome, caused by a deletion on 
chromosome 22q13.3. This deletion is very small and recent developments in genetic testing 
have made it easier to detect. There has been some research to suggest that certain 
behavioural characteristics are more common in individuals with PMS compared to other 
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individuals. These characteristics include higher levels of activity and impulsivity, lower 
mood and higher levels of ASD behaviours. There is also some limited research suggesting 
that although ASD behaviours are more common in PMS, that individuals with PMS do not 
demonstrate all three areas of ASD impairment equally. Some researchers have argued that 
although difficulties with social interaction and communication are common in PMS, 
difficulties with repetitive and restricted behaviours are less common. 
 
The published research to date in PMS has been limited by the use of assessment measures 
that do not take into account the degree of intellectual disability present in PMS. Additionally, 
there has been little research using appropriate comparison groups for individuals with PMS. 
Comparison groups are useful as they allow us work out whether behavioural characteristics 
are simply due to intellectual disability or due to the specific genetic syndrome. Comparison 
groups with ASD not associated with a genetic syndrome also allow us to find out whether the 
profile of the three areas of impairment in PMS is similar to people with ASD, or atypical, as 
the previous research had suggested. 
 
3.2.2. What did the study do? 
Parents of 30 individuals with PMS took part in a questionnaire study. The parents completed 
questionnaires that had been specifically designed for people with intellectual disabilities. 
These questionnaires measured activity levels, mood, repetitive behaviour and ASD type 
impairments. Additionally, parents of three comparison groups also completed the 
questionnaires. These comparison groups were Fragile X syndrome, Down syndrome and 
ASD not associated with a genetic syndrome.  
 
3.2.3. What did the study find? 
The study showed that the levels of activity and impulsivity in PMS did not differ from those 
with Fragile X syndrome, Down syndrome or ASD not associated with a genetic syndrome. 
Individuals with PMS were found to have lower mood than the ASD group, but higher mood 
than the Down syndrome group. Repetitive behaviours involving repetitive physical actions 
were common in the group, but compulsive repetitive behaviours were less common. 
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ASD behaviour was very common in individuals with PMS. Figure 3.3 shows that 86.7% of 
the group met criteria for ASD on the questionnaire measure. 56.7% of the group met criteria 
for a more stringent category of autism. However, it should be noted that although these 
individuals met criteria on the questionnaire measure, this does not necessarily mean they 
would fulfil criteria for a clinical diagnosis of ASD.  
 
 
Figure 3.3. Percentage of each group meeting criteria for ASD and autism 
A very fine-grained analysis of each of the three areas of ASD impairments in PMS revealed 
that individuals with PMS who meet criteria for autism, have a very similar profile of social, 
communication and repetitive behaviour impairments as individuals with ASD not associated 
with a genetic syndrome. Interestingly, for individuals with PMS, higher levels of ASD 
behaviour were associated with lower mood scores.  
 
3.2.4. What do these findings really mean? 
These findings mean that individuals with PMS are no more or less likely to have problems 
with attention and activity levels than other individuals with a similar level of intellectual 
disability. They may however have lower levels of mood than other individuals. ASD 
behaviour is very common in the group, and therefore clinical assessments should always 
include an evaluation of ASD. As the profile of ASD impairments in PMS is very similar to 
individuals with ASD not associated with a genetic syndrome, it is possible that the vast 
wealth of interventions designed for individuals with ASD could be usefully used with 
individuals with PMS. 
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Appendix A – Development of Quality Criteria 
 
Well validated quality criteria for evaluating case-control and intervention studies are 
published (e.g., Downs & Black, 1998) which provide numerical outcome data. However, 
these criteria are not suitable for evaluating the quality of prevalence studies due to significant 
differences in the design and methods of intervention and prevalence studies. There is wide 
variation in the application of quality criteria in health science meta-analyses of prevalence. 
Some studies take an inclusive approach and do not specify an evaluation of quality (e.g., an 
evaluation of the prevalence of community acquired MRSA; Salgado, Farr & Calfee, 2013). 
Others have delineated areas of potential bias, such as the type of measure used to assess 
depression, and then conducted post-hoc statistical analyses to evaluate the effect of these 
differing measurement techniques upon the identified prevalence rates (Anderson, Clouse, 
Freedland & Lustman, 2001). Whilst both of these approaches have utility, they do not allow 
for a-priori evaluation of the overall quality of the literature. For the present review, the 
ability to assess within and between syndrome variations in evidence quality will be 
paramount. Therefore, an alternative approach of pre-analysis assessment of quality was 
selected.  
 
Shamliyan and colleagues (2011) developed a preliminary checklist for assessing the quality 
of prevalence studies included in meta-analyses. The checklist includes an assessment of 
external validity (primarily sampling method, assessment of sampling bias and estimate of 
return rate) and internal validity (assessment measurement utilised to assess prevalence). 
Whilst this checklist does not generate numerical ratings for the quality of studies, it does 
provide a broad framework for assessing quality, which the present study has drawn upon. 
The authors emphasise the need for each meta-analysis to tailor the quality criteria to their 
study, in order to produce the most robust assessment of quality. A useful example of 
individually tailored quality criteria is presented by Reijnders et al., (2008) who conducted a 
meta-analysis of the prevalence of depression in Parkinson’s Disease. Similarly to the present 
study, Reijnders et al. (2008) investigated the prevalence of a behaviourally defined disorder 
(depression) within a clinically selected sample (individuals with Parkinson’s Disease). They 
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applied a simple rating scale to evaluate how each study identified cases, confirmed diagnosis 
of Parkinson’s Disease and confirmed diagnoses of depression. This system allowed for an 
evaluation of both internal and external validity and produced a numerical rating of quality 
which could be used to weight the overall prevalence data. The present study applied a similar 
model to evaluate: 1) the selection of the samples with syndromes 2) the confirmation of 
syndrome, 3) the assessment of ASD. 
 
In order to develop idiosyncratic quality ratings for each of these three areas, literature 
reviews were conducted and active research experts in the field of autism and rare syndromes 
were consulted for advice on areas of methodological concern.  
 
Quality Criterion for Sample Identification 
The primary focus of this quality criterion was whether the recruited sample could be 
considered to be representative of the total population. Downs and Black (1998) state that 
“Patients would be representative if they comprised the entire source population, an 
unselected sample of consecutive patients, or a random sample”. Similarly, Shamliyan and 
colleagues (2011) identify sampling restricted to a specific geographic area and convenience 
sampling as minor flaws, and sampling through medical records, insurance claims, work 
places and health care service (i.e., clinics and hospitals) as major flaws.  
 
Utilising similar principles, the sampling strategies employed by studies in the present meta-
analysis were ranked on a 0 – 3 scale, with a score of 0 assigned to studies where no sampling 
strategy was reported, and a score of 3 assigned for random or total population sampling. A 
score of 1 was assigned for studies sampling from a single restricted source, for example a 
specialist clinic or regional support service. A score of 2 was assigned for studies recruiting 
from multi-site restricted sources, for example national parent support groups or multi-region 
specialist clinics.  
 
Quality Criterion for Confirmation of Syndrome 
The primary focus of this quality criterion was confidence in the accuracy of the diagnosis of 
the specified syndromes. Diagnosis of syndromes can be made on the basis of the presence of 
clinical features and/or on the basis of molecular, cytogenetic or metabolic tests. The  
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diagnostic strategies employed by studies in the present meta-analysis were ranked on a 0 – 3 
scale, with a score of 0 assigned to studies where diagnosis of syndrome  was not reported or 
confirmed, or where a diagnosis based on clinical features was only suspected. A score of 1 
was assigned for studies where a clinical diagnosis had been made by a ‘generalist’, whereas a 
score of 2 was assigned for studies where a clinical diagnosis was made by an ‘expert’ or 
‘specialist’. Finally, a score of 3 was assigned only if a diagnosis of syndrome was confirmed 
by molecular, cytogenetic or metabolic testing. To ensure a conservative estimate of quality, 
in studies in which only a proportion of the sample were administered a more stringent test 
(e.g., some participants had cytogenetic testing, others clinical diagnosis by a geneticist), the 
dataset as a whole were assigned the more conservative quality rating.  
 
Quality Criterion for ASD Assessment 
The primary focus of this quality criterion was confidence in the accuracy of the identification 
of ASD phenomenology in the sample. As discussed above (see Section 1.2), ASD diagnoses 
in clinical practice are made on the basis of multi-modal comprehensive assessments, the 
breadth and depth of which are rarely conducted in a research context. However, there is a 
wide variety of tools used in research to assess ASD, which can be helpfully separated into 
categories of screening and diagnostic instruments. Screening instruments can be used as 
tools to identify an increased likelihood of ASD. However, in a detailed scope of these tools 
for the Autism NICE guidelines (2011), the Guideline Development Group (GDG) stated that 
the accuracy of these tools was very low, and whilst they ‘may be useful in gathering 
information about signs and symptoms of autism’ they ‘should not be used to make or rule out 
a diagnosis of autism’. Conversely, the accuracy of diagnostic tools was better. However, as 
discussed above (see Section 1.2) whilst many of these instruments evidence good reliability 
and validity, no diagnostic or screening instruments are validated for marginal populations, 
such as those with syndromes. Thus, whilst diagnostic tools can be seen to be more broadly 
accurate than screening tools in the assessment of ASD, none of these tools, used in isolation, 
can definitively diagnose ASD in individuals with genetic and chromosomal disorders.   
 
Therefore, a broad quality criterion of ASD assessments was constructed. The ASD 
assessments employed by studies in the present meta-analysis were ranked on a 0 – 3 scale, 
with a score of 0 assigned to studies where no information was specified or reported on the 
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type of ASD assessment conducted. A score of 0 was also assigned to studies where clinician 
judgement alone was used to assess ASD, without reference to any specified tools or 
diagnostic criteria. A score of 1 was assigned when a robust screening instrument was 
employed, for example SCQ or M-CHAT. A score of 1 was also assigned when clinician 
judgement against specified diagnostic criteria such as ICD-10 or DSM-V was used. A score 
of 2 was assigned for studies that employed robust diagnostic instruments, such as the ADI-R 
or ADOS. Finally, a score of 3 was assigned if studies used consensus from multiple 
assessments, and that at least one of these assessments would have obtained a score of 2 in 
isolation. This rating was assigned as the closest research approximation to multi-model 
diagnostic clinical assessments. Where studies have employed multiple ASD assessments of 
varying quality, the most robust assessment (as defined by this quality criterion) was used. 
Where studies have employed multiple ASD assessments of the same quality, for example 
multiple screening measures, the measure which yielded the most conservative estimate of 
prevalence was used.  
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Appendix B – Forest Plots for Pooled Prevalence Estimates for Males Only with Fragile 
X syndrome 
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Figure 1. Pooled prevalence estimates for ASD phenomenology in males with Fragile X 
syndrome using a random-effects model. 
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Figure 2. Pooled prevalence estimates for ASD phenomenology in males with Fragile X 
syndrome using a quality-effects model. 
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Appendix C – Questionnaire pack 
 
 
 
                                         
 
27th June 2011 
    
  
Dear Parent, 
 
We are writing to inform you of a new research project that is being carried out at the 
Cerebra Centre for Neurodevelopmental Disorders at the University of Birmingham. 
We would like to invite you and the person you care for to take part in this new 
research project. Briefly, the research is a questionnaire study looking at different 
behaviours in children and adults with Phelan-Mcdermid syndrome that have 
received minimal attention within the literature.  
 
We have contacted you through Unique. Your personal details will not be known to 
us unless you decide to take part in the study. There is an information sheet 
enclosed that gives you more details about why the research is being carried out and 
what participation will involve. If you feel it is appropriate you may wish to discuss the 
research with the person you care for before a decision is made about taking part.  
 
There is an information sheet enclosed that gives you more details about why the 
research is being carried out and what it will involve. If you and your child/person you 
care for would like to take part in the study then please complete the enclosed 
consent form and questionnaire pack and return them in the pre-paid envelope 
provided. 
 
Please read the information sheets before completing the questionnaires and if 
you are unclear about any aspect of the study or have any questions then 
  
 
Thank you for your time and we look forward to hearing from you. 
 
Yours sincerely 
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Consent Form A :  For individuals who are able to provide consent to participate in 
the study 
 
Understanding behaviour and family adjustment in individuals with 
neurodevelopmental disorders 
 
Study Director: Professor Chris Oliver 
 
SECTION 1:  Please complete this section if you are a person with Phelan-McDermid 
syndrome: 
 
1. Has somebody else explained the project to you?   YES/NO 
2. Do you understand what the project is about?     YES/NO 
3. Have you asked all of the questions you want?     YES/NO 
4. Have you had your questions answered in a way you understand?  YES/NO 
5. Do you understand it is OK to stop taking part at any time?   YES/NO 
6. Are you happy to take part?       YES/NO 
 
If any answers are ‘no’ or you don’t want to take part, don’t sign your name! 
 
If you do want to take part, you can write your name below 
 
You can also choose if you want to say ‘yes’ to these questions: 
7. If your Dr asks to see your results from this project is that OK?  YES/NO 
8. Are you happy for us to contact you again in the future?   YES/NO 
 
Your name:______________________________________________________________ 
 
Date:_____________________ 
 
The person who explained this project to you needs to sign too. If you are under the age of 16, 
this should be your parent/guardian. 
 
Print name:___________________________ Sign:_________________________ 
Date:__________________ 
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SECTION 2: Please complete this section if you are a parent/carer/guardian of a person 
with PMS  
who has provided their consent to participate in the study.     Please initial box… 
 
1. I confirm that I have read and understood the information sheet for the above 
study. I have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
 
2. I understand that my participation and that of my child/person I care for is 
voluntary and that I am free to withdraw at any time without giving any reason, 
without my or that of my child’s/person I care for’s medical care or legal rights 
being affected. 
 
3. I understand that relevant sections of my child’s/person I care for’s GP medical 
notes or records confirming genetic diagnosis and health status may be looked at 
by members of the Cerebra Centre for Neurodevelopmental Disorders research 
team at the University of Birmingham, where it is relevant to this research project. 
I give permission for these individuals to have access to these records. 
 
4. I agree to my child’s/person I care for’s GP being informed of my participation 
and that of my child/person I care for’s in the study, where access to my 
child’s/person I care for’s medical records is required. 
 
5. I agree to take part in the above study.  
 
Optional clause: The statement below is optional:    
  
 
1. I agree to the University of Birmingham research team sharing my research data 
with any professionals or clinicians working with me and the person I care for 
should they request to see them. 
 
Print Name: ________________________________________  
Telephone number: ______________________________ 
 
Address: ________________________________________________________ 
Email: ___________________________ 
 
Relationship to participant: ________________ 
Signature: ________________________ 
Date: _____________________ 
 
Volume One: Appendix 
166 
 
SECTION 3: This is optional and allows you to provide consent for us to keep your 
personal details on the Regular Participant Database.  See section titled ‘Regular 
Participant Database’ in the information sheet.       
                                                                                                                                                          
Please initial box… 
1. I have read and understood the section titled ‘Regular Participant Database’ and I 
would like my personal details to be added to the database. 
 
2. I understand that my name and contact details will be kept by the research team at 
the University of Birmingham in accordance with the provisions of the Data 
Protection Act 1998 and I will be contacted by an approved member of the team 
with information about future research that I and the person I care for may like to 
participate in. 
 
3. I understand that if my details are held on the database it will be possible for the 
research team to trace the results of the assessments that I complete in this project 
back to me and my child/person I care for so that they can look at changes over 
time if I take part in future projects. 
 
4. I understand that even after I have agreed for my details to be added to the database, I 
can request that they be removed by contacting Chris Oliver on 0121 414 7206 or at 
cndd-enquiries@contacts.bham.ac.uk or by post at the School of Psychology, 
University of Birmingham, Edgbaston, B15 2TT. 
 
5. I understand the Professor Chris Oliver holds ultimate responsibility for the 
database. 
 
Print Name: ____________________Signature: ____________________________Date: __________ 
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Consent Form B: For Children under the age of 16 who are not able to provide consent. 
 
Understanding behaviour and family adjustment in individuals with 
neurodevelopmental disorders 
 
Study Director: Professor Chris Oliver 
 
SECTION 1: Please complete this section if you are a parent/ guardian of a child (under 
16 years) with Phelan-McDermid syndrome who is not able to provide consent. 
           Please initial box… 
 
1. I confirm that I have read and understood the information sheet dated 01.02.2010 
for the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
2. I understand that my participation and that of my child/person I care for is 
voluntary and that I am free to withdraw at any time without giving any reason, 
without my or that of my child’s/person I care for’s medical care or legal rights 
being affected. 
3. I understand that relevant sections of my child’s/person I care for’s GP medical 
notes or records confirming genetic diagnosis and health status may be looked at 
by members of the Cerebra Centre for Neurodevelopmental Disorders research 
team at the University of Birmingham, where it is relevant to this research project. 
I give permission for these individuals to have access to these records. 
4. I agree to my child’s/person I care for’s GP being informed of my participation 
and that of my child/person I care for’s in the study, where access to my 
child’s/person I care for’s medical records is required. 
5. I agree to take part in the above study.  
 
Optional clause: The statement below is optional:      
   
6. I agree to the University of Birmingham research team sharing my research 
data with any professionals or clinicians working with me and the person I 
care for should they request to see them. 
 
Print Name: _____________________Name of person you care for___________________________ 
 
Address:_____________________________________Email: ______________________________ 
 
Telephone number:______________Relationship to participant: ______________________________  
 
Signature: ________________________Date: __________________ 
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SECTION 2: This is optional and allows you to provide consent for us to keep your 
personal details on the Regular Participant Database.  See section titled ‘Regular 
Participant Database’ in the information sheet.  
           
                                                                                                                     Please initial box… 
 
6. I have read and understood the section titled ‘Regular Participant Database’ and I 
would like my personal details to be added to the database. 
 
7. I understand that my name and contact details will be kept by the research team at 
the University of Birmingham in accordance with the provisions of the Data 
Protection Act 1998 and I will be contacted by an approved member of the team 
with information about future research that I and the person I care for may like to 
participate in. 
 
8. I understand that if my details are held on the database it will be possible for the 
research team to trace the results of the assessments that I complete in this project 
back to me and my child/person I care for so that they can look at changes over 
time if I take part in future projects. 
 
9. I understand that even after I have agreed for my details to be added to the database, I 
can request that they be removed by contacting  
         
 
 
10. I understand the Professor Chris Oliver holds ultimate responsibility for the 
database. 
 
 
Print Name: ___________________________Signature: ___________________Date: ____________ 
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Consent Form C: For individuals over the age of 16 who are not able to provide 
consent. 
 
Understanding behaviour and family adjustment in individuals with 
neurodevelopmental disorders 
 
Study Director: Professor Chris Oliver 
 
SECTION 1: Please read the following statements:     
                Please initial box… 
  
1. I (your name)___________________have been consulted about (name of 
participant)_______________’s participation in the above research project. I have 
had the opportunity to ask questions about the study and understand what is 
involved. 
2. In my opinion he/she would have no objection to taking part in the above study. 
3. I understand that I can request he/she is withdrawn from the study at any time 
without giving any reason and without his/her care or legal rights being affected. 
4. I understand that relevant sections of his/her GP medical notes or records 
confirming genetic diagnosis and health status may be looked at by members of 
the Cerebra Centre for Neurodevelopmental Disorders research team at the 
University of Birmingham, where it is relevant to this research project. I give 
permission for these individuals to have access to these records. 
5. I agree to his/her GP being informed of their participation in the study, where 
access to medical records is required. 
6. I agree to take part in the above study.  
 
 
Optional clause: The statement below is optional:      
   
7. I agree to the University of Birmingham research team sharing his/her 
research data with any professionals or clinicians working with them should 
they request to see them. 
 
 
Print Name: _________________________________ Telephone number:_______________________ 
 
Address:______________________________________________________ 
Email: _____________________________ 
 
Relationship to participant________________ 
Signature: ________________________Date: _____________________ 
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SECTION 3: This is optional and allows you to provide consent for us to keep your personal 
details on the Regular Participant Database.  See section titled ‘Regular Participant Database’ in 
the information sheet.  
           
                                                                                                                                          Please initial box… 
 
11. I have read and understood the section titled ‘Regular Participant Database’ and I 
would like my and the person I care for’s personal details to be added to the database. 
 
12. I understand that my name and contact details will be kept by the research team at the 
University of Birmingham in accordance with the provisions of the Data Protection 
Act 1998 and I will be contacted by an approved member of the team with information 
about future research that I and the person I care for may like to participate in. 
 
13. I understand that if my details are held on the database it will be possible for the 
research team to trace the results of the assessments that I complete in this project 
back to me and the person I care for so that they can look at changes over time if we 
take part in future projects. 
 
14. I understand that even after I have agreed for my details to be added to the database, I 
can request that they be removed by contacting  
         
 
 
15. I understand the Professor Chris Oliver holds ultimate responsibility for the database. 
 
Print Name: ___________________________Signature: ____________________________ 
Date: _______________ 
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Understanding behaviour in Neurodevelopmental Disorders:  Information Sheet  
 
Please read this information carefully before deciding whether you wish to take part in the 
study.  If you have any further questions please contact   
    If you have any medical/ other 
problems which make it difficult for you to read this information, please contact Professor 
Chris Oliver for a verbal explanation of the research. 
 
When you are happy that you have all of the information you need to be able to decide 
whether or not you and the person you care for would like to take part in the study, please 
complete the enclosed consent form and questionnaire pack return them to us in the prepaid 
envelope provided 
 
Background 
We would like to invite you to take part in a questionnaire study being conducted at the 
Centre for Neurodevelopmental Disorders, University of Birmingham. This research work, 
which is led by Professor Chris Oliver, looks at a range of behaviours, skills and impairments 
in individuals with Phelan-McDermid syndrome including: Repetitive behaviour, Hyperactivity, 
Mood, Challenging behaviour, Social functioning and Health. We will also ask some 
questions that are related to family well-being and the impact that having a child with a 
disability has on the family.  
 
We hope that this information will enable us to further understand the behaviours, skills and 
impairments associated with Phelan-McDermid syndrome including challenging behaviour, 
social functioning, mood, hyperactivity and health and the impact that these behaviours have 
on the family. The more people that take part in this research, the more meaningful the 
results will be. A good response will provide new and valuable information about Phelan-
McDermid syndrome. In the future we hope to follow up the progress of the people who take 
part in this study. However, participation in this stage of the project will not mean that you 
are obliged to participate in further surveys in the future. 
 
Aims of the study 
1. To further our understanding of challenging behaviour, repetitive behaviour, hyperactivity, 
mood and social functioning in individuals with Phelan-McDermid syndrome. 
2. To understand what happens with regard to these behaviours as children and adults 
develop. 
3. To understand what, if any, changes may occur with regard to these behaviours when the 
individuals reach a certain age.  
4. To understand the impact of having a child with a disability has on the family. 
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What will happen if you and your child/the person you care for decide(s) to 
participate? 
 
Where will the research take place? 
The research will involve completing the enclosed questionnaire pack. This can be 
completed by you in your own time. 
 
Who will be involved in collecting the data? 
Members of the research team at the Cerebra Centre for Neurodevelopmental disorders 
including Professor Chris Oliver and Dr. Joanna Moss.  
 
How long will participation in the study take? 
The questionnaire pack will take approximately 45 minutes to complete. 
 
In the future you may be asked if you would like to complete the questionnaire again so that 
we can start to understand what happens to people with Phelan-McDermid syndrome across 
their lifetime. We will only contact you with this invitation if you have previously agreed to be 
contacted by the research team at the University of Birmingham with information about 
research studies conducted by the team. 
 
Sometimes after you have completed the questionnaire, we may need to contact you again 
in order to clarify any information that you have provided or to ask you for further information 
regarding the diagnosis of the person you care for. This helps us to ensure that our data is as 
useful and as accurate as possible. If this happens then we would contact you again within 6 
months of receiving your questionnaire pack to ask whether or not you would be willing to 
provide us with the extra information.  
 
What will participants be required to do during the study? 
We will ask parents and caregivers to complete the enclosed questionnaire pack and return it 
to us alongside the consent form in the pre-paid envelope provided.  
 
Are there any risks that individuals taking part in the study might face? 
There will not be any risks associated with participation in this study.  
 
What are the potential benefits for participants from taking part? 
You will receive a personalised feedback regarding your child/ the person you care for. This 
study will help us to find out more about the lives of people with Phelan-McDermid syndrome 
and the difficulties that these people face.  The results might help us to improve things for 
people with Phelan-McDermid syndrome in the future.  
 
Where will data be stored? 
The data collected will be kept in locked or password protected storage at the University of 
Birmingham.  Only members of the research team at the University of Birmingham will have 
access to information that we collect about you.  Information will be treated as strictly 
confidential and handled in accordance with the provisions of the Data Protection Act 1998. 
 
If you/ the person you care for decide(s) to participate, what will happen after that 
participation? 
You and your child/ person you care for will receive an individual feedback report describing 
the results of all of the assessments that were carried out during the study.   If requested, this 
feedback report will be circulated to other interested individuals.  Descriptions of research 
findings will be published in newsletters of the relevant family support groups and 
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educational institutions involved.  Any request for advice concerning the person you care for 
will be referred to Professor Chris Oliver, Clinical Psychologist. 
The researchers will publish the findings from the study in scientific journals and will present 
the results at relevant conferences. 
 
What will happen to the data afterwards? 
The information that you provide will be locked in a filing cabinet at the University of 
Birmingham or held on a password protected database. Participants will be identified by a 
unique number so that the information you provide us with cannot be traced to your personal 
details.  You will be able to decide whether or not you want to make your research data 
available to any professionals or clinicians working with you and the person you care for 
should they wish to see it. This is optional and will not affect your participation in the current 
study. If you agree to this, then your research data will only be made available to relevant 
clinicians or professionals should they contact us directly and request to see it. If you do not 
agree to this then research data will not be made available to anyone other than the research 
team at the University of Birmingham. 
 
After 6 months of receiving your questionnaire pack, your personal details will be destroyed 
unless you tell us otherwise.  This means that we would no longer be able to trace the 
results of your assessments back to you.  The section below on ‘The Regular Participant 
Database Information’ gives information about a database that we use to store the personal 
details of some participants.  Please read this section in order to decide if you would like to 
join that database. 
 
 
Regular Participant Database Information: 
 
What is the regular participant database? 
We have a database that we keep in the Cerebra Centre where we store the names and 
contact details of some previous participants.  If you would like us to, we can add your details 
to this database.  We would use this information for two things: 
1) We will contact you with information about future research work to find out whether or 
not you would like to participate. 
2) It is often important to find out how things change over time.  By keeping your details 
we would be able to trace the results of the previous assessments that you have 
done with us back to you.  This means that if you take part in other studies with us we 
would be able to look at how things have changed over time. 
 
Who would have access to my details? 
Only approved members of out research team would have access to your details.  We would 
not share your details with anyone outside the research team. 
 
When would I be contacted? 
You would only be contacted by an approved member of the research team when we are 
starting another study or phase of a study that we think you might like to participate in or 
when we need to clarify some information that you have provided us with from participation in 
a research study.  
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What happens if I decide that I want my details to be added to the database but then I 
change my mind? 
All you would need to do is contact Chris Oliver on 0121 414 7206 or at cndd-
enquiries@contacts.bham.ac.uk or at the School of Psychology, University of 
Birmingham, Edgbaston, Birmingham, B15 2TT.  Your details would be removed from the 
database immediately. 
 
Consent 
After having read all of the information and having received appropriate responses to any 
questions that you may have about the study you and the person you care for will be asked 
to give your and your child’s/ person you care for’s consent to participate in the study if you 
decide that you do wish to participate.  The section below on ’Giving consent’ will explain 
this process.  We need to receive consent from/ on behalf of potential participants in order for 
them to participate. 
 
Withdrawal 
Even after consent has been granted, participants can request to be withdrawn from the 
study at any time, without giving a reason. Even after participation has taken place, consent 
can be withdrawn and any data collected will be destroyed.  This will not restrict the access 
of you/ the person you care for to other services and will not affect their right to treatment. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions. Please contact  
   
 
 
 
 
Confidentiality                  
The confidentiality of participants will be ensured.  If published, information on the participant 
will be presented without reference to their name or any other identifying information.  All 
personal details will be kept separately from the information collected so that it will only be 
possible to connect results to individuals via a special code.  This will ensure that results are 
kept anonymous.  In the unlikely event of any evidence of abuse being identified, this 
information will be disclosed by the research workers. 
 
Review 
The study has been approved by Coventry NHS Research Ethics Committee. For any 
queries or concerns regarding the ethical approval of this study please contact  
 
 
Further information 
If you would like any more information about the study please contact  
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IMPORTANT: 
You need to decide whether your child/the person you care for is able to understand enough about the study to 
make an ‘informed’ decision independently about whether or not they would like to participate and to 
communicate this decision to you.  If you are unsure whether or not your child/person you care for is able to 
understand enough to make a decision independently then we can provide you with some guidelines to help you to 
assess this A symbol information sheet can also be made available to you if this would be of help. Please contact 
 to request a copy of this.  
Giving consent 
Now it is up to you whether you decide that you and your child/the person you care for would 
like to participate.  The decision about whether or not to take part in the study must be 
‘informed’.  This means that anyone making the decision must understand exactly what is 
involved in the study, what will be required from participants and why.   
 
Please choose from one of the following options: 
 
1. My child/ the person I care for is able to understand what is 
involved in the study and what will be required from them if they 
participate and has communicated their decision to me: 
 
If you think that the person is able to understand enough about the study in order to make an 
‘informed’  
decision and they decide that they would like to participate then please ensure that they 
complete Section 1 of Consent Form A coloured YELLOW enclosed, or that you complete 
it with them, on their behalf.  A parent/carer will need to complete Section 2 of Consent 
From A coloured YELLOW in order to indicate that they also agree to participate in the 
study. A symbol information sheet can be made available in order to support your 
child/person you care for in making this decision if it would be of help. Please contact the 
research team if you would like a copy of the symbol consent form or if you need us to adapt 
this information further, in order to suit your child’s needs. Please return the consent form 
along with the questionnaire pack to us in the prepaid envelope provided.  
 
 
2. My child/ the person I care for is unable to understand what is 
involved in the study and what will be required from them if they 
participate (either because they are too young to understand or 
because they are unable to understand) and cannot 
communicate their decision to me: 
 
If you are reading this information on behalf of someone you care for who is under the age of 
16 years and you decide that the person is not able to make an ‘informed’ and independent 
decision about whether or not they would like to participate, then we would like to ask you to 
decide whether or not you think that it is in your child’s best interests for them to participate in 
the study and whether you would like to provide your consent to participation on their behalf. 
If you would like your child/person you care for to participate in this study, please complete 
Consent Form B coloured PURPLE enclosed. Please return the consent form along with 
the questionnaire pack to us in the prepaid envelope provided.   
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Understanding behaviour in Neurodevelopmental Disorders:  Information Sheet  
 
Please read this information carefully before deciding whether you wish to take part in the 
study.  If you have any further questions please contact   
    If you have any medical/ other 
problems which make it difficult for you to read this information, please contact Professor 
Chris Oliver for a verbal explanation of the research. 
 
When you are happy that you have all of the information you need to be able to decide 
whether or not you and the person you care for would like to take part in the study, please 
complete the enclosed consent form and questionnaire pack return them to us in the prepaid 
envelope provided 
 
Background 
We would like to invite you to take part in a questionnaire study being conducted at the 
Centre for Neurodevelopmental Disorders, University of Birmingham. This research work, 
which is led by Professor Chris Oliver, looks at a range of behaviours, skills and impairments 
in individuals with Phelan-McDermid syndrome including: Repetitive behaviour, Hyperactivity, 
Mood, Challenging behaviour, Social functioning and Health. We will also ask some 
questions that are related to family well-being and the impact that having a child with a 
disability has on the family.  
 
We hope that this information will enable us to further understand the behaviours, skills and 
impairments associated with Phelan-McDermid syndrome including challenging behaviour, 
social functioning, mood, hyperactivity and health and the impact that these behaviours have 
on the family. The more people that take part in this research, the more meaningful the 
results will be. A good response will provide new and valuable information about Phelan-
McDermid syndrome. In the future we hope to follow up the progress of the people who take 
part in this study. However, participation in this stage of the project will not mean that you 
are obliged to participate in further surveys in the future. 
 
Aims of the study 
5. To further our understanding of challenging behaviour, repetitive behaviour, hyperactivity, 
mood and social functioning in individuals with Phelan-McDermid syndrome. 
6. To understand what happens with regard to these behaviours as children and adults 
develop. 
7. To understand what, if any, changes may occur with regard to these behaviours when the 
individuals reach a certain age.  
8. To understand the impact of having a child with a disability has on the family. 
 
What will happen if you and your child/the person you care for decide(s) to 
participate? 
 
Where will the research take place? 
The research will involve completing the enclosed questionnaire pack. This can be 
completed by you in your own time. 
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Who will be involved in collecting the data? 
Members of the research team at the Cerebra Centre for Neurodevelopmental disorders 
including Professor Chris Oliver and Dr. Joanna Moss.  
 
How long will participation in the study take? 
The questionnaire pack will take approximately 45 minutes to complete. 
 
In the future you may be asked if you would like to complete the questionnaire again so that 
we can start to understand what happens to people with Phelan-McDermid syndrome across 
their lifetime. We will only contact you with this invitation if you have previously agreed to be 
contacted by the research team at the University of Birmingham with information about 
research studies conducted by the team. 
 
Sometimes after you have completed the questionnaire, we may need to contact you again 
in order to clarify any information that you have provided or to ask you for further information 
regarding the diagnosis of the person you care for. This helps us to ensure that our data is as 
useful and as accurate as possible. If this happens then we would contact you again within 6 
months of receiving your questionnaire pack to ask whether or not you would be willing to 
provide us with the extra information.  
 
What will participants be required to do during the study? 
We will ask parents and caregivers to complete the enclosed questionnaire pack and return it 
to us alongside the consent form in the pre-paid envelope provided.  
 
Are there any risks that individuals taking part in the study might face? 
There will not be any risks associated with participation in this study.  
 
What are the potential benefits for participants from taking part? 
You will receive a personalised feedback regarding your child/ the person you care for. This 
study will help us to find out more about the lives of people with Phelan-McDermid syndrome 
and the difficulties that these people face.  The results might help us to improve things for 
people with Phelan-McDermid syndrome in the future.  
 
Where will data be stored? 
The data collected will be kept in locked or password protected storage at the University of 
Birmingham.  Only members of the research team at the University of Birmingham will have 
access to information that we collect about you.  Information will be treated as strictly 
confidential and handled in accordance with the provisions of the Data Protection Act 1998. 
 
If you/ the person you care for decide(s) to participate, what will happen after that 
participation? 
You and your child/ person you care for will receive an individual feedback report describing 
the results of all of the assessments that were carried out during the study.   If requested, this 
feedback report will be circulated to other interested individuals.  Descriptions of research 
findings will be published in newsletters of the relevant family support groups and 
educational institutions involved.  Any request for advice concerning the person you care for 
will be referred to , Clinical Psychologist. 
The researchers will publish the findings from the study in scientific journals and will present 
the results at relevant conferences. 
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What will happen to the data afterwards? 
The information that you provide will be locked in a filing cabinet at the University of 
Birmingham or held on a password protected database. Participants will be identified by a 
unique number so that the information you provide us with cannot be traced to your personal 
details.  You will be able to decide whether or not you want to make your research data 
available to any professionals or clinicians working with you and the person you care for 
should they wish to see it. This is optional and will not affect your participation in the current 
study. If you agree to this, then your research data will only be made available to relevant 
clinicians or professionals should they contact us directly and request to see it. If you do not 
agree to this then research data will not be made available to anyone other than the research 
team at the University of Birmingham. 
 
After 6 months of receiving your questionnaire pack, your personal details will be destroyed 
unless you tell us otherwise.  This means that we would no longer be able to trace the 
results of your assessments back to you.  The section below on ‘The Regular Participant 
Database Information’ gives information about a database that we use to store the personal 
details of some participants.  Please read this section in order to decide if you would like to 
join that database.  
 
 
Regular Participant Database Information: 
 
What is the regular participant database? 
We have a database that we keep in the Centre where we store the names and contact 
details of some previous participants.  If you would like then we can add your details to this 
database.  We would use this information for two things: 
3) We will contact you with information about future research work to find out whether or 
not you would like to participate. 
4) It is often important to find out how things change over time.  By keeping your details 
we would be able to trace the results of the previous assessments that you have 
done with us back to you.  This means that if you take part in other studies with us we 
would be able to look at how things have changed over time. 
 
Who would have access to my details? 
Only approved members of out research team would have access to your details.  We would 
not share your details with anyone outside the research team. 
 
When would I be contacted? 
You would only be contacted by an approved member of the research team when we are 
starting another study or phase of a study that we think you might like to participate in or 
when we need to clarify some information that you have provided us with from participation in 
a research study.  
 
What happens if I decide that I want my details to be added to the database but then I 
change my mind? 
All you would need to do is contact  
  
  Your details would be removed from the 
database immediately. 
 
Consent 
After having read all of the information and having received appropriate responses to any 
questions that you may have about the study you and the person you care for will be asked 
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to give your and your child’s/ person you care for’s consent to participate in the study if you 
decide that you do wish to participate.  The section below on ’Giving consent’ will explain 
this process.  We need to receive consent from/ on behalf of potential participants in order for 
them to participate. 
 
Withdrawal 
Even after consent has been granted, participants can request to be withdrawn from the 
study at any time, without giving a reason. Even after participation has taken place, consent 
can be withdrawn and any data collected will be destroyed.  This will not restrict the access 
of you/ the person you care for to other services and will not affect their right to treatment. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions. Please contact  
   
 
 
 
 
Confidentiality                  
The confidentiality of participants will be ensured.  If published, information on the participant 
will be presented without reference to their name or any other identifying information.  All 
personal details will be kept separately from the information collected so that it will only be 
possible to connect results to individuals via a special code.  This will ensure that results are 
kept anonymous.  In the unlikely event of any evidence of abuse being identified, this 
information will be disclosed by the research workers. 
Review 
The study has been approved by Coventry NHS Research Ethics Committee. Ref: 
10/H1210/01. 8 
 
Further information 
If you would like any more information about the study please contact  
    
  
 
Giving consent 
Now it is up to you whether you decide that you and your child/the person you care for would 
like to participate.  The decision about whether or not to take part in the study must be 
‘informed’.  This means that anyone making the decision must understand exactly what is 
involved in the study, what will be required from participants and why.   
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IMPORTANT: 
You need to decide whether your child/the person you care for is able to understand enough about the study to 
make an ‘informed’ decision independently about whether or not they would like to participate and to 
communicate this decision to you.  If you are unsure whether or not your child/person you care for is able to 
understand enough to make a decision independently then we can provide you with some guidelines to help you 
to assess this A symbol information sheet can also be made available to you if this would be of help.  
 
Please contact   to request a 
copy of this.  
Please choose from one of the following options: 
 
3. My child/ the person I care for is able to understand what is 
involved in the study and what will be required from them if they 
participate and has communicated their decision to me: 
If you think that the person is able to understand enough about the study in order to make an 
‘informed’ decision and they decide that they would like to participate then please ensure that 
they complete Section 1 of Consent Form A coloured YELLOW enclosed, or that you 
complete it with them, on their behalf.  A parent/carer will need to complete Section 2 of 
Consent From A coloured YELLOW in order to indicate that they also agree to participate 
in the study. A symbol information sheet can be made available in order to support your 
child/person you care for in making this decision if it would be of help. Please contact the 
research team if you would like a copy of the symbol consent form or if you need us to adapt 
this information further, in order to suit your child’s needs. Please return the consent form 
along with the questionnaire pack to us in the prepaid envelope provided.  
 
4. My child/ the person I care for is over the age of 16 and cannot 
understand what is involved in the study or cannot communicate 
their decision to me: 
If you are reading this information on behalf of someone you care for who is over the age of 
16 and you decide that the person is not able to make an ‘informed’ decision about whether 
or not they would like to participate, then we would like to invite you to act as a ‘personal 
consultee’ (or ‘nominated consultee’ where an unpaid carer e.g. parent, legal guardian etc is 
not able to act as a ‘personal consultee’) for that person.  Please read the enclosed ‘Personal 
and Nominated Consultee Information Sheet’ coloured PINK.  Once you have finished 
reading the ‘Personal and Nominated Consultee Information Sheet’ please decide whether or 
not you feel able to act as a personal or nominated consultee for the person you care for. 
 
If you feel able to act as a personal or nominated consultee for the person you care for 
please think about whether the person would decide to participate if they were able to make 
an ‘informed’ decision themselves about whether or not to participate.  If you decide that the 
person would decide to participate, please complete Consent Form C coloured BLUE 
enclosed and return it to us alongside the questionnaire pack in the prepaid envelope 
provided. 
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ID____________ 
 
BACKGROUND INFORMATION 
 
 
1. Today’s date: ________________________ 
 
2. Gender:     Male    Female  
 
3. Date of Birth: ___/___/____  Age:______________  
 
4. Is the person you care for verbal? (i.e. more than 30 signs/words in their vocabulary)  
 
  Yes/No (delete as appropriate) 
 
5. Is the person you care for able to walk unaided? 
 
  Yes/No (delete as appropriate) 
 
6. Has the person you care for been diagnosed with a syndrome?  Yes/No (delete as appropriate)  
 
 If yes, please indicate which syndrome in 5a. and answer questions 6 to 8.  If no, please move on 
to question 9 
  
6.a Cornelia de Lange syndrome  Cri du Chat syndrome    
  Prader-Willi syndrome   Rubinstein Taybi syndrome   
  Fragile X syndrome   Down syndrome    
  Lowe syndrome    Soto Syndrome     
Rubinstein-Taybi syndrome                       9q34 deletion 
8p23deletion     Tuberous Sclerosis 
Other _____________________________ 
 
7. What is the genetic mechanism causing the syndrome in the person you care for? 
  
  Uni-parental disomy    Sequence repetition 
  Deletion     Translocation 
  Unknown     
Other __________________________________ 
 
8. When was the person you care for diagnosed? ____________________________________ 
 
9. Who diagnosed the person you care for?     
  
  Paediatrician       Clinical Geneticist 
  GP        
 Other ____________________________ 
 
10.   Has the person you care for had any medical/health difficulties in the last six months? If yes, 
please give details:                      
_______________________________________________________________________________
_______________________________________________________________________ 
Please tick or write your response to these questions concerning background details: 
 
Please answer the following about the person you care for: 
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In the information sheet and consent form we informed you that we may need to contact your child’s/person 
you care for’s GP in order to clarify any information regarding your child’s health and diagnostic status 
(see consent form and information sheet for more information). If you have already indicated on the 
consent form that you are happy for us to do this, please complete the relevant details below: 
 
11. Name of your child’s/person you care for’s  
GP_________________________________________________________ 
GPAddress____________________________________________________________________________
__________________________________________________________ 
GP Telephone number_______________________________ 
 
 
1. Are you male or female? Male            Female    
 
2. What was your age in years on your last birthday? _____________ years 
  
3. Please tick the highest level of your educational qualifications.  
     
No formal educational qualifications............................................................................    
Fewer than 5 GCSE’s or O Level’s (grades A-C), NVQ 1, or BTEC First Diploma…   
5 or more GCSE’s or O Level’s (grades A-C), NVQ 2, or equivalent……….……..   
3 or more ‘A’ Levels, NVQ 3, BTEC National, or equivalent......................................   
Polytechnic/University degree, NVQ 4, or equivalent...................................................   
Masters/Doctoral degree, NVQ 5, or equivalent…………............................................   
 
4. What is your relationship to your child with a genetic syndrome (e.g. mother, father, 
stepmother, grandmother, adoptive parent)? ______________________________ 
 
 
5. In total how many people currently live in your home? ________  Adults  _______  Children 
 
6. Does your child with a genetic syndrome normally live with you? Yes   No     
 
If no, then where do they live?______________________________________________ 
 
 
7. What is your current marital status? 
 
Married, and living with spouse...................................................................   
 
Living with partner.......................................................................................   
  
Divorced/Separated/Widowed/Single and NOT living with a partner.........   
 
     The following questions ask for background information about you and your family. Please 
tick the appropriate boxes or write in the spaces provided. 
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If living with partner/spouse, please answer the following questions, if not, please go to question 
12. 
 
8. Is your partner male or female?                 Male            Female       
 
9. What was their age in years on their last birthday? _____________ years 
 
10. Please tick the highest level of your partner/spouse’s educational qualifications.  
            No formal educational qualifications........................................................................  
Fewer than 5 GCSE or O Level (grades A-C), NVQ 1, or BTEC First Diploma.....   
5 or more GCSE or O Level (grades A-C), NVQ 2, or equivalent…………..…  
3 or more ‘A’ Levels, NVQ 3, BTEC National, or equivalent.................................   
 Polytechnic/University degree, NVQ 4, or equivalent.............................................  
Masters/Doctoral degree, NVQ 5, or equivalent…………......................................  
 11. What is your partner/spouse’s relationship to your child with a genetic syndrome 
(e.g., mother, father, stepmother, adoptive parent)?______________________________ 
 
12. Recent data from research with families of children with special needs has shown that a 
family’s financial resources are important in understanding family member’s views and 
experiences. With this in mind, we would be very grateful if you could answer the additional 
question below. We are not interested in exactly what your family income is, but we would 
like to be able to look at whether those with high versus lower levels of financial resources 
have different experiences.  
What is your current total annual family income? Please include a rough estimate of 
total salaries and other income (including benefits) before tax and national 
insurance/pensions. Please tick one box only: 
Less than £15,000…………………………………………………………………….…………..…  
£15,001 to £25,000……………………………………………………………………...………….   
£25,001 to £35,000………………………………………………………………..…….……….       
£35,001 to £45,000………………………………………………………………….…..…………    
£45,001 to £55,000……………………………………………………………..…………….……    
£55,001 to £65,000…………………………………………………….………………….…..           
£65,001 or more……………….………………………………….…                                                
Please check your answers and go on to the next questionnaire. 
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WESSEX Questionnaire 
 
These items refer to the person you care for. For each question (A, B, C, D etc …), please 
enter the appropriate code in each box. 
 
(Frequently = more than once a week) 
 
A) Wetting (nights)  1 = frequently  2 = occasionally     3 = never   
B) Soiling (nights)  1 = frequently  2 = occasionally     3 = never 
C) Wetting (days) 1 = frequently  2 = occasionally     3 = never 
D) Soiling (days) 1 = frequently  2 = occasionally     3 = never 
E) Walk with help 1 = not at all  2 = not up stairs     3 = up stairs  
                    and elsewhere 
 
(note: if this person walks by himself upstairs and elsewhere, please also code ‘3’ for ‘walk 
with help’) 
 
F) Walk by himself    1 = not at all  2 = not up stairs  3 = up stairs and 
                                         elsewhere  
G) Feed himself         1 = not at all  2 = with help      3 = without help 
H) Wash himself        1 = not at all  2 = with help      3 = without help 
I)   Dress himself        1 = not at all  2 = with help      3 = without help 
 
J) Vision                   1 = blind or almost   2 = poor        3 = normal   
K) Hearing          1 = deaf or almost     2 = poor      3 = normal 
 
L) Speech         1 = never a word        2 = odd words only 
          3 = sentences and normal    4 = can talk but doesn’t  
 
If this person talks in sentences, is his/her speech: 
1 = Difficult to understand even by acquaintances, impossible for strangers? 
2 = Easily understood for acquaintances, difficult for strangers? 
3 = Clear enough to be understood by anyone? 
M) Reads 1 = nothing 2 = a little 3 = newspapers and/or books 
N) Writes 1 = nothing 2 = a little 3 = own correspondence 
O) Counts 1 = nothing 2 = a little 3 = understands money values 
Please check your answers and go on to the next questionnaire. 
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THE MOOD, INTEREST AND PLEASURE QUESTIONNAIRE –  
SHORT FORM (MIPQ-S) 
 
 
Instructions for completing the MIPQ-S 
 
This questionnaire contains 12 questions – you should complete all 12 questions.  Each 
question will ask for your opinion about particular behaviours, which you have observed in 
the last 2 weeks.  For every question you should circle the most appropriate response e.g. 
 
6) In the last two weeks, how interested did the person appear to be in his/her surroundings? 
 
interested all interested most interested 
about 
interested some never 
of the time of the time half of the time of the time interested 
 
 
 
 
 
The Mood, Interest and Pleasure Questionnaire - Short Form 
 
1) In the last two weeks, did the person seem… 
 
sad all of sad most sad about half sad some never sad 
the time of the time of the time of the time  
 
Please comment if anything has happened in the last two weeks which you feel might explain sadness 
if it has been observed (e.g. a bereavement): 
 
 
2) In the last two weeks, how often did you hear positive vocalizations* when the person 
was engaged in activities*? 
 
all of the most of the about half of some of the never 
time the time the time time  
 
*positive vocalizations: e.g. laughing, giggling, “excited sounds” etc. 
*engaged in activities: i.e. when someone is actively involved in any activity such as a 
mealtime, a social interaction, a self-care task or social outing etc. 
 
3) In the last two weeks, do you think the facial expression of the person looked 
“flat”*… 
 
all of the most of the about half of some of the never 
time the time the time time  
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*flat expression: expression seems lifeless; lacks emotional expression; seems unresponsive. 
 
4) In the last two weeks, would you say the person… 
 
cried every cried nearly cried 3-4 times cried once or cried less than 
day every day each week twice each 
week 
once each week 
 
 
5) In the last two weeks, how interested did the person appear to be in his/her 
surroundings? 
 
interested all interested most interested about interested some never 
of the time of the time half of the time of the time interested 
 
6) In the last two weeks, did the person seem to have been enjoying life… 
 
all of the most of the about half of some of the never 
time the time the time time  
 
Please comment if there are any reasons why this person might not have been enjoying him/herself 
e.g. illness, being in pain, experiencing a loss etc.: 
 
 
7) In the last two weeks, would you say the person smiled… 
 
at least once at least once 3-4 times  once or  twice less than once 
every day nearly every 
day 
each week each week each week 
 
8) In the last two weeks, how disinterested did the person seem to be in his/her 
surroundings? 
 
disinterested disinterested disinterested 
about  
disinterested never 
all of the time most of the time half of the time some of the time disinterested 
 
9) In the last two weeks, when the person was engaged in activities*, to what extent did 
his/her facial expressions* suggest that s/he was interested in the activity? 
 
interested all interested most interested about interested some never 
of the time of the time half of the time of the time interested 
         
*engaged in activities: i.e. when someone is actively involved in any activity such as a 
mealtime, social interaction, self-care task or social outing etc. 
*facial expressions: interest might be indicated by the degree to which the person’s gaze is 
being directed at the person/things involved in an activity. 
 
10) In the last two weeks, would you say that the person… 
 
laughed laughed nearly laughed 3-4 laughed once or laughed less 
than 
every day every day times each week twice each week once each week 
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11) In the last two weeks, how often did you see gestures which appeared to demonstrate 
enjoyment* when the person was engaged in activities*? 
 
all of the most of the about half of some of the never 
time the time the time time  
 
*gestures which appear to demonstrate enjoyment: e.g. clapping, waving hands in excitement 
etc. 
*engaged in activities: i.e. when someone is actively involved in any activity such as a meal 
time, social interaction, self-care task or social outing etc. 
 
12) In the last two weeks, did the person’s vocalizations* sound distressed… 
 
all of the most of the about half of some of the never 
time the time the time time  
 
*vocalizations: any words, noises or utterances. 
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THE RBQ  
 
INSTRUCTIONS 
 
1. The questionnaire asks about 19 different behaviours. 
 
2. Each behaviour is accompanied by a brief definition and examples. The examples given 
for each behaviour are not necessarily a complete list but may help you to understand the 
definitions more fully. 
 
3. Please read the definitions and examples carefully and circle the appropriate number on 
the scale to indicate how frequently the person you care for has engaged in each of the 
behaviours within the last month. 
 
4. If a particular behaviour does not apply to the person you care for because they are not 
mobile or verbal please circle the number 0 on the scale 
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1. Object stereotypy: repetitive, seemingly purposeless movement of 
objects in an unusual way E.g. twirling or twiddling objects, twisting or 
shaking objects, banging or slapping objects. 
 
0 1 2 3 4 
2. Body stereotypy:  repetitive, seemingly purposeless movement of 
whole body or part of body (other than hands) in an unusual way. E.g. body 
rocking, or swaying ,or  spinning, bouncing, head shaking, body 
posturing.. Does not include self-injurious behaviour. 
 
0 1 2 3 4 
3. Hand stereotypy: repetitive, seemingly purposeless movement of 
hands in an unusual way. E.g. finger twiddling, hand flapping, wigging or 
flicking fingers, hand posturing. Does not include self-injurious behaviour. 
 
0 1 2 3 4 
4. Cleaning: Excessive cleaning, washing or polishing of objects or parts 
of the body         E.g. polishes windows and surfaces excessively, washes 
hands and face excessively,  
 
0 1 2 3 4 
5. Tidying up:  Tidying away any objects that have been left out. This 
may occur in situations when it is inappropriate to put the objects away. 
Objects may be put away into inappropriate places. E.g. putting cutlery left 
out for dinner in the bin, removes all objects from surfaces. 
  
0 1 2 3 4 
6. Hoarding: Collecting, storing or hiding objects to excess, including 
rubbish, bits of paper, and pieces of string or any other unusual items. 
 
0 1 2 3 4 
7. Organising objects: Organising objects into categories according to 
various characteristics such as colour, size, or function. E.g. ordering 
magazines according to size, ordering toy cars according to colour, 
ordering books according to topic.  
 
0 1 2 3 4 
8. Attachment to particular people: Continually asking to see, speak 
or contact a particular ‘favourite’ person. E.g. continually asks to see or 
speak to particular friend, carer, babysitter or schoolteacher. 
 
0 1 2 3 4 
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9. Repetitive questions: Asking specific questions over and over. E.g. 
always asking people what their favourite colour is, asking who is taking 
them to school the next day over and over 
 
0 1 2 3 4 
10. Attachment to objects: Strong preference for a particular object to 
be present at all times. E.g. Carrying a particular piece of string 
everywhere, taking a particular red toy car everywhere, attachment to soft 
toy or particular blanket. 
 
0 1 2 3 4 
11.  Repetitive phrases/signing: Repeating particular sounds, phrases 
or signs that are unrelated to the situation over and over. E.g. repeatedly 
signing the word ‘telephone’.  
 
0 1 2 3 4 
12. Rituals: carrying out a sequence of unusual or bizarre actions before, 
during or after a task. The sequence will always be carried out when 
performing this task and will always occur in the same way. E.g. turning 
round three times before sitting down, turning lights on and off twice 
before leaving a room, tapping door frame twice when passing through it.  
 
0 1 2 3 4 
13. Restricted conversation: Repeatedly talks about specific, unusual 
topics in great detail. E.g. conversation restricted to: trains, buses, 
dinosaurs, particular film, country, or sport. 
 
0 1 2 3 4 
14. Echolalia: Repetition of speech that has either just been heard or has 
been heard more than a minute earlier. E.g.: Mum:‘ Jack don’t do that’  
Jack: ‘Jack don’t do that’.         
 
0 1 2 3 4 
15. Preference for routine: Insist on having the same household, school 
or work schedule everyday. E.g. likes to have the same activities on the 
same day at the same time each week, prefers to eat lunch at exactly the 
same time every day, wearing the same jumper everyday. 
 
0 1 2 3 4 
16. Lining up or arranging objects:  Arrangement of objects into lines 
or patterns E.g. placing toy cars in a symmetrical pattern, precisely lining 
up story books,  
 
0 1 2 3 4 
17. Just right behaviour: Strong insistence that objects, furniture and 
toys always remain in the same place. E.g. all chairs, pictures and toys 
have a very specific place that cannot be changed. 
 
0 1 2 3 4 
18. Completing behaviour: Insists on having objects or activities 
‘complete’ or ‘whole’ E.g. Must have doors open or closed not in between,  
story must be read from beginning to end, not left halfway through. 
 
0 1 2 3 4 
19. Spotless behaviour: Removing small, almost unnoticeable pieces of 
lint, fluff, crumbs or dirt from surfaces, clothes and objects. E.g.  Picking 
fluff off a jumper, removing crumbs from the kitchen table. 
0 1 2 3 4 
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THE ACTIVITY QUESTIONNAIRE 
                  Instructions: 
 Please read each item carefully and circle the appropriate number on the scale, for the 
person you care for. 
 Please ensure that you indicate a response for every item.  If the particular behaviour 
does not apply, 
for example, if the person is not verbal or not mobile, please circle 0 on the scale. 
 
 
 
 
 
 
 
 
 
 
 
Never/ 
almost 
never 
 
 
 
Some 
of the 
time 
 
 
 
 
Half of 
the time 
 
 
 
 
A lot of 
the 
time 
 
 
 
 
Always/ 
almost all 
the time 
 
 
1. Does the person wriggle or squirm about when 
seated  or lying down? 
 
0 1 2 3 4 
2. Does the person fidget or play with their hands 
and/or  feet when seated or lying down? 
 
0 1 2 3 4 
3. Does the person find it difficult holding still? 0 1 2 3 4 
4. Does the person find it difficult to remain in their 
seat  even when in situations where it would be 
expected? 
0 1 2 3 4 
5. Does the person prefer to be moving around or
 becomes    
        frustrated if left in one position for too long? 
 
0 1 2 3 4 
6. When the person is involved in a leisure activity 
(e.g.  watching TV, playing a game etc.) do they make a 
lot  of noise? 
 
0 1 2 3 4 
7. When the person is involved in an activity, are 
they  boisterous and/or rough? 
 
0 1 2 3 4 
8. Does the person act as if they are “driven by a 
motor”  (i.e. often very active)? 
 
0 1 2 3 4 
9. Does the person seem like they need very little 
rest to  recharge their battery? 
 
0 1 2 3 4 
10. Does the person often talk excessively? 
 
0 1 2 3 4 
11. Does the person’s behaviour seem difficult to 
 manage/contain whilst out and about (e.g. in 
town, in  supermarkets etc.)? 
 
0 1 2 3 4 
12. Do you feel that you need to “keep an eye” on the  
         person at all times? 
 
0 1 2 3 4 
13. Does the person you care for seem to act/do things  
         without stopping to think first? 
 
0 1 2 3 4 
14. Does the person blurt out answers before 
questions  have been completed? 
 
0 1 2 3 4 
15. Does the person start to respond to instructions 
before  they have been fully given or without seeming 
to  understand them? 
 
0 1 2 3 4 
16. Does the person want things immediately? 
 
0 1 2 3 4 
17. Does the person find it difficult to wait? 
 
0 1 2 3 4 
18. Does the person disturb others because they have 
 difficulty waiting for things or waiting their turn? 
 
0 1 2 3 4 
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                              SOCIAL COMMUNICATION QUESTIONNAIRE © Rutter et al 2003         
  
1.  Is she/he now able to talk using short phrases or sentences? If no, skip to question 8.  Yes      No 
  
2.  Can you have a to and fro “conversation” with her/him that involves taking turns or 
building on what you have said?        
Yes      No 
  
3. Has she/he ever used odd phrases or said the same thing over and over in almost exactly the 
same way (either phrases that she/he has heard other people use or ones that she/he has 
made up?  
Yes      No 
  
4.  Has she/he ever used socially inappropriate questions or statements?  For example, has 
she/he ever regularly asked personal questions or made personal comments at awkward 
times? 
Yes      No 
  
5.   Has she/he ever got her/his pronouns mixed up (e.g., saying you or she/he for I)? 
 
Yes      No 
  
6.  Has she/he ever used words that she/he seemed to have invented or made up her/himself; 
put  things in odd, indirect ways; or used metaphorical ways of saying things (e.g., saying 
hot rain for steam)? 
 
Yes      No 
  
7.  Has she/he ever said the same thing over and over in exactly the same way or insisted that 
you say the same thing over and over again?  
Yes      No 
  
8.  Has she/he ever had things that she/he seemed to have to do in a very particular way or 
order or rituals that she/he insisted that you go through?  
Yes      No 
  
9.   Has her/his facial expression usually seemed appropriate to the particular situation, as far 
as you could tell? 
Yes      No 
  
10. Has she/he ever used your hand like a tool or as if it were part of her/his own body (e.g., 
pointing with your finger, putting your hand on a doorknob to get you to open the door)? 
    
Yes      No 
  
11. Has she/he ever had any interests that preoccupy her/him and might seem odd to other 
people (e.g., traffic lights, drainpipes, or timetables)? 
Yes      No 
  
12. Has she/he ever seemed to be more interested in parts of a toy or an object (e.g., spinning 
the wheels of a car), rather than using the object as it was intended? 
Yes      No 
  
13. Has she/he ever had any special interests that were unusual in their intensity but otherwise 
appropriate for her/his age and peer group (e.g., trains, dinosaurs)? 
Yes      No 
  
14. Has she/he ever seemed to be unusually interested in the sight, feel, sound, taste, or smell 
of things or people? 
Yes      No 
  
15. Has she/he ever had any mannerisms or odd ways of moving her/his hands or fingers, such 
as flapping or moving her/his fingers in front of her/his eyes? 
Yes      No 
  
16. Has she/he ever had any complicated movements of her/his whole body, such as spinning Yes      No 
Please circle ‘yes’ if any one of the following behaviours is present.  Although you may be 
uncertain about whether some behaviours are  present or not, please do answer ‘yes’ or ‘no’ 
to every question on the basis of what you think. 
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or repeatedly bouncing up and down?  
  
17. Has she/he ever injured her/himself deliberately, such as by biting her/his arm or banging 
her/his head? 
Yes      No 
  
18. Has she/he ever had any objects (other than a soft toy or comfort blanket) that she/he had 
to carry around? 
Yes      No 
  
19. Does she/he have any particular friends or a best friend? Yes      No 
  
20. When she/he was 4 to 5, did she/he ever talk with you just to be friendly (rather than to get 
something)? 
Yes      No 
 
 
21. When she/he was 4 to 5, did she/he ever spontaneously copy you (or other people) or what 
you were doing (such as vacuuming, gardening, or mending things)? 
 
Yes      No 
  
22. When she/he was 4 to 5, did she/he ever spontaneously point at things around her/him just 
to show you things (not because she/he wanted them)? 
Yes      No 
  
23. When she/he was 4 to 5, did she/he ever use gestures, other than pointing or pulling your 
hand, to let you know what she/he wanted 
Yes      No 
  
24. When she/he was 4 to 5, did she/he nod her/his head to mean yes? Yes      No 
  
25. When she/he was 4 to 5, did she/he shake her/his head to mean no? Yes      No 
  
26. When she/he was 4 to 5, did she/he usually look at you directly in the face when doing 
things with you or talking with you? 
Yes      No 
  
27. When she/he was 4 to 5, did she/he smile back if someone smiled at her/him? Yes      No 
  
28. When she/he was 4 to 5, did she/he ever show you things that interested her/him to engage 
your attention? 
Yes      No 
  
29. When she/he was 4 to 5, did she/he ever offer to share things other than food with you? Yes      No 
  
30. When she/he was 4 to 5, did she/he ever seem to want you to join in her/his enjoyment of 
something? 
Yes      No 
  
31. When she/he was 4 to 5, did she/he ever try to comfort you if you were sad or hurt? Yes      No 
  
32. When she/he was 4 to 5, when she/he wanted something or wanted help, did she/he look at 
you and use gestures with sounds or words to get your attention? 
Yes      No 
  
33. When she/he was 4 to 5, did she/he show a normal range of facial expressions? Yes      No 
  
34. When she/he was 4 to 5, did she/he ever spontaneously join in and try to copy the actions 
in social games, such as The Mulberry Bush or London Bridge Is Falling Down? 
Yes      No 
  
35. When she/he was 4 to 5, did she/he play any pretend or make-believe games? Yes      No 
  
36. When she/he was 4 to 5, did she/he seem interested in other children of approximately the 
same age whom she/he did not know? 
Yes      No 
  
37. When she/he was 4 to 5, did she/he respond positively when another child approached 
her/him? 
Yes      No 
  
38. When she/he was 4 to 5, if you came into a room and started talking to her/him without 
calling her/his name, did she/he usually look up and pay attention to you? 
Yes      No 
  
39. When she/he was 4 to 5, did she/he ever play imaginative games with another child in Yes      No 
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such a way that you could tell that they each understood what the other was pretending? 
  
40. When she/he was 4 to 5, did she/he play cooperatively in games that required joining in 
with a group of other children, such as hide-and-seek or ball games? 
Yes      No 
 
 
Please check your answers and go on to the next questionnaire. 
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Appendix E – Validation of ASD reference group to the SCQ normative sample. 
 
Table 1. Odds ratios with 99% confidence for each item of the SCQ, comparing the ASD reference group to the ASD normative 
sample published in the SCQ manual. 
 
Item 
Number 
Item 
ASD Normative Sample 
(SCQ Manual) 
ASD Reference Group 
Odds 
Ratio 
99% CI for 
Odds Ratio 
With 
Abnormality 
(N) 
Without 
Abnormality 
(N) 
With 
Abnormality 
(N) 
Without 
Abnormality 
(N) 
Lower Upper 
29 Offering to share 122 38 23 7 1.02 0.30 3.44 
36 Interest in children 127 33 26 4 1.69 0.39 7.38 
40 Group play 129 31 26 4 1.56 0.36 6.85 
37 Response to other children’s approaches 126 34 26 4 1.75 0.40 7.65 
34 Imitative social play 112 48 23 7 1.41 0.42 4.67 
31 Offering comfort 116 44 26 4 2.47 0.57 10.61 
28 Showing and directing attention 99 61 11 19 0.36 0.12 1.03 
30 Seeking to share enjoyment 101 59 11 19 0.34 0.12 0.98 
21 Imitation 113 47 25 5 2.08 0.54 7.95 
39 Imaginative play with peers 138 22 30 0 -
a 
- - 
22 Pointing to express interest 108 52 21 9 1.12 0.37 3.43 
27 Social smiling 83 77 20 10 1.86 0.63 5.46 
26 Eye gaze 104 56 17
b 
12
 
0.76 0.26 2.21 
35 Imaginative play 117 43 24
c 
4 2.21 0.51 9.57 
33 Range of facial expressions 87 73 24 6 3.36 0.96 11.68 
38 Attention to voice 100 60 20 10 1.20 0.41 3.55 
23 Gestures 107 53 18 12 0.74 0.26 2.13 
32 Quality of social overtures 65 95 14 16 1.28 0.46 3.59 
19 Friends 114 46 23 7 1.33 0.40 4.41 
17 Self-injury 64 96 18 12 2.25 0.79 6.42 
25 Head shaking to mean no 106 54 23 7 1.67 0.51 5.53 
2 Conversation 34 70 11 9 2.52 0.70 9.04 
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Item 
Number 
Item 
ASD Normative Sample 
(SCQ Manual) 
ASD Reference Group 
Odds 
Ratio 
99% CI for 
Odds Ratio 
With 
Abnormality 
(N) 
Without 
Abnormality 
(N) 
With 
Abnormality 
(N) 
Without 
Abnormality 
(N) 
Lower Upper 
24 Nodding to mean yes 110 50 25
b 
4 2.84 0.66 12.20 
20 Social chat 28 132 27 3 42.43 8.07 223.00 
9 Inappropriate facial expressions 44 116 12 18 1.76 0.61 5.10 
15 Hand and finger mannerisms 122 38 27 3 2.80 0.54 14.48 
3
d 
Stereotyped utterances 85 19 18 2 2.01 0.26 15.34 
7
d 
Verbal rituals 72 32 15 5 1.33 0.32 5.63 
4
d 
Inappropriate questions 59 45 13 7 1.42 0.38 5.26 
6
d 
Neologisms 49 55 16
b 
3 5.99 10.9 32.79 
5
d 
Pronoun reversal 55 49 17 3 5.05 0.93 27.45 
12 Repetitive use of objects 106 54 23 7 1.67 0.51 5.53 
14 Unusual sensory interests 86 74 25 5 4.30 1.14 16.24 
8 Compulsions and ritual 111 49 25 5 2.21 0.58 8.42 
11 Unusual preoccupations 108 52 21 9 1.12 0.37 3.43 
10 Use of other’s body to communicate 98 62 26 4 4.11 0.97 17.49 
16 Complex body mannerisms 98 62 20 10 1.27 0.43 3.74 
18 Unusual attachment to objects 36 124 15 15 3.44 1.19 9.95 
13 Circumscribed interests 87 73 18 12 1.26 0.44 3.58 
 
a. Due to N=0 participants in the ASD group without the abnormality, it was not possible to calculate odds ratio for this item. Chi 
square analysis revealed no significant differences between the two groups 
2
(1, N = 190) = 3.41, p = .06 
b. One participant in the ASD reference group had missing data for this item. 
c. Two participants in the ASD reference group had missing data for this item. 
d. This item was only calculated for verbal individuals. In the ASD normative sample (SCQ manual), 104 individuals were verbal. For 
the ASD reference sample, 20 individuals were verbal.
